The role of the corticomotorneurons in pathogenesis of amyotrophic lateral sclerosis by Menon, Parvathi
Copyright and use of this thesis
This thesis must be used in accordance with the 
provisions of the Copyright Act 1968.
Reproduction of material protected by copyright 
may be an infringement of copyright and 
copyright owners may be entitled to take 
legal action against persons who infringe their 
copyright.
Section 51 (2) of the Copyright Act permits 
an authorized officer of a university library or 
archives to provide a copy (by communication 
or otherwise) of an unpublished thesis kept in 
the library or archives, to a person who satisfies 
the authorized officer that he or she requires 
the reproduction for the purposes of research 
or study. 
The Copyright Act grants the creator of a work 
a number of moral rights, specifically the right of 
attribution, the right against false attribution and 
the right of integrity. 
You may infringe the author’s moral rights if you:
-  fail to acknowledge the author of this thesis if 
you quote sections from the work 
- attribute this thesis to another author 
-  subject this thesis to derogatory treatment 
which may prejudice the author’s reputation
For further information contact the University’s 
Director of Copyright Services
sydney.edu.au/copyright
1 
 
THE ROLE OF THE CORTICOMOTORNEURONS IN 
PATHOGENESIS OF AMYOTROPHIC LATERAL SCLEROSIS 
 
PARVATHI MENON 
 
A THESIS SUBMITTED IN FULFILMENT OF THE REQUIREMENTS FOR 
THE DEGREE OF DOCTOR OF PHILOSOPHY 
 
FACULTY OF MEDICINE, WESTERN CLINICAL SCHOOL, WESTMEAD 
HOSPITAL. 
UNIVERSITY OF SYDNEY 
 
MARCH 2014 
 
 
 
 
2 
 
ACKNOWLEDGEMENTS 
The completion of the research studies undertaken as part of my PhD degree and culminating in 
the submission of this thesis has involved  significant contributions from a number of individuals 
and institutions to whom I am extremely grateful and whose efforts I would like to acknowledge. 
My supervisor, Associate Professor Steve Vucic, had conviction in my abilities and encouraged 
me to undertake this career path. He has generously provided constant support, guidance and 
encouragement to achieve my goals and most importantly to acquire the skills to pursue the path 
of ongoing clinical research work. My co-supervisor Professor Matthew Kiernan has constantly 
provided encouragement, valuable advice and high standards to aspire towards. I owe them 
sincere gratitude for providing me with a career opportunity which provides immense daily work 
satisfaction. Scholarship funding by the University of Sydney, Lake-Bonnamy post graduate 
scholar ship and the Motor Neuron Disease Research Institute of Australia/National Health and 
Medical Research Council co-funded postgraduate scholarship is gratefully acknowledged. My 
colleagues in the department of Neurology, Westmead Hospital, have, at all levels, been 
extremely generous and supportive of my research efforts and I would like to acknowledge their 
constant support and encouragement. I am also grateful to all patients and subjects who 
participated in the research studies. To the ever hopeful and generous patients, in particular, I am 
grateful for a perspective on life and for the inspiration to continue ongoing research work. 
Lastly, but most importantly, I would like to acknowledge my teachers through the years and my 
family for their immeasurable contribution to my present achievement, their belief in my ability 
and constant encouragement to achieve my best. 
 
 
3 
 
 
 
 
 
ABSTRACT 
 
 
 
 
 
 
 
 
4 
 
Amyotrophic lateral sclerosis (ALS) is a progressive, degenerative disease of the motor system 
clinically defined by the presence of upper and lower motor neuron (LMN) signs. The site of 
onset of pathophysiology within the motor system in ALS remains unresolved and this thesis 
examines the role of the corticomotor neuron in the pathogenesis of ALS.  
 
The diagnostic utility of the split-hand sign in ALS involving preferential wasting of the ‗thenar‘ 
group of intrinsic hand muscles namely the abductor pollicis brevis (APB) and first dorsal 
interosseous (FDI) was established by recording the split-hand index (SI) which was noted to 
reliably differentiate ALS from mimic neuromuscular disorders. The cortical and axonal 
excitability characteristics of the ‗thenar‘ muscles namely the APB and FDI was compared with 
the hypothenar abductor digiti minimi (ADM) with threshold tracking transcranial magnetic 
stimulation (TMS) studies revealing cortical hyperexcitability to be a feature of ALS pronounced 
over the ‗thenar‘ muscles while axonal hyperexcitability while a feature of ALS, did not 
selectively affect the prominently wasted ‗thenar‘ muscles. Cortical hyperexcitability was also 
noted to precede the development of lower motor neuron dysfunction in a clinically and 
neurophysiologically normal APB muscle. The selective vulnerability of muscles in ALS was 
further defined by the split hand plus sign with a greater degree of cortical hyperexcitability over 
the preferentially wasted APB muscle in ALS patients when compared with a similarly 
innervated and relatively preserved flexor pollicis longus (FPL) muscle.  
 
In summary, corticomotorneuronal hyperexcitability as a marker of corticomotorneuronal 
dysfunction predominates over the muscles which are preferentially wasted in ALS and precedes 
evidence of lower motor neuron loss. The findings presented in this thesis support the primacy of 
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the corticomotor neuron in the pathogenesis of the split hand phenomenon and suggest a 
mechanism for the pathogenesis of ALS.  
Keywords: ALS, split-hand sign, cortical hyperexcitability 
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 PREFACE 
 
The term amyotrophic lateral sclerosis was introduced by the French neurologist Jean-Martin 
Charcot (1825-1893) in 1874 in his two lectures gathered in Volume 2 of his Oeuvres 
Completes. Using the technique known as the ―anatomo-clinical method‖, a two-part method to 
determine the correlation between clinical signs detected during life and anatomical lesions seen 
at death, Charcot synthesized prior studies and enumerated the steps that led to the unified 
concept presented in 1874 of a condition resulting in weakness involving both muscle atrophy as 
well as spasticity and contractures and associated with spinal gray matter involvement 
(amyotrophy) and white matter damage (lateral sclerosis). The wording of the term reflects 
Charcot‘s belief that the amyotrophy was, in fact, due to spread of the disease from the lateral 
columns to the spinal and bulbar gray matter. However, mechanisms underlying the pathogenesis 
of amyotrophic lateral sclerosis (ALS) remain unresolved specifically the sequence of progress 
of pathology. Selective vulnerability of the ‗thenar‘ intrinsic hand muscles to wasting, a 
phenomenon termed the split hand sign has been noted to be a specific feature of ALS and 
provides a unique opportunity to understand the pathogenesis of ALS. The present thesis 
attempts to assess the role of the corticomotor neuron in the pathogenesis of ALS utilising 
threshold tracking cortical and axonal excitability studies along with clinical assessment, routine 
neurophysiology studies and motor unit potential analysis.  
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Introduction 
Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease (MND), is a rapidly 
progressive and universally fatal neurodegenerative disorder of the human motor system, first 
described in the mid-19th century by the French neurologist Jean Martin Charcot (1).  Although 
ALS is clinically characterised by progressive neurological deterioration and co-existence of 
upper and lower motor neuron signs, recent discoveries have indicated a heterogeneous nature of 
ALS (2).   In addition to the ALS phenotype, the varied clinical presentations of ALS/MND 
include (i) progressive muscle atrophy (PMA), a clinically pure LMN phenotype, (ii) primary 
lateral sclerosis (PLS), a clinically pure UMN phenotype and (iii) progressive bulbar palsy 
(PBP), an isolated bulbar phenotype with relative preservation of spinal motor neurons.  More 
recently, an association between ALS and frontotemporal degeneration (FTD) has been 
established, suggesting that ALS forms a continuum with primary neurodegenerative disorders, a 
notion underscored by the identification of the c9orf72 hexanucleotide expansion (3-5).  Despite 
the clinical heterogeneity, median survival of ALS/MND remains 3 years, with 10% of patients 
surviving over 8 years (6, 7).   
 
Amyotrophic lateral sclerosis 
In European-based population studies the incidence of ALS appears uniform at 2.16 per 100,000 
person-years with a prevalence of 4-6 per 100,000 (8).  The overall lifetime risk of developing 
ALS is 1 in 400, with incidence slightly higher in males [1.2-1.5:1] (8).  Sporadic ALS peaks 
between the ages of 50 to 75 years and declines after the age of 80 (6),  with the age-specific 
incidence remaining stable over the past decade (9).  The frequency of ALS is significantly lower 
in non-Caucasian populations (10, 11), suggesting a role for genetic factors in ALS 
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susceptibility. Other ALS/MND phenotypes are less frequent, including PMA (10% of cases), 
PLS (1-3%) and progressive bulbar palsy (1-2%) of all cases.  A genetic etiology has been 
identified in up to 20% of apparently ―sporadic‖ and 60% of familial ALS cases, in which two or 
more family members are clinically affected, with at  least 16 genes and genetic loci implicated 
in ALS pathogenesis (12).  For the purposes of this thesis, MND is synonymous with ALS. 
 
Clinical Features  
Amyotrophic lateral sclerosis exhibits a diverse and complex clinical phenotype, critical for 
understanding of disease pathophysiology and diagnosis.  Clinically, ALS is characterised by co-
existence of upper and lower motor neuron signs encompassing multiple body regions, with 
evidence of progressive deterioration (2, 13, 14).  Lower motor neuron signs are clinically 
characterized by fasciculations, muscle wasting and weakness, while UMN signs include 
slowness of movement, increased tone, hyper-reflexia and extensor plantar responses.  The 
majority of ALS patients present with limb-onset disease (65-75%) (15-17), typically spreading 
along the neuraxis to affect contiguous motor neurons (18, 19).  Preferential wasting and 
weakness of thenar muscles, termed the split-hand phenomenon (see below) is a specific feature 
of ALS (20, 21).  While fasciculations are a cardinal feature of ALS, they are infrequently the 
presenting symptom (22, 23).  Patients presenting solely with fasciculations and muscle 
cramping should be monitored as these patients may infrequently progress to develop ALS (24).  
Extra-ocular and sphincter muscles are preserved until advanced stages of the disease (25), and 
sensory nerves are not typically affected (6). 
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Bulbar-onset disease, evident in 20% of cases, is characterized by flaccid or spastic dysarthria, 
dysphagia, hoarseness, tongue wasting, weakness and fasciculations as well as emotional lability 
and pathologically brisk jaw reflexes (2).  Dysphasia may potentially result in aspiration 
pneumonia, malnutrition and weight loss, all adverse prognostic features (26).  Respiratory 
dysfunction develops in advanced stages of ALS, ultimately resulting in terminal respiratory 
failure (27), although rarely may be the presenting symptom (28-30).   
 
Of further relevance, atypical ALS phenotypes include progressive muscular atrophy, the ―pure‖ 
LMN phenotype, encompassing the flail-arm and flail leg variants of ALS.  The flail-limb 
variants are characterised by neurogenic weakness confined to the shoulder girdle (flail-arm > 24 
months) or lower limbs (flail-leg) for a prolonged period with absence of UMN signs (31-36). 
One-third of PMA cases develop UMN dysfunction (37, 38), while PLS patients may develop 
LMN signs within four years of disease-onset (39).  The PBP phenotype remains localized 
within the bulbar region for a prolonged period (>6 months) and is characterized by female 
predominance and UMN bulbar dysfunction, although clinical features of ALS typically develop 
in the upper and lower limbs (40).  Although survival is typically prolonged in these unusual 
phenotypes, the mortality rates for the generalized forms of PMA appear similar to ALS (37).   
 
In addition to pure motor symptoms, subtle cognitive abnormalities may be evident in up to 50% 
of ALS patients (41, 42), characterized by executive dysfunction, language and memory 
impairment along with behavioural abnormalities, which may precede the onset of motor 
symptoms (6, 41, 42).  Recognition of cognitive dysfunction has implication for vital 
management of ALS, as these symptoms may adversely impact on patient compliance and 
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decision-making abilities.  At the extreme end of the spectrum, frontotemporal dementia may 
develop in up to 15% of ALS patients (8, 41), and is clinically characterized by executive and 
language dysfunction, irrational behavioural, personality changes, apathy, poor insight, loss of 
empathy, irritability and disinhibition (43).   The presence of psychiatric features in the setting of 
FTD-ALS may be indicative of the c9orf72 expansion (43).   
 
Split-hand sign 
The ―split hand‖ sign refers to preferential wasting of the thenar group of muscles, including the 
abductor pollicis brevis (APB) and first dorsal interosseous (FDI), when compared to the 
abductor digit minimi (ADM) (Fig. 1) (21, 44).  This pattern of dissociated muscle atrophy is 
frequently observed in ALS, and may differentiate ALS from potential mimic disorders (20, 44).  
The ability to quantify the split hand sign, through the development of a split-hand index (SI), 
was recently demonstrated to be of diagnostic significance in ALS (Chapter 1). 
 
The mechanisms underlying the development of the split hand in ALS remains to be fully 
elucidated, and resolution of this issue could be of pathophysiological significance in ALS.  
Dysfunction of local spinal segments are unlikely to account for the split hand phenomena given 
that all involved muscles are innervated by the same myotomes (C8, T1).  Currently, three 
potential mechanisms have been suggested as possible pathophysiological processes underlying 
the development of the split hand, including cortical hyperexcitability, increased peripheral nerve 
excitability and increased metabolic demands of the motor neurons innervating the APB and FDI 
muscles (20, 44). 
 
16 
 
 
 
 
 
A cortical mechanism was suggested by the notion of corticomotoneuronal primacy in ALS 
pathogenesis, a view first considered by Charcot (1).  Subsequently, the dying forward” 
hypothesis was proposed, which suggested that corticomotoneuronal hyperexcitability induced 
motor neuron degeneration via an anterograde glutamate-mediated excitotoxic process (25).  
Support for a dying forward hypothesis was based on a number of important clinical and 
neurophysiological observations, including: (i) a relative preservation of extraocular and 
sphincter muscles in ALS, postulated to be due to a paucity of corticomotoneuronal projections 
onto the motor nuclei innervating the extraocular muscles; (ii) absence of an animal model of 
ALS, ascribed to a lack of direct corticomotoneuronal-anterior horn cell connections (45); (iii) 
rarity of pure lower motor neuron forms of ALS, with subclinical upper motor neuron 
dysfunction invariably detected with TMS studies (46); (iv) that asymmetric and variable motor 
deficits evident in ALS may be a explained by the complex anatomical association of the 
Figure 1: The split hand sign refers to preferential atrophy of the abductor pollicis brevis (APB) 
and first dorsal interosseous (FDI) muscles when compared to abductor digit minimi (ADM).  
The split hand phenomenon sign appears to be a specific feature of ALS. 
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corticomotoneuron-anterior horn cell synaptic relationship (45, 47, 48); and (v) that transcranial 
magnetic stimulation (TMS) studies have reported that cortical hyperexcitability is an early 
feature of sporadic ALS (49), preceding the development of familial ALS (50).  Further, this 
increase in cortical excitability appeared to be a process specific for ALS in the context of 
neuromuscular disorders, clearly differentiating ALS from mimic disorders (51-53), thereby 
arguing against the notion that the increase in cortical excitability representing cortical plasticity.   
The association between the split hand sign and cortical hyperexcitability may be explained by a 
greater cortical representation of the thenar complex group of muscles (APB and FDI).  This 
greater cortical representation is required in humans since the thenar complex group of muscles 
(both APB and FDI) are vital for fine fractionated hand movements (45).  As a result, a greater 
corticomotoneuronal input onto the anterior horn cells innervating the APB and FDI muscles 
may result in greater anterior horn cell degeneration, via a glutamate excitotoxic process leading 
to the split hand sign.  Support for such a mechanism was provided by TMS studies that revealed 
larger motor evoked potential (MEP) amplitudes over the thenar muscles when compared to the 
ADM in healthy controls, thereby suggesting a stronger corticomotoneuronal input to the thenar 
muscle complex (54). In addition, the MEP amplitudes were significantly reduced when 
recording over the thenar muscles in ALS patients, but not when recording over the ADM 
muscle, thereby suggesting that corticomotoneuronal dysfunction contributed to the split hand 
pattern of muscle atrophy in ALS.    
 
Alternatively, it has also been suggested that the split hand sign may be explained by differences 
in membrane properties of motor axons innervating the various intrinsic hand muscles.  
Specifically, an increase of strength-duration time constant (SDTC) and latent addition (LA) was 
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reported in motor axons innervating the APB and FDI when compared to ADM in a group of 
healthy controls (55).  Given that both SDTC and LA are biomarkers for persistent nodal sodium 
conductances, these findings suggest that upregulation of nodal persistent sodium conductances 
may contribute to the development of the split hand sign in ALS.   Interestingly, upregulation of 
persistent nodal sodium conductances is a well-documented pathophysiological feature of ALS 
(56-58), linked to the process of neurodegeneration (59).  Recently, axonal excitability studies 
have reported hyperexcitability of motor axons innervating the APB muscle when compared to 
axons innervating the ADM, suggesting a potential role of altered axonal properties in 
development of the split hand in ALS.  The finding of upregulated nodal persistent sodium 
conductances in spinobulbar muscular atrophy (or Kennedy‘s disease) (60), a mimic disorder in 
which the split hand sign does not appear to be a feature, may potentially argue against such a 
mechanism.   
   
In addition to central and peripheral nerve hyperexcitability, increased metabolic demands on the 
anterior horn cells (AHCs) innervating the APB and FDI muscles has also been suggested as a 
potential mechanism underlying the development of the split hand.  Humans are distinct from 
animals in that fine fractionated movement are well developed and frequently used for daily 
activities (45).  Give that the thenar complex groups of muscles (APB and FDI) are vital for the 
proper execution of these complex fine fractionated movements, it is apparent that the FDI and 
APB are used more frequently than the hypothenar muscles in daily activities.  As a result, the 
metabolic demand on the spinal motor neurons innervating the APB or FDI muscles might be 
increased which in turn would result in greater oxidative stress and ultimately degeneration. A 
potential weakness of the metabolic demand hypothesis is that over a lifetime the whole of the 
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hand is used very actively, thereby making it difficult to see how the median aspect of the hand, 
namely the APB/FDI muscles, would be selectively involved. Consequently, while the 
mechanisms underlying the development of the split hand sign remain to be fully elucidated in 
ALS, a cortical basis seems to be supported. 
 
Neurophysiological features 
Nerve conduction studies (NCS) and electromyography (EMG) are essential investigations in 
ALS that may assist in the exclusion of ALS-mimic disorders (2), such as  demyelinating 
neuropathies (61), and aid with the diagnosis.  In ALS, motor NCS are normal in early stages of 
the disease, but with disease progression there is decline in the compound muscle action 
potential (CMAP) amplitude, reflecting axonal loss (62).  Importantly, the CMAP amplitude 
correlates with outcome and functional  disability (63) and has been utilised as a prognostic 
biomarker in clinical trials (63, 64).  The changes in CMAP amplitude may be accompanied by a 
mild reduction in motor conduction velocity (> 70% of the lower limit of normal) and mild 
prolongation of distal motor and F-wave latencies (more than 30% of upper limit of normal) due 
to loss of large diameter fast-conducting fibres (62, 65, 66).  The neurophysiological index, 
derived by multiplying the CMAP amplitude with the F-wave frequency and dividing the 
product by the distal motor latency, has been as a sensitive biomarker of disease progression in 
ALS (67, 68).  Sensory NCSs are normal and overt abnormalities of sensory NCSs should raise 
suspicion of an alternative diagnosis (62, 65, 66). 
 
Electromyography (EMG) is essential in identifying LMN loss in ALS and the most frequently 
recognized abnormalities include fasciculations, ongoing changes [fibrillation potentials and 
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positive sharp waves (PSWs)], along with chronic neurogenic changes (large-amplitude, long-
duration, polyphasic motor unit potentials [Figure 2) (62, 66).  Importantly, ongoing changes 
may be evident in clinically normal muscles and hence EMG may aid in an early diagnosis of 
ALS (24, 39).   
 
Surviving motor units may fire spontaneously, resulting in fasciculations which are a classical 
feature of ALS and usually become generalised although they are rarely the presenting feature 
(22, 24).   Importantly widespread fasciculations exhibiting a  higher firing rate and increased 
frequency of double fasciculations in ALS (69), and when detected in the tongue are highly 
specific for ALS .  Fasciculations are generated at the nerve terminals, though some arise at more 
proximal regions including at the level of the motor neuron (70-72).   With disease progression, 
fasciculations may develop a complex morphology reflecting remodelling of the underlying 
motor unit (73).  At a molecular level, upregulation of persistent sodium conductances combined 
with reduced potassium currents, appears to underlie the development of fasciculations in ALS 
(56).   
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A
B
C
Figure 2: (A)  Ongoing degeneration of motor neurons along with collateral sprouting of 
surviving motor neurons results in classical electromyography findings including (B) ongoing 
denervation (fibrillation potentials and positive sharp waves) along with (C) chronic neurogenic 
changes (large amplitude, long-duration, polyphasic motor units action potentials with reduced 
voluntary recruitment).   
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While the EMG changes may not be specific for ALS when found in isolation, the sensitivity and 
specificity of the EMG findings, as they conform to the Awaji criteria, has been recently 
established (74-81).  Specifically, the Awaji criteria were developed in order to facilitate an 
earlier diagnosis of ALS, primarily in a research setting (82).  These consensus criteria proposed 
that neurophysiological findings of ongoing and chronic neurogenic changes could be equated 
with the clinical features of LMN dysfunction.  In addition, the presence of fasciculation 
potentials was deemed to be a biomarker of denervation, equivalent to the finding of ongoing 
changes.  Quantitative dysfunction of UMNs was not captured with the Awaji criteria, thereby 
potentially precluding the diagnosis of ALS prior to development of widespread neurogenic 
changes or in the setting of atypical phenotypes such as such as the flail-arm variant (31).  
 
Less conventional neurophysiological techniques for establishing LMN dysfunction in ALS 
include motor unit number estimation (83), electrode impedance myography (84),  and axonal 
excitability [see below] (85, 86), although these techniques are not routinely applicable.  
Separately, TMS techniques (see below) may be utilised to assess UMN dysfunction, and 
features of cortical hyperexcitability, prolonged central motor conduction time and cortical 
inexcitability have been documented in ALS (87).  Recently, beta-band intramuscular coherence 
was developed to assess UMN dysfunction in ALS (88), although at present it is utilized as a 
research tool. 
 
Pathophysiology of ALS 
Although the mechanisms underlying ALS pathogenesis remain to be fully elucidated, emerging 
evidence suggests the importance of genetic factors and dysfunction of vital molecular pathways 
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including oxidative stress, glutamate excitotoxicity, mitochondrial dysfunction, axonal transport 
systems, and dysfunction of glial cells, with resultant damage of critical target proteins and 
organelles within the motor neuron, thereby underlying neurodegeneration (89-94) (Fig. 3).  A 
genetic etiology has been identified in up to 20% of apparently sporadic and 60% of familial 
ALS cases, with at  least 16 genes and genetic loci implicated in ALS pathogenesis (12).    
 
 
 
 
 
 
Glutamate excitotoxicity   
Figure 3:  The pathophysiological mechanisms underlying neurodegeneration in amyotrophic 
lateral sclerosis (ALS) appear to be multifactorial with evidence of a complex interplay between 
molecular and genetic pathways.  Dysfunction of the astrocytic excitatory amino acid transporter 
2 (EAAT2) results in reduced uptake of glutamate from the synaptic cleft and thereby glutamate 
excitotoxicity.  Glutamate-induced excitotoxicity results in increased influx of Na
+
 and Ca
2+
 ions 
and ultimately neurodegeneration through activation of Ca
2+
-dependent
 
enzymatic pathways.  In 
addition, glutamate excitotoxicity results in generation of free radicals which in turn contributes 
to neurodegeneration.  Mutations in the c9orf72, TDP-43 and FUS result in dyregulated RNA 
metabolism that ultimately leads to formation of intracellular aggregates which are harmful to 
neurons.  Of further relevance, mutant SOD-1 enzyme increases oxidative stress, induces 
mitochondrial dysfunction, forms intracellular aggregates and adversely affect neurofilament 
and axonal transport processes.  Activation of microglia results in secretion of proinflammatory 
cytokines, producing further toxicity.  
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Glutamate-mediated excitotoxicity appears to be an important mechanism in ALS pathogenesis 
(2, 95).  Glutamate is the major excitatory neurotransmitter in the central nervous system (96, 
97), synthesized from reductive deamination of alpha-ketoglutarate or from the action of amino 
acids aminotransferases (97). Approximately 20% of the total glutamate pool is stored in 
presynaptic nerve terminals and during impulse transmission; glutamate is released from 
presynaptic neurons through the effects of depolarization, diffusing across the synaptic cleft to 
activate postsynaptic receptors.  Their excitatory signal is terminated upon removal of glutamate 
from the synaptic cleft by specific glutamate re-uptake transporters located on both neurons and 
astrocytes (98, 99).  Within astrocytes, glutamate is converted into glutamine by the enzyme 
glutamine synthetase, and then returned to the neuron for resynthesis of glutamate (100).   
 
Glutamate excitotoxicity is mediated by excessive activation of the postsynaptic glutamate 
receptors (97).  Glutamate receptors are broadly classified into ionotropic or metabotropic 
receptors (97).  Binding of glutamate to ionotropic receptors results in a conformational change 
within the receptor thereby enabling the passage of Na
+
 and Ca
2+
 ions through a central pore.  
Metabotropic glutamate receptors are linked via G-proteins to second-messenger enzymes, 
which in turn can regulate a host of cellular activities (101).  Based on pharmacological studies, 
glutamate ionotropic receptors are further classified as: (i) N-methyl-D-aspartate (NMDA), (ii) 
α-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA), and (iii) kainite receptors.  
This pharmacological classification is supported by cloning studies that have identified six 
different families of glutamate ionotropic receptors that conform to the original agonist studies 
(101).  N-methyl-D-aspartate receptors are permeable to influx of Na
+
 and Ca
2+
 and efflux of K
+
 
(101).   An essential feature of NMDA receptors is their voltage-dependent blockade by Mg
2+
 
25 
 
binding within the channel pore, which can be alleviated by depolarization (102).  NMDA 
receptors are involved in excitatory neurotransmission, which is characterized by a slow rise time 
and decay.  As such, the NMDA receptors are involved in complex physiological processes, such 
as generation of rhythmic motor activity (103), regulation of neuronal migration during 
embryogenesis (104) and in memory (105).   
 
The NMDA receptor complex is composed of different subunits derived from 6 genes; 
NMDAR1 (eight splice variants described), NMDAR2 (A-D) and NMDAR3 (A,B) (97, 101).  
While the NMDAR1 subunit forms the basic structure of the receptor (97), the NMDAR2 
subunit determines ion channel properties and forms ligand-binding sites (106-108).  Functional 
and pharmacological properties of NMDA receptors are determined through specific 
combination of NMDAR1 and NMDAR2 subunits (106, 109).  In addition, there are regional 
variations in the expression of NMDA receptor subtypes (106, 109-115), with the NMDAR3B 
subunit heavily expressed in somatic motoneurons (116, 117).   
 
AMPA receptors mediate a rapid influx of monovalent ions, such as Na
+
, K
+
 and chloride (Cl
-
), 
but unlike NMDA receptors are impermeable to Ca
2+
 (97).  Four AMPA receptor subtypes have 
been cloned (GluR1-4) and are composed of three transmembrane domains (M1, M3, M4) and a 
fourth cytoplasmic hairpin loop (M2), which contributes to the pore-lining region (101, 118).  
The AMPA receptor exists as a pentameric structure in vivo, which is formed by the arrangement 
of subunits to create receptor diversity (97).  The GluR2 subunit influences the Ca
2+
 permeability 
of AMPA receptors, whereby those receptors expressing an immature GluR2 subunit are more 
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permeable to Ca
2+
 ions.  Following activation of these AMPA receptors, excessive influx of Ca
2+
 
results in neurodegeneration through activation of Ca
2+
-dependent pathways (97, 101).   
 
Functional kainate receptors are likely to be heteromeric pentamers of the various kainate 
subunits. It is recognized that the receptor complexes are present in both presynaptic and 
postsynaptic neuronal membranes. It may be that they have inhibitory effects when presynaptic 
receptor complexes are stimulated(119). Studies suggest that the specific kainate receptor subunit 
composition influences function(120). The kainite receptors are thought to modulate slow, albeit 
small, synaptic responses. Their longer duration and the concomitantly longer integration time 
provide synapses with specific integrative capabilities. Kainate receptors are involved in short-
term synaptic plasticity, particularly at the mossy fiber synapses and also seem to be involved in 
long-term plastic phenomena. However, their signal transduction pathways, which are probably 
dual, need to be clarified and despite their wide distribution their exact role in excitability needs 
to be elucidated(121). 
 
The role of glutamate in ALS pathogenesis   
In ALS, glutamate excitotoxicity has been postulated to induce anterior horn cell degeneration 
via a transsynaptic anterograde process mediated by corticomotoneurons (25).  Support for such 
a mechanism has been provided by transcranial magnetic stimulation studies (TMS) which have 
demonstrated that cortical hyperexcitability, a biomarker of glutamate excitotoxicity, is an early 
feature in sporadic and familial ALS, linked to motor neuron degeneration (49, 50, 94, 122-127).  
In addition, longitudinal studies in asymptomatic SOD-1 mutation carriers revealed that cortical 
hyperexcitability developed prior to the clinical onset of ALS (50), a feature also evident in the 
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G93A SOD-1 mouse model (128).  Of relevance, loss of γ-amino butyric acid (GABA) secreting 
parvalbumin-positive inhibitory interneurons in the motor cortex of ALS patients may further 
contribute to the development of cortical hyperexcitability (129), a finding underscored by recent 
neuroradiological studies reporting a significant reduction of GABA within the motor cortex of 
ALS patients (130).    
 
Molecular-based studies have provided further evidence for glutamate-mediated excitotoxicity in 
ALS.  Specifically, molecular studies established significant reduction in the expression and 
function of the astrocytic glutamate transporter (EAAT2), which mediates glutamate reuptake at 
synapses thereby inducing glutamate excitotoxicity, in the superoxide dismutase-1 (SOD-1) 
mouse model and the motor cortex and spinal cord of ALS patients (95, 131-134).  Of further 
relevance, dysfunction of the EAAT2 transporter appears to be a pre-clinical feature in the SOD-
1 mouse model (135, 136), and an increase in the expression and transporter activity of EAAT2 
increases the lifespan of mutant SOD-1 mice (137).  In addition, activation of caspase-1, which 
normally inhibits the EAAT2 transporter, was reported in the SOD-1 mouse model prior to onset 
of motor neuron degeneration and clinical features of ALS (135, 136).  However, the presence of  
EAAT2 appears to delay motor neuron degeneration rather than being a primary process and 
other mechanisms, such as SOD-1 aggregation and caspase-3 activation, appeared to be 
important (138). 
 
At a postsynaptic level, increased expression of AMPA receptors with the unedited GluR2 
subunit has been reported in ALS (139-143).  This editing defect appears to be specific for ALS, 
thereby rendering the motor neurons more permeable to Ca
2+
, potentially explaining the 
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increased sensitivity of motor neurons to excitotoxicity (97, 144).  Further support for glutamate 
excitotoxicity has been provided by the clinical benefit of riluzole in ALS patients (145-149).  
Specifically, riluzole is a glutamate antagonist that exerts effects in the central nervous system by 
reducing the release of glutamate from pre-synaptic nerve terminals and enhancing the reuptake 
of glutamate (150-153).  
 
For the glutamate hypothesis to be a plausible mechanism of motor neuron degeneration in ALS, 
it must explain how motor neurons became selectively damaged through overactivity of the 
glutamatergic system and provide a mechanism by which degeneration occurs.  A number of 
cell-specific molecular features possessed by the motor neurons render them vulnerable to 
glutamate toxicity in ALS.  Motor neurons affected in ALS preferentially express AMPA 
receptors lacking the functional GluR2 subunit, thereby rendering the motor neurons more 
permeable to Ca
2 
  (139, 140, 142, 143).  In addition, motor neurons vulnerable to degeneration 
lack the intracellular expression of proteins parvalbumin and calbindin D28k which are required 
to buffer intracellular Ca
2+
 (154).  Of further relevance, increased expression of the inositol 
1,4,5-triphosphate receptor 2 (ITPR2) gene was reported in ALS (155).  The ITPR2 is involved 
in glutamate-mediated neurotransmission, whereby stimulation of glutamate receptors results in 
binding of inositol 1, 4, 5-triphosphate to ITPR2, which subsequently increases intracellular 
calcium (155, 156).  Aberrant activity of ITPR2 results in higher intracellular concentration of 
Ca
2+
 leading ultimately to neurodegeneration (157).   Of further relevance, motor neurons in 
ALS, at least in animal models, appear to be larger, with an increase in distal dendritic branching 
(158).  Consequently, the input conductance of the motor neurons is increased rendering the 
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motor neuron more vulnerable to electrical and metabolic stresses, in particular those imparted 
by glutamate excitotoxicity (150).  
  
Although details of the molecular mechanisms by which glutamate exerts neurotoxicity are still 
to be fully elucidated, several pathways have been defined.  Initially, an influx of Na
+
 and Cl
- 
 
ions occurs along with water molecules, resulting in acute neuronal swelling that is reversible 
with removal of agonist (159-161).  Subsequently, an influx of Ca
2+
 ions occurs via activation of 
ionotropic receptors such as the NMDA and Ca
2+
-permeable AMPA receptors, as well activation 
of voltage-gated Ca
2+
 channels (159, 162).  Ultimately, activation of these ionic pathways results 
in increased intracellular Ca
2+
 concentration and activation of Ca
2+
-dependent
 
enzymatic 
pathways leading to neuronal death (144, 160, 163, 164).  Further, glutamate excitotoxicity 
results in production of free radicals that can further damage the intracellular organelles thereby 
causing cell death (165-167). 
 
Glutamate excitotoxicity and site of disease onset in ALS 
In his original manuscript, Charcot concluded that in ALS the amyotrophy was, in fact, due to 
spread of the disease from the lateral columns to the spinal and bulbar gray matter as a 
downstream effects (1, 168).  This view was not universal and Charcot‘s contemporary, 
Gower‘s, argued that the degeneration was a uniform and single event. Over the past two 
decades the site of ALS onset has been revisited (11), to a large extent precipitated by the advent 
of modern non-invasive technology such as TMS. Three schools of thought have developed 
pertaining to the role of the UMN, and related pathophysiological processes in ALS:         
30 
 
(i) ―the dying forward‖ hypothesis; (ii) ―the dying back‖ hypothesis and (iii) ―the independent 
degeneration‖ hypothesis (Fig. 2).   
 
The dying forward hypothesis proposed that ALS was primarily a disorder of the 
corticomotoneurons, which connect monosynaptically with anterior horn cells (25).  
Corticomotoneuronal hyperexcitability was postulated to induce anterior horn cell degeneration 
transsynaptically via an anterograde glutamate-mediated excitotoxic process (25, 94).  This 
dying forward hypothesis was based on a number of poignant clinical observations including: (i) 
relative preservation of extraocular and sphincter muscles in ALS, postulated to be due to a 
paucity of corticomotoneuronal projections onto the motor nuclei innervating these muscles; (ii) 
absence of an animal model of ALS, ascribed to a lack of direct corticomotoneuronal-anterior 
horn cell connections (45, 169); (iii) rarity of pure lower motor neuron forms of ALS, with 
subclinical upper motor neuron dysfunction invariably detected with TMS studies (46); and (iv) 
the specificity of dissociated muscle atrophy (20, 21, 44), termed the split hand phenomenon in 
ALS remains best explained by a dying forward mechanism (44) (Chapter 1).    
 
Utilising TMS technology, it is becoming increasingly apparent that cortical hyperexcitability 
develops as an early feature in sporadic and familial ALS, linked to the process of motor neuron 
degeneration (49, 50, 94, 122-126).  Furthermore, longitudinal studies in asymptomatic SOD-1 
mutation carriers established that cortical hyperexcitability developed prior to the clinical onset 
of ALS (50), a feature also reported in the G93A SOD-1 mouse model (128).  In keeping with a 
cortical origin of ALS is the now accepted view that ALS and frontotemporal dementia (FTD) 
represent an overlapping continuum of the same disorder (170, 171), an observation further 
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underscored by recent genetic discoveries that increased hexanucleotide repeat expansions in the 
first intron of C9ORF72 gene (9p21) [see below] was associated with both ALS and FTD (172, 
173).    
 
Some have argued that the development of cortical hyperexcitability in ALS, is not a primary 
event, but rather a compensatory down-regulation of inhibitory control in order to compensate 
for spinal motor neuron loss (174).  This possibility was investigated by undertaking cortical 
excitability studies in Kennedy‘s disease (KD), a slowly progressive, X-linked recessive 
inherited neurodegenerative disorder of motor and sensory neurons (175), resulting from 
increased expansion of the CAG repeat sequence (coding glutamine) in the androgen receptor 
(AR) gene (Xq11-12)  (176).  Threshold tracking transcranial magnetic stimulation (TMS) 
studies in KD patients revealed normal cortical excitability when compared to typical ALS 
patients.  Furthermore, comparison of KD to a pure lower motor neuron variant of ALS (177, 
178), termed flail arm variant ALS, established the presence of cortical hyperexcitability in the 
latter cohort of patients (178).  Together, these findings suggest that the development of cortical 
hyperexcitability does not represent a simple down-regulation of intracortical inhibitory 
processes in ALS.      
 
The dying back hypothesis proposed that ALS was primarily a disorder of the lower motor 
neurons, with pathogens retrogradely transported from the neuromuscular junction to the cell 
body where they exert their deleterious effects (179).  Although some pathological studies have 
indirectly supported a dying back process (180-182), no pathogens of any type have been 
identified in relation to ALS.  The presence of widespread dysfunction within the frontal cortex, 
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including the primary, supplementary and pre-frontal motor cortices in ALS remains difficult to 
reconcile with any dying back process (183-185).  In addition, the absence of central pathology 
in other lower motor neuron disorders such as Kennedy‘s disease or poliomyelitis provides a 
further argument against a dying back process (51, 186).   
 
The independent degeneration hypothesis suggests that the upper and lower motor neurons 
degenerate independently and concurrently (187).  Limited neuropathological studies provide 
indirect support for independent degeneration whereby the degeneration of upper and lower 
motor neurons appeared to be independent (188, 189).  These correlative morphological 
techniques, however, were significantly confounded by the anatomical and functional complexity 
of the corticomotoneuronal system (190).  In particular, there remains considerable variability in 
the corticomotoneuronal to anterior horn cell ratio, due to synaptic changes, and as such, 
attempts to correlate upper and lower motor neurons as a ―one-off‖ on autopsy studies are 
divorced from clinical and in-vivo reality (186).           
 
Oxidative stress and SOD-1 gene 
In concert with glutamate excitotoxicity, oxidative stress appears to be important 
pathophysiological mechanisms in ALS, in part as a result of mutations in the SOD-1 gene (94).  
Mutations in the SOD-1 gene, the first ALS gene reported and mapped to the long arm of 
chromosome 21 [21 q22.1] (191), was postulated to exert pathogenic effects by acquisition of 
aberrant cytotoxic enzyme activity (192-194).   The SOD-1 gene spans 11 kilobases of genomic 
DNA, comprising five exons and four introns (195), and encodes a highly conserved 153-amino 
acid protein, which together with a catalytic copper (Cu) ion and a stabilizing zinc (Zn) ion form 
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a subunit (192, 195).  A disulfide bridge stabilizes each subunit, and the two identical subunits 
combine through non-covalent bonds to form the Cu-Zn SOD-1 enzyme.  The main function of 
the SOD-1 enzyme involves free radical scavenging whereby the enzyme catalyses the 
conversion of the superoxide anion to molecular oxygen and hydrogen peroxide, which in turn is 
reduced to water by glutathione peroxidase and catalase (160, 192, 196).  The Cu-Zn SOD 
enzyme constitutes 0.5-1% of soluble protein in the brain and spinal cord, and is located within 
the cytosol, nucleus and between mitochondrial membranes (192, 197, 198).   
 
To date, 166 SOD-1 mutations have been reported, underlying 14-23% of familial and 1-7 % of 
sporadic ALS cases (192, 199-202).  The majority are missense mutations resulting in a single 
amino acid substitution and preserving the SOD-1 protein length, while nonsense or deletion 
mutations have also been reported that either introduce novel nucleotides or remove existing 
nucleotides resulting in alteration of the polypeptide length (192, 193, 203).  Globally, the most 
frequent mutation is the substitution of aspartate for alanine (D90A), followed by alanine to 
valine (A4V) and isoleucine for threonine (I113T) (192, 193).  An autosomal dominant pattern of 
inheritance is evident with most mutations, except for the D90A mutation, which may be 
transmitted in an autosomal recessive manner.  Intra- and interfamilial variation in penetrance, 
age and site of disease onset, rate of disease progression and survival  has been reported for most 
SOD-1 mutations(192), with  approximately  50% of patients expressing the disease by age 43 
and more than 90% by 70 years (192, 194, 199, 204-206).  Some mutations, such as the I113T 
may be transmitted asymptomatically from grandparents to grandchildren (207, 208).   
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The pathophysiological mechanisms by which SOD-1 gene mutation leads to neurodegeneration 
remains enigmatic (90).  Aberrant biochemical activity of the SOD-1 enzyme (toxic gain of 
function) has been suggested as a potential pathogenic mechanism in ALS (209-213).  
Specifically, SOD-1 mutations may induce structural changes regulating increased production of 
hydroxyl and free radicals (214, 215), as well as nitration of tyrosine residues on proteins (212, 
216, 217).  Evidence for oxidative damage has been inferred from biomarker and pathological 
studies in ALS patients (218-223) as well as studies in the transgenic SOD-1 mouse models 
(213).  While oxidative damage seems an attractive pathogenic mechanism, findings of normal 
SOD-1 activity in some mutants (224), absence of correlation between dismutase activity and 
disease severity (225), and lack of beneficial effects of antioxidants in ALS patients (226), 
suggests that mechanisms other than oxidative stress may contribute to pathogenesis in ALS. 
 
Alternatively, mutations in the SOD-1 gene may lead to conformational instability and 
misfolding of the SOD-1 peptide, resulting in formation of toxic intracellular aggregates.  In the 
transgenic SOD-1 mouse model and human ALS cases, immunoreactive SOD-1 aggregates were 
reported in motor neurons and glial cells (210, 227, 228).  Whether the intracellular aggregates 
were neurotoxic to motor neurons remains unknown, although a number of possible cytotoxic 
mechanisms have been proposed, including; (i) co-aggregation with vital cellular constitutes, (ii) 
inhibition of normal proteosomic function, and (iii) exerting mechanical or biochemical effects 
on the cell, such as disruption of axonal transport systems (90, 209, 210, 229). 
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Mitochondrial dysfunction  
 In conjunction with glutamate excitotoxicity and oxidative stress, there is mounting evidence 
that mitochondrial dysfunction exerts an important role in the pathophysiology of ALS (90, 230-
235).  Mitochondria are intracellular organelles whose main function is to generate energy for 
the cell in the form of ATP.  Under conditions of excessive Ca
2+
 load, as may be evident with 
glutamate excitotoxicity (236), mitochondrial production of free radicals induces  injury of 
critical neuronal cellular proteins and DNA.  In addition, mitochondria remain sensitive to free 
radical damage at both the protein and DNA level, resulting in further mitochondrial dysfunction 
(237). Mitochondrial damage may in turn enhance glutamate excitotoxicity by disrupting the 
normal resting membrane potential, thereby resulting in a loss of the normal voltage-dependent 
Mg
2+
 mediated block of NMDA receptor channels (97, 160).    
 
Mitochondrial degeneration and dysfunction has been reported in ALS patients and in the 
transgenic SOD-1 mouse model (232, 235, 238).  Ultrastructural abnormalities of muscle 
mitochondria, paracrystalline inclusions, and abnormal cristae have been reported in ALS (231, 
234, 239).  Dysfunction of mitochondrial enzymes involved in energy generation, such as 
Cytochrome C Oxidase and respiratory chain complexes I and IV, as well as down-regulation of 
nuclear genes encoding mitochondrial components within the motor cortex have been reported in 
ALS (233, 234, 239-241).  Of further relevance, mitochondrial dysfunction including reduction 
in protein import, impairment in Ca
2+
 sequestering ability and an exaggerated depolarizing 
response of the inner mitochondrial membrane to  Ca
2+
 stimulation may occur in the pre-
symptomatic stages of ALS (242-246).  Ultimately, severe damage to the mitochondrial 
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membrane potential, respiration, and electron transfer chain ensues, resulting in reduced ATP 
synthesis and neurodegeneration (150).   
 
The transportation and distribution of mitochondria within the neurons appears to be impaired in 
ALS (150).  Mitochondria are normally highly mobile organelles, evident in both the axons and 
dendrites (247).  The movement of mitochondria is regulated through Ca
2+
 signalling and 
synaptic activity (247).  An increase in intracellular Ca
2+
 concentration, as occurs with glutamate 
excitotoxicity, interrupts the movement of mitochondria within the cell, in particular at the level 
of the synapse (248).  Abnormalities of mitochondrial distribution and transport have been 
reported in ALS, with evidence of reduced distribution in the axons and more frequent pauses in 
mitochondrial movements (249).  Importantly, the slow and fast axonal transport systems, vital 
for mitochondrial transport, seem to be impaired in ALS and have been linked to glutamate 
excitotoxicity (150, 249, 250).  Ultimately, this interruption in mitochondrial mobility may result 
in depletion of energy supply in critical neuronal segments, essential for the maintenance of the 
resting membrane potential and generation of action potentials, with resultant neuronal 
degeneration.    
 
From a therapeutic perspective, a recent phase II trial of dexpramipexole, a pharmacological 
agent that enhances mitochondrial function (251), was shown to be effective in slowing ALS 
disease progression and reducing mortality over a 24 week period potentially offering hope in 
ALS (252).  Unfortunately, a phase III, multicenter international trial, undertaken to assess the 
clinical efficacy of dexpramipexole as add on therapy to riluzole in ALS, was shown to be 
ineffective (253).   
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Other molecular mechanisms  
Other mechanisms like impairment of axonal transport systems (229, 254, 255), dysfunction of 
endosomal trafficking (229, 256-258) along with neuroinflammation (259-261) and endoplasmic 
reticulum stress response (262, 263) have all been implicated in ALS pathogenesis.  While these 
mechanisms contribute to neurodegeneration, they appear to be secondary events in ALS. 
 
Non-cell autonomous processes  
An emerging concept in ALS pathogenesis pertains to non-cell autonomous processes, whereby 
neighbouring glial cells mediate motor neuron cell death (92, 95, 264).  Studies in transgenic 
mouse models reported that modulation of mutant SOD-1 expressed in microglia, slowed disease 
progression (264).  In addition, astrocytes expressing the mutant SOD-1 gene exerted toxic 
effects in cultured primary motor neurons(265, 266), and silencing of mutant SOD-1 genes in 
astrocytes significantly slowed disease progression (267).  Importantly, non-neuronal cells 
appear to be important in regulating disease progression rather than initiating motor neuron 
disease (259, 264), and an interaction between motor neurons and non-neuronal cells seems to be 
critical in ALS pathogenesis (268-270).   The mechanisms by which non-neuronal cells exert 
toxicity remain unclear, although multiple interacting mechanisms appear to be responsible 
(271).  Specifically, impairment of passive properties of astrocytes, such as uptake or recycling 
of neurotransmitters and regulation of extracellular ion homeostasis, along with activation of 
microglia cells with consequently increased secretion of neurotoxic agents, such as glutamate 
and pro-inflammatory cytokines, appear to be important mechanisms (92).    
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Insights into pathogenesis from recent advances in ALS genetics  
C9orf72 hexanucleotide expansion   
A major advance in the genetic understanding of ALS pathogenesis occurred with the discovery 
of the dominantly inherited c9orf72 gene [increased hexanucleotide repeat expansion 
(GGGGCC)], which appeared to underlie over 40% of familial and 20% of sporadic ALS cases 
in the original series (172, 173), although subsequent studies have established a frequency of 4.1-
8.3% of c9orf72 mutations in apparently ―sporadic‖ ALS cases (272).  This monumental 
discovery has radically altered the understanding of ALS pathogenesis, implying that ALS is a 
multisystem neurodegenerative disorder, rather than a pure neuromuscular disease (12), with 
potentially central origins.  Underscoring this notion are findings that the c9orf72 hexanucleotide 
expansions are causative in both ALS and frontotemporal dementia (172, 173).  Importantly, 
accumulation of TDP-43 along with p62 positive TDP-43 negative inclusions in hippocampus 
and cerebellar neurons appears to be the neuropathological hallmark of c9orf72 associated ALS 
and FTD (273), suggesting the existence of a common pathophysiological pathway. 
 
The mechanisms by which c9orf72 gene expansion leads to neurodegeneration in ALS remains 
to be fully elucidated (172, 173), although three potential pathogenic mechanisms have been 
proposed, including (i) haploinsufficiency, (ii) repeat RNA-mediated toxicity and (iii) dipeptide 
protein toxicity related to repeat associated non-ATG (start codon) translation (RAN) of the 
expanded c9orf72 gene (274).  Evidence for haploinsufficiency is suggested by studies reporting 
a reduction in the c9orf72 short and long isoforms in ALS patients (172, 173, 275), although a 
reduction in the corresponding c9orf72 protein is yet to be established.  In addition, reduced 
expression of the c9orf72 transcript in the zebra fish model of ALS resulted in motor axonal 
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degeneration with locomotion deficit, providing additional support for the notion that 
haploinsufficiency may be a contributing factor in ALS pathogenesis (276).    
 
Of further relevance, RNA-mediated toxicity, via sequestration of RNA-binding proteins, has 
also been proposed as a potential pathophysiological mechanism.  Such a mechanism was 
inferred from observations of intranuclear RNA foci containing c9orf72 hexanucleotide repeats 
(173), and supported by findings that specific RNA-binding proteins (hnRNP A3 and ADARB2) 
associate with the c9orf72 expansion resulting in formation of intranuclear and cytoplasmic 
inclusions (277).  More recently, studies utilizing induced pluripotent stem cell differentiated 
neurons from C9orf72 patients provided additional support for RNA toxicity, questioned the 
haploinsufficiency  theory, and importantly established that the pathophysiological and 
pathological changes were mitigated by antisense oligonucleotide therapeutic approaches (278).  
 
In addition, non-ATG related translation of the c9orf72 expansion, referred to as RAN 
translation(279), has also been proposed as a potential pathogenic mechanism (280, 281).  
Specifically, RAN translation results in generation of insoluble di-peptides (anti-C9RANT), 
which form intraneuronal (nuclear and cytoplasmic) inclusions within the CNS and appear to be 
specific for c9orf72 associated ALS/FTD (281).  Given that neuronal degeneration and 
dysfunction may result from accumulation of insoluble proteins, and that C9RANT-positive 
pathology appears specific for c9orf72 related ALS/FTD, novel therapeutic strategies aimed at 
modulating such a process, including the aforementioned antisense strategies, may prove useful. 
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Transactive-region DNA-binding protein (TARDBP) and fused in sarcoma 
(FUS)  Mutations in DNA/RNA-processing genes, transactive-region DNA-binding protein 
gene (TARDBP) (282) and fused in sarcoma (FUS) gene (283) have also been linked with 
development of ALS, representing 4-6% of familial and 0.7-2% of sporadic ALS (202, 284).  
TDP-43 and FUS are ubiquitously expressed proteins involved in DNA repair, regulation of 
RNA translation, splicing, transport, micro RNA biogenesis and formation of stress 
granules(274, 285-288).  To date, approximately 50 mutations have been identified in each gene, 
and most mutations are dominantly inherited (282, 289).  The mutations are localized to a highly 
conserve C-terminal glycerine-rich domain of the protein (282), while FUS mutations are located 
in the C-terminal nuclear localization signal domain that appears important in translocation of 
the FUS protein into the nucleus (289).  The mutant proteins (TDP-43 and FUS) are redistributed 
from the nucleus to the cytoplasm, resulting in toxicity. Although most TARDBP and FUS 
mutation cases exhibit an ALS phenotype; association with FTD and Parkinsonism has been 
reported (290-297). 
 
While the pathophysiological mechanisms by which mutations in these RNA-processing genes 
result in motor neuron degeneration remains to be fully defined, emerging evidence suggests the 
existence of multiple mechanisms including gain of toxicity, loss of nuclear function, or 
formation of large stress granules(274).  Support for a toxic gain of function has been provided 
by studies in the transgenic mouse models, whereby increased expression of the mutated TDP-43 
protein levels leads to neurodegeneration through dysfunction of cellular organelles and 
proteins(298-305).  The severity of cortical and spinal motor neuron degeneration appears 
proportional to the TDP-43 protein levels (299), suggesting a potential role for TDP-43 in 
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regulating disease severity.  Alternatively, loss of nuclear TDP-43 accompanied by accumulation 
of TDP-43 aggregates in the cytoplasm has been well established in ALS patients(306), implying 
a potential role for a TDP-43 loss of nuclear function mechanism in ALS pathogenesis.  
Emerging evidence from transgenic mouse models provides support for such a notion, whereby 
inactivation of the TARDBP gene leads to development of the ALS phenotype (307, 308).  As 
with TDP-43, the finding of cytoplasmic FUS positive inclusions in ALS patients (283, 289) 
implies a loss of nuclear function of FUS as a potential mechanism in ALS pathogenesis.  
Support for such a notion was provided by studies demonstrating that expression of a FUS 
variant in transgenic mice, at lower levels than endogenous FUS, leads to selective motor neuron 
degeneration (309).  Conversely, a toxic-gain of function of mutated FUS has also been inferred 
from studies demonstrating that expression of mutated FUS in Caenorhabditis elegans leads to 
progressive motor dysfunction in that could not be rescued by over expression of wild-type FUS 
(310).   
 
Of further relevance, TDP-43 and FUS associate with cytoplasmic stress granules, that under 
physiological conditions function to temporarily suppress translation of mRNA and store pre-
RNA complexes during periods of cellular stress, thereby safe-guarding the coded RNA 
information from deleterious chemicals (285, 311, 312).  Pathological TDP-43 and FUS mutants 
appear to exhibit a greater propensity to associate with cytoplasmic stress granules and to form 
larger stress granules with altered dynamics (283, 285, 313-315).  While the mechanisms by 
which altered stress granule dynamics induce neuronal degeneration in ALS remains to be fully 
elucidated, sequestration of RNA-binding proteins and repression of RNA translation along with 
formation of pathological inclusions have been proposed as potential mechanisms(285, 316-318). 
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Interestingly, a two-hit hypothesis has been proposed for FUS related ALS, whereby 
mislocalization of the mutated FUS protein may occur as the first step followed by cellular stress 
which induces formation of cytoplasmic inclusions and ultimately neurodegeneration (283, 317).    
Therapeutic interventions involving FUS or TDP43 are far more challenging and require a better 
understanding of the mechanisms of toxicity. 
 
Other genes in ALS 
Mutations in genes regulating ubiquitination (ubiquilin-2, UNC13A)(319, 320), endosomal 
trafficking [vesicle-associated membrane protein/synatobrevin-associated protein, charged 
multivesicular body protein ] (256, 257, 321), autophagy and protein homeostasis (valosin-
containing protein, optineurin, p62/SQSTM1) (322-324), have all been associated with ALS.  
These genetic mutations are dominantly inherited and appear to exert a pathogenic effect by 
disrupting the function of vital cellular processes ultimately leading to neurodegeneration (274).   
 
Axonal Excitability Testing 
Indirect information regarding resting membrane potential and axonal ion channel function may 
be gained through axonal excitability studies by using a technique called threshold tracking (85, 
86).  Threshold in this context refers to the stimulus current required to produce a specific 
potential.  With threshold tracking, changes in the test stimulus current intensity required to 
generate a preset amplitude can be adjusted on-line to keep the target amplitude constant (see 
Methodology).  Assessment of axonal excitability, and thereby axonal ion channel function, may 
provide unique insights into mechanisms underlying the generation of symptoms in ALS, such as 
fasciculations and cramps, as well as processes responsible for motor neuron degeneration in 
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ALS (56, 57, 325-327). Using a recently developed protocol, the following parameters of axonal 
excitability are measured: threshold; strength-duration time constant; rheobase; threshold 
electrotonus; current/threshold relationship; and recovery cycle. 
 
(i)  Threshold  
Threshold is defined as the stimulus current required to activate an axon or to produce a 
compound muscle action potential of fixed size and can be used as a surrogate marker of 
membrane potential (85). Threshold may be utilised as a surrogate biomarker of membrane 
potential, whereby membrane hyperpolarization increases and depolarization decreases the 
membrane threshold.  It should be stressed that threshold may not accurately reflect membrane 
potential, in conditions such as hyperventilation or nerve ischemia, and in such circumstances the 
ambiguity may be resolved by measuring other indices of axonal excitability (328-332).   
 
(ii)  Strength duration time constant and rheobase  
The strength-duration time constant (SD), also known as chronaxie, is a measure of the rate at 
which the threshold current for a target potential declines as the stimulus duration is increased 
(333-335). In human peripheral nerves, SD can be calculated by using the ratio between 
stimulus-response curves for two different stimulus durations according to Weiss' formula (336).  
Rheobase is the threshold current (mA) for stimulus of infinitely long duration (85). Both the SD 
and rheobase are properties of the nodal membrane, being dependent on passive membrane 
properties and persistent Na
+
 channel conductances [INaP] (337).  
 
44 
 
Persistent Na
+
 currents, which constitute 1-2% of the total Na
+
 current  (337-339), are conducted 
through voltage-gated Na
+
 channels composed of one alpha (α) and four beta (β1-4) subunits 
(340, 341).  The α subunits are organized in four homologous domains (I-IV), each consisting of 
six transmembrane α helices (S1-S6) and a pore loop located between the S5 and S6 segments 
that acts as a selectivity filter.  The S4 segments of each domain functions as a voltage sensor.  
Inactivation of Na
+
 channels is mediated by a short intracellular loop connecting homologous 
domains III and IV, which fold into the channel structure and blocks the pore from the inside 
during sustained membrane depolarization.  Inactivation of INaP is either very slow or incomplete 
(342).  To date, ten distinct Na
+
 channel isoforms have been identified, Nav 1.1 to Nav 1.9 and 
Nax (340, 341, 343), with INaP conducted by the Nav1.6 isoform which is expressed at the nodes 
of Ranvier  (340, 341, 343, 344).   
 
Although the exact mechanisms underlying INaP are yet to be determined, it has been suggested 
that a uniform population of Na
+
 channels may generate both transient and persistent Na
+
 
currents by switching between different gating modes (345).  Phosphorylation of amino-acid 
residues within the alpha subunit of voltage-gated Na
+
 channels may underlie these gating 
changes (346, 347).   
 
The strength duration-time constant and rheobase may be influenced by the resting membrane 
potential, such that depolarization reduced the rheobase and prolonging the SD , while 
hyperpolarization exerts the opposite effects.  In addition, changes in nerve architecture, as may 
occur with axonal loss or demyelination, may also influence the SD, as may discrete changes in 
nodal Na
+
 conductances (348-351).  In ALS, the SD is prolonged, thereby suggesting that 
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upregulation of INaP may underlie the generation of fasciculations and cramping, as well as 
neurodegeneration (49, 56, 58, 59, 126, 351, 352). 
 
(iii)  Threshold Electrotonus  
Threshold electrotonus describes the changes in threshold produced by long-lasting subthreshold 
currents and provides insight into into both nodal and internodal membrane conductances (86). 
Conditioning currents are subthreshold and do not trigger an action potential, but rather result in 
local changes in the membrane potential (85, 86).  TE is usually measured with 1 ms current 
pulses, a duration which is long compared to the time constant of the nodes of Ranvier but short 
compared with the time constants of the internodal membrane and slowly activating ion channels 
(353).  Changes in threshold current are measured at varying conditioning-time intervals in 
response to a subthreshold conditioning current (354, 355).   Conventionally, TE is plotted such 
that an increase in excitability (threshold reduction) produces an upwards deflection and a 
decrease in excitability a downward deflection.  This convention was adopted so that changes in 
threshold electrotonus would resemble the underlying changes in membrane potential. The 
threshold tracking protocol of axonal excitability testing utilizes test stimuli of 1-ms duration to 
produce the target CMAP response (40% of maximal) and changes in threshold induced by 
subthreshold polarizing currents of 100 ms in duration, set to + 40% (depolarizing) and − 40% 
(hyperpolarizing) of the control threshold current (354).   
 
The initial fast response (―F‖ phase, Fig. 4) reflects rapid changes in threshold at the node of 
Ranvier, resulting from the application of either a depolarizing or hyperpolarizing subthreshold 
current.  Subsequently, an ―S1‖ phase develops, as indicated by slower changes in threshold over 
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tens of milliseconds in depolarizing and hyperpolarizing directions, and reflects the spread of 
current to the internodal membrane (Fig. 4). During depolarization, the S1 phase peaks at 20 ms 
after the onset of the current pulse, after which threshold begins to return to baseline, the S2 
phase.  This S2 phase occurs due to activation of nodal and internodal slow K
+
 channels (86, 
356).   
 
In hyperpolarization, the S1 phase peaks at 100-150 ms after the onset of the subthreshold 
conditioning current and proceeds to return to baseline thereafter, termed the S3 phase (Fig. 4).  
The S3 phase probably reflects activation of inward rectifying currents (IH) (85, 86, 357, 358).  
On termination of the subthreshold conditioning currents there is an overshoot of threshold with 
both depolarization and hyperpolarization.  With depolarization, slow K
+
 channels mediate the 
overshoot, while in hyperpolarization the overshoot is mediate by IH. 
 
Voltage-gated K
+
 channels are members of the voltage-gated ion channel protein superfamily 
(359), and are composed of four alpha pore-forming subunits and accessory β subunits (360).   
Voltage-gated K
+ 
currents are activated by depolarization, and three types of currents have been 
identified, including two fast (IKf1 and IKf2) and one slow current (IKs).  The slow (S) channels 
underlie the S2 phase of TE, exhibit slower deactivating kinetics and are located at both the node 
and internode (357, 361-365).  The main function of S channels is to limit inappropriate 
repetitive firing of axons after an action potential and to maintain the internodal resting 
membrane potential (361, 366). 
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Threshold electrotonus is influenced by changes in the membrane potential such that 
depolarization leads to a reduction in the S1 and S2 phases, termed ―fanning in‖ appearance,  and 
is due to activation of paranodal and internodal K
+
 channels (85, 86, 367).  Conversely, 
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Figure 4:  Threshold changes to polarising currents of 100 ms duration set to ± 40% of resting 
threshold.  Changes are plotted with threshold reductions, with depolarisation represented as an 
upward deflection and hyperpolarization in a downward direction.   
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hyperpolarization closes the paranodal and internodal K
+
 channels, thereby increasing the S1 and 
S2 phases producing a fanning out appearance (85, 86, 367). 
 
Changes in TE were described in ALS, with two distinct responses previously reported, 
including (i) the type I response, whereby greater threshold reductions in TE were evident during 
depolarization and (ii) type II response, describing an unexpected rapid increase in threshold 
during depolarisation (56, 368).  Reduction in internodal slow K
+
 channel conduction was 
reported as the underlying mechanism.  Importantly, abnormalities of TE have also been reported 
in autoimmune neuropathies, such as multifocal motor neuropathy (369), in metabolic and 
chemotherapeutic related neuropathies (357, 370-376). 
 
(iv) Current threshold relationship (I/V)  
The current-threshold relationship (I/V, Fig. 5) refers to changes in threshold occurring in 
response to long duration subthreshold currents (200ms duration) that are applied in a ramp like 
fashion from +50% (depolarizing) to −100% (hyperpolarizing) of the control threshold in 10% 
steps (354, 355).  Conventionally, threshold increases are plotted to the left and threshold 
decreases to the right (Fig. 5).  The I/V relationship estimates rectifying properties of both nodal 
and internodal axonal segments (86).  The I/V gradient induced by depolarizing sub-threshold 
currents reflects conduction through outward rectifying K
+
 channels, while the I/V gradient 
during hyperpolarizing sub-threshold currents reflects inwardly rectifying conductances [IH] 
(86).    
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Figure 5:  Current-threshold relationship:  normalised threshold changes at the end of 200 ms 
duration currents are plotted, with depolarization represented to the right and hyperpolarization 
to the left.  The conditioning current is varied from +50 % to –100 % of control threshold. 
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Two types of current underlie inward rectification (377).  The first type, the classic inward 
rectifier, is a pure K
+
 conducting channel, which is activated at membrane potentials negative to 
the K
+
 equilibrium potential (378, 379).  The second type of inward rectification is mediated by a 
channel that exhibits conductance for both Na
+
 and K
+
 (380, 381).  This current begins to 
activate at between -45 mV and -60 mV and peaks at -110 mV(378, 382).  The second IH current 
activates and deactivates slowly, and the magnitude of the IH current is also dependent on 
extracellular K
+
 concentration (381).   
 
A major function of internodal IH is to limit axonal excitability in response to high-frequency 
activity (380).  The IH current may be critical in preventing conduction failure resulting from 
high-frequency activity which can induce failure of impulse conduction in axons with a reduced 
safety factor of transmission (383).  Motor nerves may have a predilection to develop activity-
dependent conduction failure when affected by disease, particularly primary demyelinating 
neuropathies (384, 385), in contrast to sensory nerves, due to the reduced expression of IH in 
motor nerves (386, 387).  
 
(v) The recovery cycle of axonal excitability  
Following conduction of an action potential, axons undergo a series of stereotyped excitability 
changes known as the recovery cycle (Fig. 6).  Initially, a period of total axonal inexcitability 
develops lasting for 0.5-1 ms during which the axon cannot generate an action potential, termed  
absolute refractory period.  Subsequently, the axon enters a relative refractory period (RRP), 
which may last for up to 4 ms, during which an action potential may be generated by a stronger 
than normal stimulus current.  The RRP may be measured as either the point at which the 
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recovery cycle curve crosses the x-axis (ms) or as an increase in current required to generate a 
potential [termed refractoriness] (Fig 6).  
 
The absolute refractory period results from inactivation of nodal voltage-gated transient Na
+
 
channels, while the RRP results from gradual recovery of these channels from inactivation (388).  
These transient Na
+
 channels are of the Nav1.6 isoform, and consist of alpha and beta (β) 
subunits (341), and exhibit ―fast‖ activation and inactivation kinetics, namely the channels open 
rapidly with depolarization and inactivate rapidly (341, 389).  Transient Na
+
 currents appear to 
underlie the rapid phase of depolarization of the action potential (85).   
 
Changes in membrane potential influence Na
+ 
channel kinetics, and thereby affect refractoriness 
(85).  At resting membrane potential, ~ 30% of Na
+ 
channels are inactivated and with 
hyperpolarization there is a shift to reduce the degree of ―inactivated‖ Na+ channels leading to a 
decrease in refractoriness. Conversely, depolarizing increases the extent of Na
+ 
channel 
inactivation and thereby increases refractoriness (85).  In addition, refractoriness is extremely 
temperature sensitive, with refractoriness being increased by reduction in limb temperature (390, 
391). 
 
Refractoriness is followed by a period of increased axonal excitability, termed superexcitability, 
which may last for ~ 15 ms and is mediated by re-excitation of the nodal membrane by the 
current spreading from the internodal membrane following an action potential, the depolarizing 
long-lasting after depolarization [DAP] (392).  The amplitude and time course of DAP is limited 
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Figure 6:  Recovery cycle of excitability is assessed by tracking the changes in threshold that 
occur following a supramaximal conditioning stimulus of 1-ms duration.  RRP refers to the 
relative refractory period. 
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by activation of paranodal and juxtaparanodal K
+
 channels, which serve to reduce the degree of 
DAP, and thereby superexcitability, by shunting the internodal current (393).  Paranodal K
+
 
channels are classified into fast (F) channels and intermediate (I) channels (363, 364, 394).  F 
channels are activated at potentials between -40 and +40 mV and deactivate very rapidly at 
potentials between -120 mV and -65 mV (365, 395, 396).  In contrast, I channels are first 
activated by depolarization to around -70 mV, become fully activated at around -40 mV and 
deactivate slowly (396).   
 
Superexcitability is influenced by changes in membrane potential, such that membrane 
depolarization reduces superexcitability by limiting Na
+
 influx and increasing K
+
 efflux through 
paranodal and juxtaparanodal fast K
+
 channels (397).  Conversely, membrane hyperpolarization 
increases DAP and therefore superexcitability.  As such, superexcitability may be used as an 
indicator of membrane potential (354).   
 
The last phase of the recovery cycle, referred to as late sub excitability, denotes a reduction in 
axonal excitability and lasts for ~ 100ms.  Late sub excitability is mediated by activation of 
nodal slow K
+
 channels (380) and is influenced by both the membrane potential and the K
+
 
equilibrium potential.  Consequently,   current induced membrane depolarization would serve to 
increase late sub excitability, while membrane depolarization secondary to increases in 
extracellular K
+
 concentration, as may occur with ischemia or renal failure, will lead to reduction 
of late subexcitability (367, 370, 373, 398). 
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Assessment of cortical excitability  
In order to assess the function of the central nervous system, and thereby shed further light on 
ALS pathophysiology, transcranial magnetic stimulation (TMS) was utilised.  TMS is a 
relatively painless neurophysiological technique which non-invasively stimulates the human 
motor cortex, and was first described by Barker and colleagues (399).   
 
Principles of magnetic stimulation 
Magnetic stimulators consist of a capacitor, a device for storing charge, which when discharged, 
initiates a flow of current through a coil and generates a magnetic field.  The magnetic field 
induces an electric field in a nearby conductor (cortical neurons), thereby resulting in current 
flow and neural stimulation (400, 401).  The position at which the nerve is excited by magnetic 
stimulation depends on the voltage gradient parallel to the nerve fibre.  Given that neural 
anatomy in the brain is complex, the point of excitation occurs at bends, branch points or at the 
transition from cell body to axon (402).  As such, the orientation of neurons, relative to the 
induced electric field, is critical in determining which neurons are activated. 
 
Importantly, the physical properties of the coil also influence neural excitation, such that circular 
coils induce maximum current at the coil circumference.  Consequently, coils placed at the 
vertex, with the edge overlying the hand area, will preferentially stimulate the primary motor 
area.  Of further relevance, the more focal ―figure-of-eight coil‖, formed by two smaller adjacent 
circular coils, requires specific positioning and orientation over the motor cortex to ensure 
adequate activation (400, 401, 403).  The direction of current flow will dictate which hemisphere 
is stimulated, with current flowing from a posterior-anterior direction (i.e. inion to nasion) most 
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effective at stimulating the motor cortex.  For a circular coil positioned at the vertex, clockwise 
current in the coil (viewed from above) stimulates the right hemisphere (400, 401, 403).   
 
From animal experiments it has been demonstrated that cortical stimulation results in generation 
of complex corticomotoneuronal volleys composed of direct  [D]-waves (due to direct 
stimulation of the corticospinal axon) and multiple indirect  [I]-waves arising from transsynaptic 
excitation of pyramidal cells via excitatory cortical interneurons (404).  In humans, TMS 
activates the motor cortex at a depth of approximately 1.5 to 2.1 cm (405) and cervical epidural 
recordings have confirmed the presence of D and I-waves, at intervals of 1.5-2.5 ms (406, 407).  
The I-waves are numerically labelled such that the first I-wave is called I1, the second I2, the 
third I3 and so on (407).  I-waves are best elicited by cortical currents directed in a posterior-
anterior direction, whereas D-waves are produced preferentially if the current runs in a lateral to 
medial direction (408-412).  The production of I-waves may not be sequential, such that I3 
waves may be recruited initially, prior to prior to other I-waves, if the stimulating conditions are 
optimal (413).  Although numerous models have been proposed to attempt to explain how I-
waves are produced within the motor cortex, the mechanisms continue to remain elusive (414). 
 
In the clinical setting, and for the purpose of this thesis, the assessment of cortical excitability 
and the integrity of corticospinal pathways are best assessed by measuring the following 
parameters: (i) threshold; (ii) motor evoked potential (MEP) amplitude; (iii) central conduction 
time; (iv) cortical silent period; and (v) short interval intracortical inhibition and facilitation. 
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(i) Motor threshold 
Motor threshold (MT) reflects the ease with which corticomotoneurons are excited and is 
proposed to be assessed by the International Federation of Clinical Neurophysiology as the 
minimum stimulus intensity required to elicit a small (usually >50 μV) motor evoked potential 
(MEP) in the target muscle in 50% of trials (415).  With recent adaptation of threshold tracking 
techniques, MT can also be measured as the stimulus intensity required to elicit and maintain a 
target MEP response of 0.2 mV (416-418).  Motor threshold reflects the density of 
corticomotoneuronal projections onto spinal motor neurons, with intrinsic hand muscles 
exhibiting the lowest MTs due to the highest density of projections (419-421).  MTs are lower in 
the dominant hand (421) and correlate with the ability to perform fine fractionated finger 
movements (422) as well as reflecting the density of corticomotoneuronal projections, MTs may 
also be a biomarker of cortical neuronal membrane excitability (405, 423, 424).  Motor 
thresholds are influenced by the glutamatergic neurotransmitter system, through AMPA 
receptors, whereby excessive glutamate activity reduces MTs (425). In contrast pharmacological 
blockade of voltage-gated sodium channels raises MT (426).  Of further relevance, MTs are 
influenced by the state of wakefulness and by the extent of target muscle activation (400, 427). 
 
In ALS, abnormalities in MT have been inconsistent. While some TMS studies reported an 
increased MT or even an inexcitable motor cortex (428-435), others have documented either 
normal or reduced MT (49, 50, 122, 174, 436, 437).  Importantly, longitudinal studies have 
established a reduction of MTs early in the disease course, increasing to the point of cortical 
inexcitability with disease progression (437).  The early reduction in MTs appears most 
pronounced in ALS patients with profuse fasciculations, preserved muscle bulk and hyper-
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reflexia (186).  Fasciculations may precede other features of ALS by many months and taken in 
association with reduced MT may in some cases suggest a cortical origin of fasciculations (438).  
Glutamate excitotoxity along with reduced GABA inhibition may underlie the development of 
reduced motor thresholds in ALS. As such, a reduction of MT early in the disease process may 
supports an anterograde transsynaptic process, whereby cortical hyperexcitability underlies the 
development of progressive neurodegeneration.  
 
(ii)  Motor evoked potential (MEP Amplitude)  
The MEP amplitude reflects a summation of complex corticospinal volleys consisting of D and I 
waves onto the spinal motor neuron (423, 439).  At threshold, TMS elicits I-waves at intervals of 
1.5 ms, that increase in amplitude with increasing stimulus intensity (439).  The increase in MEP 
amplitude with increasing stimulus intensity may be utilised to generate a stimulus-response 
curve which follows a sigmoid function (440).  The MEP amplitude reflects the density of 
corticomotoneuronal projections onto spinal and bulbar motor neurons (441), but probably 
assesses the function of cortical neurons that are less excitable or are positioned further away 
from the centre of the TMS field (401).  In order to account for LMN dysfunction, the MEP 
amplitude should be expressed as a percentage of the maximum peripheral CMAP response 
(415).  It should be stressed that the sensitivity, and thereby diagnostic utility of the MEP/CMAP 
ratio in detecting UMN dysfunction, is limited by a large inter-subject variability (401, 442).  
 
The MEP responses may also be modulated by a variety of neurotransmitter systems within the 
central nervous system (441, 443).  Specifically, GABAergic neurotransmission via GABAA 
receptors suppresses while glutamatergic and noradrenergic neurotransmission enhances the 
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MEP amplitude (444).  Of interest, these changes in MEP amplitude occur independently of MT 
changes, suggesting that physiological mechanisms underlying the generation of the MEP 
amplitude and MT are varied. 
 
In ALS, abnormalities of MEPs have been extensively documented (87, 401).  Specifically, the 
MEP amplitude is reportedly increased in both the sporadic and familial forms of ALS, being 
most prominent in early stages of the disease process (31, 49, 50).  In addition, the MEP 
amplitude correlates with surrogate biomarkers of axonal degeneration, thereby providing an 
association between cortical hyperexcitability and motor neuron degeneration (49, 126).  The 
increase in MEP amplitude in ALS is not evident in mimic disorders, despite a comparable 
degree of LMN dysfunction, arguing against the notion that such increases represent simple 
cortical plasticity (51-53, 445).   
 
(iii) Central motor conduction time (CMCT)  
Central motor conduction time refers to the time from stimulation of the motor cortex to the 
arrival of corticospinal volley at the spinal motor neuron (415).  Multiple factors contribute to the 
CMCT including, time to activate the corticospinal cells, conduction time of the descending 
volley down the corticospinal tract, synaptic transmission and activation of spinal motor neurons 
(446).  The CMCT may be calculated by using either the F-wave method (see Methodology) or 
cervical (or lumbar) nerve root stimulation methods (447, 448).  Given that both methods 
estimate the CMCT (400, 446), and that a variety of technical, physiological and pathological 
factors influence CMCT (446), a range of normative CMCT data exists.  
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In ALS, CMCT is may be prolonged in approximately 20% of cases (430, 437, 449),  probably 
reflecting degeneration of the fastest conducting corticomotoneuronal axons and/or increased 
desynchronization of corticomotoneuronal volleys secondary to the axonal loss (436, 450, 451). 
Assessment of CMCT may be especially useful when UMN signs are equivocal (430, 437).  The 
sensitivity of detecting a prolonged CMCT may be improved by recording from both upper and 
lower limb muscles, or from cranial muscles in ALS patients with bulbar-onset disease (87, 403, 
435).  
 
(iv)  Cortical silent period (CSP)  
The cortical silent period (CSP) refers to the interruption of voluntary electromyography (EMG) 
activity in a target muscle induced by a magnetic stimulation over the contralateral motor cortex 
(452).  The CSP duration is measured from the onset of the MEP response to resumption of 
voluntary EMG activity (441, 452).  Increases in magnetic stimulus intensity lead to more 
prolonged CSP duration (452-454).   
 
The mechanisms underlying the development of CSP appear complex.  The early segment of the 
CSP is mediated by spinal processes (453, 455), while the late segment of is mediated by long-
lasting inhibitory post-synaptic potential (IPSP), generated via gamma-aminobutyric acid type B 
(GABAB) receptors (401, 453, 455, 456), a notion supported by pharmacological studies (457, 
458).  GABAB receptors are metabotropic receptors that couple to Ca
2+
 and K
+
 channels via G 
proteins and second messenger systems and  are located at both the pre-and postsynaptic nerve 
terminals (459).  Post-synaptic GABAB receptors mediate CSP by inducing an increase in K
+
 
efflux upon activation of a specific G-protein, thereby resulting in hyperpolarization of the 
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postsynaptic membrane (459).  In contrast, presynaptic GABAB receptors mediate inhibition of 
voltage-gated Ca
2+
 channels resulting in inhibition of neurotransmitter release (460-462).  In 
addition to being modulated by GABAB receptors, CSP is also influenced by density of the 
corticomotoneuronal projections onto motor neurons, motor attention, the extent of voluntary 
drive and other neuromodulators, such as dopamine (401, 426, 463, 464). 
 
In ALS, abnormalities of CSP duration are well documented (441).   Specifically, an unchanged 
or reduced CSP duration both have been reported in ALS, with CSP duration reduction being 
most prominent early in the disease process (49-51, 125, 174, 445, 449, 465-467).  The reduction 
of CSP duration appears to be specific for ALS among neuromuscular disorders, being normal in 
Kennedy‘s disease, acquired neuromyotonia and distal hereditary motor neuronopathy with 
pyramidal features (51-53, 445).  Although the mechanisms underlying CSP duration reduction 
in ALS remain to be fully established, decreased motor drive and reduced GABAergic inhibition, 
either due to degeneration of inhibitory interneurons or dysfunction of GABAB receptors, may 
underlie the reduction of CSP duration in ALS.   
 
(v)  Paired-pulse techniques 
Transcranial magnetic stimulation may assess cortical excitability via a paired-pulse technique in 
which a conditioning stimulus modulates the effects of a second test stimulus.  Several different 
paired-pulse paradigms have been developed (87, 401, 441), but use of short interval 
intracortical inhibition (SICI), intracortical facilitation (ICF) and long interval intracortical 
inhibition (LICI) have been most frequently utilised in ALS clinical research as methods to 
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determine cortical excitability. For the purposes of the current thesis, the following discussion 
will focus on paradigms measuring SICI and ICF. 
 
Short interval intracortical inhibition is measured via a paired-pulse paradigm, in which a 
subthreshold conditioning stimulus (set to 70 of RMT) is delivered at a pre-determined time 
intervals before a suprathreshold test stimulus (417, 468-470).  In the original paradigm, the 
conditioning and test stimuli remained constant and the effects of the conditioning stimulus was 
measured by recording changes in the MEP amplitude.  When the interstimulus interval (ISI) 
was set between 1-5 ms, the test response was inhibited (SICI).  Increasing the interstimulus 
interval to between 7 and 30 ms resulted in the facilitation of the test response (ICF) (401). 
 
There is compelling evidence that SICI and ICF originate at the level of the motor cortex (439, 
470).  Specifically, epidural recordings of descending corticospinal volleys with a reduction in 
the number and amplitude of late I-waves, namely I2 and I3, with I-wave suppression remaining 
up to an ISI of 20 ms, which is the typical duration of the inhibitory postsynaptic potential  
mediated through GABAA receptors (469, 471).  Conversely ICF was associated with an increase 
in the I-wave amplitude, being reduced by GABAA receptor agonists (426).  The inhibitory 
properties of the ionotropic GABAA receptors is related to selective gating of  Cl− ions resulting 
in hyperpolarization (472, 473).  The GABAA receptors consist of five protein subunits arranged 
around a central pore, whereby each subunit consists of an extracellular N-terminal domain, 
followed by three membrane spanning domains (M 1-3), of which the M2 domain forms the pore 
channel, an intracellular loop and a fourth membrane spanning domain (M4) (474).  Sixteen 
different subunits could potentially comprise the GABAA receptor, including α1–6, β1–3, γ1–3, 
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δ, ɛ, π and θ, with the α1β2/3γ2, α2β3γ2, and α3β3γ2 subunit combinations being the most 
frequent (474-476).  Importantly, SICI appears to be mediated by GABAA receptors comprised 
of the alpha 1 subtype (477). Of further relevance, SICI and ICF are also modulated by other 
cortical neurotransmitter systems including  glutamate (87, 478-480), dopamine (426, 481) and 
norepinephrine (426), and selective serotonin re-uptake inhibitors (482).  Importantly, SICI and 
ICF appear to be physiologically distinct processes as evident by lower thresholds for activation 
of SICI and that SICI remains independent of the direction of subthreshold conditioning current 
flow within the motor cortex, while ICF appears to be preferentially generated by current 
flowing in a posterior-anterior direction (483). 
 
A potential limitation of the original ―constant stimulus‖ technique related to marked variability 
in the MEP amplitude with consecutive stimuli (469, 484).  The variability of the MEP responses 
may in part relate to spontaneous fluctuations in the resting threshold of cortical neurons.  To 
overcome this limitation, a threshold tracking technique was developed, whereby a constant 
target MEP response (0.2 mV) was tracked by a test stimulus (416, 417).  Utilizing threshold 
tracking, two phases of SICI were identified (416, 417, 485, 486), a smaller phase at ISI ≤1 ms 
and larger phase at ISI 3 ms. Synaptic neurotransmission through the GABAA receptor has been 
shown to  mediate the second phase of SICI (471, 487-489), however, the precise mechanisms 
underlying the first phase of SICI remains a matter of debate.  It was initially suggested that the 
first phase of SICI reflected local excitability properties, particularly relative refractoriness of 
cortical axons, with resultant resynchronization of cortico-cortical and corticomotoneuronal 
volleys (416, 490).  Subsequently, it was argued that synaptic processes may best explain the 
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development of the initial phase of SICI, possibly driven by activation of cortical inhibitory 
circuits that were distinct from circuits mediating the later SICI phase (485, 486, 491).  
A reduction or absence of SICI, together with an increase in ICF, all indicative of cortical 
hyperexcitability, have been documented in sporadic and familial ALS patients (49-51, 53, 174, 
290, 478, 492-495).  Of relevance, cortical hyperexcitability appears to be an early feature in 
ALS, correlating with measures of peripheral neurodegeneration and preceding the clinical 
development of familial ALS (49, 50).   
 
Abnormalities of SICI in ALS, are mediated by degeneration of inhibitory cortical interneurons 
(496) along with glutamate-mediated excitotoxicity (478, 480).  Underscoring this notion that a 
complex pathophysiological process may underlie SICI abnormalities in ALS are findings of 
SICI reduction at low (40% of resting motor threshold (RMT), medium (70% of RMT) and high 
(90% of RMT) conditioning stimulus intensities (497).  As such, preserving the integrity of 
intracortical inhibitory circuits, and counteracting excitatory cortical circuits, may serve as 
potential therapeutic options in ALS.  Consequently, the current thesis will utilize novel cortical 
and axonal excitability techniques in sporadic ALS patients, in order to determine the 
pathophysiological processes underlying neurodegeneration in ALS, particularly whether cortical 
dysfunction precedes the development of LMN dysfunction and underlies the development of the 
split-hand sign. 
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METHODOLOGY 
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Subjects 
 
The healthy subjects used as controls had no clinical evidence of a peripheral nerve disorder or 
any history of medical conditions known to affect peripheral nerve function. Further, they were 
confirmed to not be on medication which could alter the parameters of cortical excitability 
testing (426, 498-500).  Patients with ALS with a history of other illnesses like diabetes mellitus, 
known to cause neuropathy were excluded from all axonal excitability studies. All patients were 
diagnosed with clinically possible, probable or definite ALS as defined by the Awaji criteria(82).  
All patients were followed up over the three year period to confirm the progression of disease 
and confirmation of the diagnosis. All patients and subjects gave written informed consent to the 
procedures, which had been approved by the Sydney West Area Health Service Human Research 
Ethics Committees and the University of Sydney Human Research Ethics committee. 
 
Equipment 
The following equipment was used to carry out the studies in this thesis: 
Hardware requirements:  
1) Personal computer fitted with a 16-bit data acquisition card (National Instruments PCI-MIO-
16E-4) that sampled signals at 10 kHz. 
2) Isolated linear bipolar constant stimulator (maximal output ± 50 mA) (DS5, Di                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
gitimer, Welwyn Garden City, UK) 
3) Conventional non-polarisable 5-mm Ag-AgCl surface EMG electrodes (3M Healthcare, MN, 
USA) for stimulation and recording. 
66 
 
4) Preamplifier and filter (3 Hz-3 kHz) for recording sensory and motor potentials Nikolet-
Biomedical EA-2 amplifier (Cardinal Health Viking Select version 11.1.0, Viasys Healthcare 
Neurocare Group, Madison, USA).  
5) Electronic noise was further filtered by using a Hum Bug (Hum Bug 50/60 Hz Noise 
Eliminator, Quest Scientific Instruments, North Vancouver, Canada) 
6) Two high-power magnetic stimulators which were connected via a BiStim device (Magstim 
Co., Whitland, South West Wales, UK). 
7) Circular stimulation coil for transcranial magnetic stimulation (Magstim Company: High 
Power 90mm Coil -P/N9784-00)    
8) Purpose built thermometer for measuring skin temperature. 
9) Synergy EMG machine, Neurocare Group, Madison, USA. 
10) 26 G concentric EMG needle (Dantec DCN™ Disposable Concentric Needle Electrodes) 
Software requirements:  
1) Data acquisition and stimulation delivery (both electrical and magnetic) were controlled by a 
computerised threshold tracking programme, QTRACS software version 16/02/2009 (© 
Professor Hugh Bostock, Institute of Neurology, Queen Square, London, UK). 
2) Quantitative EMG was performed using the Multi-MUP software (Synergy EMG machine, 
Neurocare Group, Madison, USA) 
 
Stimulating and Recording Paradigms 
Peripheral nerve studies described in Chapters 1-5 were undertaken on motor axons of the 
median nerve (Fig. 7a) and or the ulnar nerve (Fig 7b,7c) using conventional non-polarisable 5-
mm Ag-AgCl surface EMG electrodes (3M Healthcare, MN, USA).  The median nerve was 
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stimulated electrically at the wrist, with the cathode placed at the wrist crease and the anode 
located in the mid-forearm.  The resultant compound muscle action potentials (CMAPs) were 
recorded via surface electrodes with the active recording electrode positioned over the motor 
point of the abductor pollicis brevis (APB) and the reference electrode placed 4 cm distally(354) 
over the proximal phalanx of the thumb (Fig 7A).  The ulnar nerve was stimulated electrically at 
the wrist with the cathode repositioned to the medial wrist crease lateral to the flexor carpi 
ulnaris tendon. CMAP amplitude was recorded over the first dorsal interosseous (FDI) muscle 
with the active electrode positioned over the motor point of the FDI while the reference electrode 
remained positioned approximately 4 cm distal at the base of the thumb (Fig 7B). Abductor digiti 
minimi (ADM) muscle CMAP recording was performed with the recording electrode positioned 
over the belly of the muscle and the reference electrode positioned approximately 4 cm distal on 
the little finger (Fig 7C).  Peripheral nerve studies described in Chapter 7 and 8 with recording of 
CMAP over the flexor pollicis longus (FPL) muscle was performed with the active electrode 
positioned over the motor point of the FPL in the lateral forearm and reference electrode placed 
over the radial styloid and stimulation of the median nerve at the elbow. The baseline-to-negative 
peak amplitude and onset latency for the CMAP were determined.  
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Figure 7A      
                                                                                                                                                                                                                          
               
 
Figure 7B 
  
    
 
        
Recording electrodes
(APB)
Stimulating electrode
(median nerve)
Temperature 
Ground
Stimulating electrode
(
Ground
ulnar nerve)
Temperature 
Recording Electrodes (FDI) 
(dorsum of the hand)
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Figure 7C 
               
 
 
 
 
 
 
Cortical excitability studies, described in Chapters 2,3,5,7,8  were performed by transcranial 
magnetic stimulation (TMS), whereby the motor cortex was stimulated by means of a 90 mm 
circular coil oriented to induce a current flow in a posterior-anterior direction in order to activate 
the motor cortex.  The coil, initially centered over the vertex, was moved in the antero-posterior 
and medial-lateral directions in order to find the optimal position for evoking responses of 
maximal amplitude from the target muscle namely the abductor pollicis brevis (APB), first dorsal 
interosseous (FDI), abductor digiti minimi (ADM) and the flexor pollicis longus (FPL) muscle.  
The currents were generated by two high-power magnetic stimulators which were connected via 
Stimulating electrode
(
Ground
ulnar nerve)
Temperature 
Recording Electrodes 
(ADM)
Figure 7:(A) Configuration of stimulating and recording electrodes for peripheral nerve 
stimulation.  The median motor is stimulated at the wrist with recording over the abductor 
pollicis brevis muscle (APB) (B) Stimulating electrode is moved medially to be positioned over 
the ulnar nerve at the wrist with recording over the first dorsal interosseous (FDI) and (C) 
abductor digiti minimi (ADM) muscle. The motor evoked potentials are recorded over the three 
intrinsic hand muscles using the same recording electrode configuration. 
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a BiStim
 
device (Magstim Co., Whitland, South West Wales, UK) so that conditioning and test 
stimuli could be independently set and delivered through one coil.  The magnetic evoked 
potentials (MEPs) were recorded using surface electrodes and the peak-to-peak amplitude and 
onset latency were determined for MEPs. 
 
Threshold tracking and excitability protocols 
Axonal excitability can be investigated using threshold tracking, where ‗threshold‘ refers to the 
stimulus current required to produce a target potential (85, 86).  Axonal excitability studies 
incorporating threshold tracking provide information about the membrane properties of axons at 
the site of stimulation.  With threshold tracking, resting threshold is measured and nerve 
excitability is altered by changing the nerve environment, by applying a conditioning polarizing 
current(85).  This technique provides information about membrane potential and axonal ion 
channel function. 
 
The threshold tracking software used in this thesis was an automated tracking system whereby 
the test stimulus intensity was automatically increased or decreased in percentage steps after 
each response, depending on the difference between the recorded and target responses (Fig. 8).  
For measurement of multiple excitability parameters, an automated multiple excitability 
protocol, TRONDF version 16/02/2009 (© Professor Hugh Bostock, Institute of Neurology, 
Queen Square, London, UK) was used that contained a proportional tracking system, in which 
the change in test stimulus current intensity was proportional to the difference (or error) between 
the recorded response and target response.  Proportional tracking can be more efficient, 
especially when excitability changes abruptly. 
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Multiple excitability measures:  sequence of recordings 
To commence the protocol, stimulus-response (SR) curves were generated using test current 
impulses of 0.2- and 1-ms (Fig. 9A, B).  The peak amplitude, measured from baseline to negative 
peak, generated by the current intensity of 1 ms duration was used to set the target response 
(40% of supramaximal CMAP response).  Stimuli were increased in 4% steps, with two 
responses averaged at each step until three averages were considered maximal. The ratio between 
the SR curves for two different stimulus durations that produced the same CMAP response were 
used to calculate the rheobase, defined as the threshold current for a target response when the 
stimulus is of infinitely long duration (85, 86), and strength-duration time constant (τSD; Fig. 9D) 
of motor axons of different thresholds using Weiss‘ formula (85, 86, 334).   
The threshold changes that occur in response to subthreshold depolarizing and hyperpolarizing 
pulses, referred to as threshold electrotonus, were measured by altering nerve excitability using 
Target response
(40% maximum)
Figure 8:  In threshold tracking, the target response is set to 40% of the supramaximal 
compound muscle action potential (CMAP) amplitude.  When the CMAP amplitude is smaller 
than the target response (dashed black line), the subsequent test stimulus current intensity is 
increased.  When the CMAP amplitude is larger than the target response (grey line), the 
subsequent test stimulus current intensity is reduced.  If the CMAP amplitude is equal to the 
target response, the subsequent test stimulus intensity remains unchanged. 
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prolonged sub-threshold polarizing currents of 100 ms duration, set to + 40% (depolarizing) and 
- 40% (hyperpolarising) of controlled threshold current(85, 86).  Three stimulus combinations 
were tested sequentially: test stimulus alone (measured control threshold current); test stimulus + 
depolarizing current; test stimulus + hyperpolarizing current.  Threshold was tested at 26 time 
points before, during and after the 100 ms polarizing pulse.  The stimulus combinations were 
repeated until three valid estimates were recorded within 15% of target response(354).   
 
A current-threshold relationship (I/V) was obtained by tracking the changes in threshold of 1 ms 
test pulses that occurred following sub-threshold polarizing currents of 200-ms duration which 
were altered in ramp fashion from +50% (depolarizing) to  -100% (hyperpolarizing) of 
controlled threshold in 10% steps.  Stimuli with conditioning currents were alternated with test 
stimuli until three valid threshold estimates were recorded.  The I/V relationship estimates 
rectifying properties of both nodal and internodal segments of the axon(380, 501).  The I/V 
gradient during depolarizing sub-threshold currents reflects conduction through outward 
rectifying K
+
 channels, while the I/V gradient during hyperpolarizing sub-threshold currents 
reflects inwardly rectifying conductances activated by hyperpolarization(354, 378).   
 
Finally, the recovery of axonal membrane excitability, referred to as the recovery cycle, was 
assessed by tracking the changes in threshold that occurred following a supramaximal 
conditioning stimulus of 1 ms duration.   Eighteen conditioning-test stimulus intervals were 
studied, decreasing from 200 to 2 ms.  Three stimulus combinations were recorded: (i) 
unconditioned test stimulus (1 ms duration); (ii) supramaximal conditioning stimulus alone; (iii) 
conditioning and test stimuli in combination.  The response in (ii) was subtracted on-line from 
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response in (iii) so as to eliminate contamination of the measured CMAP response by the 
supramaximal conditioning response at short interstimulus intervals.  Each stimulus combination 
was repeated until 4 valid estimates were obtained(354).   
 
Following completion of the recovery cycle, a profile of nerve excitability was generated using a 
customized plotting program (QTRACP version 16/02/2009), consisting of six different plots 
(Fig. 9A-F). The 95% confidence limits were calculated as mean ± t 0.05 SD (where t 0.05  is the 
value of Student‘s t-test which the probability of a larger value is 0.05) such that 95% of 
individual observations would fall within the limits if the variables were distributed normally.  
For data plotted on logarithmic axes (Fig 9A, 9F), the logarithm of the variable was assumed to 
be normally distributed, and the mean plotted is the geometric mean.  Differences in excitability 
parameters were analysed using Student‘s t-test.  A probability (P) value of < 0.05 was 
considered statistically significant. All results are expressed as mean ± standard error of the 
mean. 
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Figures 9:  Six plots of excitability parameters recorded from abductor pollicis brevis muscle 
for a single subject.  (A) Absolute stimulus-response relationship.  (B) Normalised stimulus-
response relationship.  (C) Current-threshold relationship.  (D) Strength-duration time constant.  
(E) Threshold electrotonus.  The conditioning-test interval corresponding to hyperpolarising 
threshold electrotonus at 90-100 ms (The 90-100 ms) and depolarising threshold electrotonus at 
the same time interval (Ted 90-100 ms) are depicted.  (F) Recovery cycle, demonstrating the 
time point at which the relative refractory period (RRP) is measured, as well as superexcitability 
and late subexcitability.  
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Upon completion of the excitability protocol, values for multiple excitability measures were 
automatically generated.  The stimulus intensity (mA) was measured as the current required to 
elicit a target response set to 40% of maximal CMAP for a stimulus of 1 ms duration.  Strength-
duration time constant (ms), which reflects nodal persistent Na
+
 conductances(502), was 
calculated for nine motor axonal populations, starting from axons contributing to CMAP 
responses between 5-15% up to the maximum of 85-95%, increasing in 10% batches(354) 
Rheobase (mA), defined as the threshold current for a target response when the stimulus is of 
infinitely long duration, was also calculated.  Stimulus-response slope was calculated from the 
normalized SR curves by subtracting the stimulus that evoked a 25% maximal CMAP response 
from that which evoked a 75% response and dividing the result by the stimulus evoking a 50% 
response.  
 
Threshold electrotonus parameters were calculated from data in Fig. 9E.  TEd (peak) refers to the 
peak threshold reduction produced by a subthreshold depolarizing current.  The reduction in 
threshold was measured at three time points relative to onset of the subthreshold depolarizing 
current, i.e. at 10-20 ms, TEd (10-20 ms), 40-60 ms TEd (40-60 ms), and at 90-100 ms TEd (90-
100 ms).  Threshold changes were also measures at similar latencies following a subthreshold 
hyperpolarizing current and are referred to as TEh (10-20 ms) and TEh (90-100 ms).  S2 
accommodation was calculated as the difference between the peak threshold reduction in the 
depolarizing direction and the plateau value, i.e. TEd (peak) – TEd (90-100 ms).  The peak 
threshold increase at the end of depolarizing current and peak threshold reduction at the end of 
hyperpolarizing current were averaged over 20 ms and are referred to as TEd (undershoot) and 
TEh (overshoot).   
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From the I/V graph, the following parameters were recorded; (i) resting I/V slope, calculated 
from polarizing currents between +10% to -10%, minimal I/V slope, calculated by fitting a 
straight line to each three adjacent points in turn, and (iii) hyperpolarizing I/V slope, calculated 
from polarizing current between 0-100%. 
 
For the recovery cycle of axonal excitability the following parameters were measured; (i) relative 
refractory period (RRP, ms), defined as the first intercept at which the recovery curve crosses the 
x-axis; (ii) superexcitability, expressed as a percentage reduction in threshold current, was 
calculated as the minimum mean of three adjacent point at conditioning-test intervals of 5-15 ms 
and (iii) late subexcitability (%), as the maximum mean of three adjacent points at interstimulus 
intervals > 15 ms. 
 
Normative values for these parameters have been established for the median nerve motor 
axons(56, 354); while normative values for the ulnar motor axons to the FDI and ADM muscles 
were established as part of the current project(503). 
 
Cortical excitability studies 
For studies assessing cortical excitability described in Chapters 2, 4, 5, 7 and 8; TMS was 
applied to the motor cortex by means of a 90 mm circular coil oriented to induce a current flow 
in a posterior-anterior direction in order to activate the motor cortex.  The coil, initially centered 
over the vertex, was moved in the antero-posterior and medial-lateral directions in order to find 
the optimal position for evoking responses of maximal amplitude from the target muscle.  The 
currents were generated by two high-power magnetic stimulators which were connected via a 
77 
 
BiStim (Magstim Co., Whitland, South West Wales, UK) so that conditioning and test stimuli 
could be independently set and delivered through one coil. 
 
TMS threshold tracking (Fig. 10): Paired pulse cortical stimulation was performed using the 
threshold tracking TMS protocol(417). Briefly, the output (MEP response) was fixed and 
changes in the test stimulus intensity required to generate a target response, when preceded by 
either sub- or suprathreshold conditioning stimuli, were measured.  This technique is analogous 
to that used in the assessment of peripheral nerve excitability. 
 
Fisher and colleagues (2002) established that the relationship between the logarithm of the MEP 
amplitude and the stimulus was close to linear over a hundred-fold range of responses, from 
about 0.02 to 2 mV(504).  Based on these observations a small target response of 0.2 mV 
(±20%), in the middle of this linear range, was selected for the present study and subsequently 
tracked.  Resting motor threshold (RMT) was defined as the stimulus intensity required to 
produce and maintain the target MEP response (0.2 mV peak-to-peak)(417). 
 
Initially, the SR curve for cortical stimulation was determined by increasing the intensity of the 
magnetic stimulus to the following levels: 60, 80, 90, 100, 110, 120, 130, 140 and 150% RMT.  
Three stimuli were delivered at each level of stimulus intensity.  The maximum MEP amplitude 
(mV) and MEP onset latency (ms) were recorded.  Central motor conduction time (CMCT, ms) 
was calculated according to the F-wave method(505, 506). 
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The cortical silent period (CSP) induced by single-pulse TMS was recorded while performing a 
weak voluntary contraction, estimated by the investigators as representing 10-30 % of maximum 
voluntary contraction. Audio feedback was provided to the subject to sustain the contraction at 
the required force while the magnetic stimulus intensity was varied as for the SR curve.  The 
duration of the silent period was measured from the beginning of MEP to the return of EMG 
activity(507). 
Figure 10: Threshold tracking transcranial magnetic stimulation: equipment and recording 
configuration. 
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A paired-pulse paradigm was developed(417) whereby a subthreshold conditioning stimulus 
preceded a suprathreshold test stimulus at increasing interstimulus intervals (ISIs) as follows: 1, 
1.5, 2, 2.5, 3, 3.5, 4, 5, 7, 10, 15, 20, and 30 ms.  The subthreshold conditioning stimulus  
(70% RMT) was such that it did not evoke a response.  Stimuli were delivered sequentially as a 
series of three channels (Fig. 11): channel 1 tracked the stimulus intensity required to produce 
the unconditioned test response (i.e., RMT; shown in Fig. 12A,B); channel 2 monitored the 
subthreshold conditioning stimulus so as to ensure that an MEP response was not produced and 
that the subject remained relaxed; and channel 3 tracked the stimulus required to produce the 
target MEP when conditioned by a subthreshold stimulus equal in intensity to that on channel 2.  
Tracking was deemed acceptable when the test stimulus produced two consecutive MEP 
responses that were within 20% of the target response (0.2 mV) or consistently oscillated about 
the target.  The three channels were applied sequentially.  Stimuli were delivered every 5-10 
seconds (stimulus delivery was limited by the charging capability of the BiStim system) and the 
computer advanced to the next ISI only when tracking met the target criteria.  Precision of the 
tracking method was limited by the fact that the intensity of the magnetic stimulus was restricted 
to integral values from 1% to 100% of maximum stimulator output. 
 
Intracortical inhibition induced by a conditioning stimulus was measured as the increase in the 
test stimulus intensity required to evoke the target MEP.  Inhibition was calculated off-line using 
the following formula(504):  
 
 
Inhibition = (Conditioned test stimulus intensity – RMT)/RMT * 100 
Facilitation was measured as the decrease in the conditioned test stimulus intensity required to 
evoke the target MEP. 
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Each data point was weighted (QTRACS software version 16/02/2009) such that any measures 
recorded outside the threshold target window (0.2mV, peak-to-peak) contributed least to the data 
analysis.  All results are expressed as mean ± standard error of the mean.  Student t-test was used 
for assessing differences between two groups.  Analysis of variance (ANOVA) was used for 
multiple comparisons to assess the difference between the conditioned test and unconditioned 
test stimuli at different ISIs.  A probability (P) value of  < 0.05 was considered statistically 
significant. 
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Conditioned test stimulus
Unconditioned test stimulus
Conditioning stimulus 
(70% RMT)
ISI
Ch 3
Ch 1
Ch 2
Figure 11:  Experimental paradigm and configuration of stimulus patterns used in Chapters 4-8.  
Cortical excitability was assessed by measuring changes in stimulus intensity required to 
generate a target magnetic evoked potential response of 0.2 mV, recording over the abductor 
pollicis brevis.  Channel 1 = unconditioned test stimulus, measuring resting motor threshold 
(RMT); Channel 2 = conditioning stimulus, which was set to subthreshold (70% RMT) when 
assessing short interval intracortical inhibition; Channel 3 = conditioned test stimulus at 
different interstimulus intervals (ISIs).  SICI was measured by increasing ISI from 1-30 ms. 
Reproduced with permission S.Vucic 2007  
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Figure 12:  (A) Illustration of threshold tracking.  The dashed horizontal line represents the 
target output of 0.2 mV which was ―tracked‖.  The circles (clear and filled) represent the 
magnitude of the motor evoked potential (MEP) amplitude with each stimulus.  (B)  Illustration 
of three MEP responses of different amplitude.  The MEP response is initially larger (a), then 
smaller (b), and again larger (c) then the target output of 0.2 mV in three consecutive stimuli.  
These are depicted as filled circles in Figure A.  The dashed horizontal lines represent the 
tracking windows, which were set to 0.2 mV (peak-to-peak). Reproduced with permission 
S.Vucic 2007 
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Multi MUP technique of Quantitiative EMG  
Motor unit potential (MUP) analysis for compensatory renervation, which may be an early 
feature of LMN involvement in ALS (73), was performed in the experiment detailed in Chapter 
5.The Multi MUP technique was utilised which is an automated decomposition technique of 
EMG analysis based on a multiple template matching technique, which makes it possible to 
identify several clearly definable MUPs from each recording site. It is not used primarily to study 
their firing pattern; hence it is considered quite acceptable that some MU discharges are not 
identified in the epoch. The method is called multi-MUP analysis since many different MUPs are 
usually obtained from each recordings site (508-510).  
 
Multi MUP acquisition involved EMG recording from an electrode position with crisp EMG 
signal with filter settings of 5 Hz for high pass and 10 kHz for low pass with a free running 
sweep. Muscle contraction was maintained at 5-30% of maximum force and several MUPs were 
seen which were separated from each other by a discernible baseline. The recording was 
continued without needle movement during the analysis epoch (5-10 s). One to two skin 
insertions were required and a few different sites were sampled with each insertion. Roughly 
more than 20 MUPs are collected, with the aim of having at least 20 MUPs after editing. 
Duration of recording averaged about 3-5 min (508, 510).  
 
Multi MUP analysis Signals with amplitude exceeding 50µV and a short rise time (Fig 13) 
were identified and each identified MUP was checked against previous templates for 
classification. The new MUP was considered to match a template when the difference in shape 
was less than a  
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predefined value. 
                                   
 
Multi MUP acquisition involves EMG recording from an electrode position with crisp EMG  
 
Identical MUPs formed a class while unmatched MUP‘s were taken as the template for a new 
class. At each recording site, the classes were sorted in descending order of 
the number of matches and six classes with the highest number of matches were averaged. 
Classes must contain more than a predetermined number of data to be accepted and the 
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Figure 13: representation of a motor unit with the parameters of significance to distinguish 
pathological states from normal controls 
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individual MUPs and the averaged MUP were displayed superimposed. Each detected discharge 
of the averaged MUP was displayed on the time axis.  
 
MultiMUP editing MUPs that were duplicates and those with a noisy baseline or other 
obvious artifacts were first deleted. Among the remaining MUPs, the automatic duration cursor 
setting was manually corrected if necessary. 
 
Clinical Scores in Amyotrophic Lateral Sclerosis 
A neurological history and physical examination were undertaken in all ALS patients.  All ALS 
patients were clinically staged using the amyotrophic lateral sclerosis functional rating scale-
revised (ALSFRS-R)(511) .  The ALSFRS-R is a questionnaire-based, 12-item functional rating 
scale administered to the patient or, if the patient cannot communicate effectively, to an 
informant such as the carer.  The ALSFRS-R incorporates assessment of bulbar function, fine 
motor function, gross motor function and respiratory function.  Functional scores in each domain 
are graded from 0 (complete dependence for that function) to 4 (normal function), resulting in a 
total ALSFRS-R score ranging from 0 to 48 (normal).  
 
Muscle strength in all patients was assessed using the Medical Research Council (MRC) rating 
scale (512) with the following group of muscles tested bilaterally yielding a total MRC score of 
90:  shoulder abduction; elbow flexion; elbow extension; wrist dorsiflexion; finger abduction; 
thumb abduction; hip flexion; knee extension; ankle dorsiflexion. The MRC scale is a five point 
scale ranging from 0 (no movement) to 5 (normal strength).    
 
86 
 
The Triggs hand score (513) was utilised to evaluate hand function in chapter 8 with  function 
graded as follows: 0 = normal; 1 = mild to moderate hand weakness without impairment of 
dexterity; 2 = weak with significant impairment of dexterity (i.e., difficulty with handwriting and 
buttoning clothes); and 3 = marked weakness-major disability and loss of fine motor control. 
Patients were also graded in terms of upper motor neuron (UMN) ―burden‖, by totalling the 
number of pathological UMN signs on examination. These were taken as pathologically brisk 
biceps, supinator, triceps, finger, knee and ankle reflexes, and extensor plantar responses 
assessed bilaterally and brisk facial and jaw jerks. Tendon reflexes were graded as 0 = normal, 1 
= brisk without spread or present in a wasted muscle, 2 = brisk with reflex spread (maximum 
possible score 16)(514). 
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Chapter 1 
Diagnostic Utility of the Split-Hand Sign in 
ALS 
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Summary 
 Preferential wasting of the ‗thenar‘ group of muscles including the first dorsal interosseous; the 
split hand sign, appears to be a specific feature of ALS. The present study developed a novel 
split hand index (SI) and assessed its diagnostic utility in ALS.  170 consecutive patients with 
neuromuscular symptoms (44 ALS, 126 patients with other neuromuscular disorders) were 
prospectively recruited according to standards for reporting of diagnostic accuracy (STARD) 
criteria. The SI was derived by dividing the product of the compound muscle action potential 
(CMAP) amplitude recorded over the first dorsal interosseous and abductor pollicis brevis by the 
CMAP amplitude recorded over the abductor digiti minimi. The SI was significantly reduced in 
ALS patients (ALS 3.5±0.6; compared with patients with other neuromuscular disorders 9.1±0.3, 
P<0.0001), particularly in limb-onset ALS (2.3±0.5, P<0.0001).  Receiver operating 
characteristic curve analysis indicated that SI reliably differentiated ALS from patients with 
other neuromuscular disorders (area under curve ALS 0.83, P<0.0001) with an optimal SI cut-off 
value of 5.2 exhibiting a sensitivity of 74% and specificity 80. The split hand index robustly 
differentiates ALS from mimic disorders. The split hand index is a simple measure that could be 
utilized in a standard neurophysiology setting.  A reduction in SI distinguishes ALS from mimic 
disorders, potentially facilitating an earlier diagnosis of ALS. 
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Introduction 
The diagnosis of amyotrophic lateral sclerosis (ALS) relies on the identification of combined 
upper and lower motor neuron signs in the same body region, with evidence of disease 
progression (2). The absence of a diagnostic test and the heterogeneity of the ALS clinical 
phenotypes has tended to result in diagnostic delay, estimated to be 14 months (515).  As a 
consequence, institution of neuroprotective therapies such as riluzole is often delayed (184), and 
recruitment into clinical trials may be  reduced (516).   
  
The clinically based El Escorial criteria developed in order to aid  the diagnosis of ALS (14) 
were too stringent and insensitive at diagnosing ALS in the early stages of the disease (17, 184, 
515, 517).  A recent modification, termed the Awaji-Shima criteria, were developed whereby the 
presence of neurophysiological parameters of lower motor neuron (LMN) dysfunction such as 
fasciculation‘s, fibrillation potentials, positive sharp waves and chronic neurogenic changes were 
regarded as equivalent to the clinical findings of LMN dysfunction (82). The Awaji-Shima 
criteria have been established to be sensitive (74-77, 518), although, the increase in diagnostic 
sensitivity appeared to be restricted to ALS patients with bulbar onset disease (518).  
 
Dissociated atrophy of intrinsic hand muscles, including the abductor pollicis brevis (APB) and 
first dorsal interosseous (FDI), with relative preservation of the hypothenar muscles, the split 
hand sign (Figure 1.1), appears to be an early clinical feature of ALS (20, 21, 54).  A recent 
study has addressed the specificity of the sign and suggested a potential role in facilitating the 
clinical diagnosis of ALS (20).  
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The clinical observation of dissociated hand muscle atrophy may provide an opportunity to 
develop a simple neurophysiological biomarker for the diagnosis of ALS.  The split hand index 
(SI) was  derived by multiplying the compound muscle action potential (CMAP) amplitude 
recorded over the APB muscle by the CMAP amplitude recorded over the FDI muscle and 
dividing this product by the CMAP amplitude recorded over the abductor digiti minimi (ADM)  
(519).  The aim of the present study was to assess the diagnostic utility of the split hand index in 
ALS, and in particular to determine whether SI may reliably differentiate ALS from mimic 
disorders.   
 
 
                    
 
 
 
Figure 1.1: An illustration of the split-hand sign in a patient with amyotrophic lateral sclerosis.  
Specifically, the split hand sign refers to preferential wasting of the abductor pollicis brevis 
(APB) and first dorsal interosseous (FDI) muscles in comparison to the abductor digit minimi 
(ADM).  The novel split hand index is calculated by multiplying the compound muscle action 
potential (CMAP) amplitude recorded over the APB by that recorded over the FDI and dividing 
the product by the CMAP amplitude recorded over the ADM 
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Materials and Methods 
In total, 170 patients were prospectively and consecutively recruited into the study according to 
the standards for reporting of diagnostic accuracy (STARD) criteria.  The inclusion criteria 
included all patients with clinical neuromuscular features affecting the upper limbs, referred to 
the neurophysiology laboratories at Westmead and Prince of Wales Hospitals from June 2010 to 
December 2011 (Figure 1.2).  Patients deemed not to be suffering with a neuromuscular 
disorders were excluded from the study.  After extensive investigations and clinical follow-up 
26% patients (26 males, 18 females, mean age 59.6 years: age range 29-81 years) were 
eventually diagnosed with ALS according to the Awaji-Shima criteria (82)  of whom 76%  were 
in the definite or probable diagnostic category.  All ALS patients were consecutively recruited 
and no preference was given to ALS patients followed for a longer period of time. The remaining 
74% patients were confirmed to have patients with other neuromuscular disorders (64 males, 62 
females; mean age 54 years; age range 20-89 years, Figure 1.2) following extensive 
investigations and follow-up.   
 
All ALS patients were clinically staged using the Amyotrophic Lateral Sclerosis Functional 
Rating Scale-Revised (ALSFRS-R)  (511) and ALSFRS-R progression rate, a marker of survival, 
was estimated according to the previously reported formula; (48-ALSFRS-R)/duration of 
symptoms (520). Muscle strength was assessed using Medical Research Council (MRC) rating 
scale (521).  Specifically, the following muscle groups were assessed bilaterally yielding a total 
MRC score of 90:  shoulder abduction; elbow flexion; elbow extension; wrist dorsiflexion; finger 
abduction; thumb abduction; hip flexion; knee extension; ankle dorsiflexion.   ALS patients were 
classified according to the site of disease onset as either limb or bulbar-onset.  All ALS patients 
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gave informed consent to the procedures, which were approved by the South East Sydney and 
Sydney West Area Health Service Human Research Ethics Committees.     
 
 
 
 
 
 
Patients who underwent 
neurophysiology testing 
n=170
Assessment of Split-Hand 
Index
Reference Standard
ALS n=44
Bulbar Onset n=26 Limb Onset n=18
Patients with other 
neuromuscular disorders 
n=126*
Pure CTS (50)
UNE (8)
CTS plus UNE (4)
Demyelinating PN (7)
Axonal  PN (29) 
CTS plus axonal PN (7)
Cervical Radiculopathy (11)
Others (MMNCB, SBMA,
Hirayama’s Disease, SMA) (5)
No neuromuscular 
symptoms 
Excluded
Figure 1.2: Flow diagram of patient recruitment according to the standards for reporting of 
diagnostic accuracy (STARD) criteria which subsequent differentiation into the amyotrophic 
lateral sclerosis (ALS), based on Awaji criteria, and patients with other neuromuscular disorders 
based on the reference standard. The ALS group was further subdivided into limb-onset and 
bulbar-onset. The group comprising patients with other neuromuscular disorders included 
entrapment neuropathies [carpal tunnel syndrome (CTS) and ulnar neuropathy at the elbow 
(UNE)], axonal sensorimotor polyneuropathy [PN] (axonal neuropathy of undetermined etiology 
(N=24), diabetic neuropathy (N=4), amyloid neuropathy (n=1)] demyelinating polyneuropathy 
[Guillain-Barre syndrome] (N=2), chronic inflammatory demyelinating polyradiculoneuropathy 
(N=3) and Charcot-Marie Tooth disease type 1A (N=2)], cervical radiculopathy (11), multifocal 
motor neuropathy with conduction block (MMNCB, N=2), spino-bulbar muscular atrophy 
(SBMA, N=1), Hirayama‘s disease (N=1), spinal muscular atrophy (SMA, N=1).  *In 5 patients, 
the neurophysiological study was normal, despite the patients presenting with neuromuscular 
symptoms. 
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Neurophysiological studies 
Prior to assessing the split hand index patients underwent routine nerve conduction studies and 
electromyography (EMG) using the Oxford Teca Synergy EMG machine (Oxford Instruments, 
Old Woking, Surrey, England).  In all patients median, ulnar, common peroneal and tibial motor 
nerves, as well as the sural, median and ulnar sensory nerves were assessed.  Needle EMG 
testing was performed in at least 3 regions on the ALS patients.  Needle EMG testing was not 
routinely undertaken in patients with other neuromuscular disorders unless the diagnosis was not 
apparent on NCS, or if there was a suspicion of cervical radiculopathy, vasculitic neuropathy or 
ALS.  Filter settings were set between 3 Hz and 10 KHz while the upper limb temperature was 
maintained at 32ºC.  The median and ulnar nerves were stimulated electrically at the wrist, and 
the resultant baseline-to-peak CMAP amplitude (mV) was recorded over the APB, FDI and 
ADM muscles using 10-mm gold disc electrodes (Grass, USA) positioned in a belly tendon 
arrangement.  Specifically, the G1 electrode (active) was positioned over the midpoint of the 
respective muscle ensuring a negative take-off of the CMAP response, while the G2 electrode 
(reference) was positioned over the base of thumb (APB and FDI) and base of digit 5 (ADM).  
The distance between the cathode and active (G1) recording electrodes for APB and ADM 
muscles was 5 cm, while the distance between the cathode and active (G1) electrode was not 
measured for the FDI muscle.  The split-hand index (SI), which quantifies the extent of 
dissociated intrinsic hand muscle atrophy, was derived by multiplying the CMAP amplitude 
recorded over the APB and FDI muscles, and dividing this product by the CMAP amplitude 
recorded over the ADM muscle, as follows: 
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In addition to the CMAP amplitude, the median nerve distal motor latency (ms), and F-wave 
frequency were recorded.  Subsequently, the neurophysiological index (NI) for the median nerve 
was derived according to the following formula (522): 
 
 
 
 
 
Statistical Analysis 
To assess for significant differences in the split hand index between ALS and patients with other 
neuromuscular disorders patients a Student‘s t-test was used.  In addition, an analysis of variance 
(ANOVA) was utilized for multiple comparisons.  Receiver operating characteristic (ROC) 
curves were undertaken to determine the diagnostic utility of the split hand index.   From ROC 
curve analysis the sensitivity, defined as the probability of having the disease when the test is 
positive, and specificity, defined as the probability of not having the disease when the test is 
negative, were determined.  From the sensitivity and specificity data, the positive and negative 
likelihood ratios (LR), were defined.  Spearman‘s rho (non-parametric data) and Pearson‘s 
correlation coefficient (parametric data) were used to examine the relationship between the SI, 
clinical measures of ALS and the neurophysiological index.  A probability (P) value of < 0.05 
APB CMAP * FDI CMAP 
   ADM CMAP 
 
SI = 
===
= 
                  CMAP amplitude *F wave frequency (%) 
             Distal motor latency 
 
NI = 
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was considered statistically significant.  Results are expressed as mean ± standard error of the 
mean for parametric data and median with interquartile range for non-parametric data.    
 
Results 
Clinical features 
Of the 44 ALS patients 76% satisfied the Awaji-Shima criteria for inclusion in the ―definite‖ or 
―probable‖ diagnostic category, while 24% were classified as ―possible‖.  The mean disease 
duration in ALS patients from symptom onset to testing was 18.9 ± 3.1 months. Limb-onset 
disease was evident in 59% of patients while bulbar-onset was noted in 41% of patients.  The 
median ALSFRS-R score at time of testing was 41(32-45), while the median value for the MRC 
sum score was 75 (66-87), both indicating a moderate degree of disability in the ALS patient 
cohort.  The diagnosis in patients with other neuromuscular disorders is outlined in figure 1.2, 
and none of the patient in this cohort developed ALS.  In addition, there were no exclusions from 
the prospectively recruited cohort of 170 patients.  
 
Neurophysiological studies disclosed a significant reduction of CMAP amplitude recorded over 
the APB (ALS, 3.9 ± 0.5 mV; patients with other neuromuscular disorders 8.1 ± 0.2 mV, P < 
0.001), FDI (ALS, 4.8 ± 0.7 mV; patients with other neuromuscular disorders 10.7 ± 0.3 mV, P < 
0.001) and ADM (ALS, 6.1 ± 0.5 mV; patients with other neuromuscular disorders 9.7 ± 0.2 
mV, P < 0.001) in ALS patients when compared to the patients with other neuromuscular 
disorders.  In addition, the neurophysiological index recorded from the median nerve was 
significantly reduced in ALS patients when compared to patients with other neuromuscular 
disorders (ALS 0.8±0.1; patients with other neuromuscular disorders 2.1±0.1 P<0.001).   
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Split hand index 
Of relevance, the reduction in the CMAP amplitude was significantly greater when recorded over  
the abductor pollicis brevis (APB 3.9 ± 0.5mV; ADM 6.1 ± 0.5mV P < 0.0001, Fig. 1.3A) and 
first dorsal interosseous (FDI 4.8 ± 0.7mV; ADM 6.1 ± 0.5mV P < 0.05, Fig. 1.3A) muscles 
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Figure 1.3: (A) The compound muscle action potential (CMAP) amplitude was significantly 
reduced when recorded over the abductor pollicis brevis (APB) (P<0.0001) and first dorsal 
interosseous (FDI) (P<0.05) muscles compared to abductor digiti minimi (ADM) muscle in 
amyotrophic lateral sclerosis (ALS). (B) Interestingly, the CMAP amplitudes recorded over the 
FDI was greater than that recorded over the ADM (P<0.01) muscles and APB (P<0.0001) 
muscles in patients with other neuromuscular disorders (NMS).  (C) There was a significant 
reduction of the split-hand index (SI) in ALS patients when compared to patients with other 
neuromuscular disorders (P<0.0001). (D) Although the reduction in SI was a uniform finding in 
ALS, it was most pronounced in patients with limb-onset disease (P<0.0001).  
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compared to CMAP responses recorded over the abductor digit minimi muscle in ALS patients.  
In contrast, the FDI CMAP amplitudes (10.7±0.3mV) were significantly greater compared to 
CMAP amplitudes recorded over APB (8.1±0.2mV P <0.0001, Fig. 1.3B) and ADM (9.7±0.2mV 
P <0.01, Fig.1.3B) muscles in patients with other neuromuscular disorders.   
 
Combining the CMAP amplitudes into the split hand index, it was evident that the SI was 
significantly reduced in ALS patients when compared to patients with other neuromuscular 
disorders (ALS 3.5 ± 0.6, [0-8.3]; patients with other neuromuscular disorders 9.1 ± 0.3, 0-18.9, 
P < 0.0001, Fig. 1.3C).  Sub-group analysis revealed that although the reduction in the split hand 
index was a uniform finding in ALS patients evident in both bulbar-onset (bulbar-onset ALS SI 
5.3 ± 1.2 [0-15.0]; patients with other neuromuscular disorders 9.1 ± 0.3, P < 0.0001, Fig. 1.3D), 
and limb-onset ALS (2.3 ± 0.5 [0-9.9], P < 0.0001, Fig 1.3D), the reduction in SI was most 
prominent in patients with limb-onset disease (P < 0.0001). In addition, there was also a 
significant reduction of SI in ALS when compared to a control group where only focal 
compressive neuropathies, such as CTS, were excluded (ALS 3.5 ± 0.6, [0-8.3]; ―non-
compressive‖ neuromuscular disorder patients 8.1 ± 0.5, [0-17.2], P < 0.0001). 
                  
Diagnostic utility of the split hand index 
To determine the diagnostic utility of the split hand index, analysis of ROC curves in the entire 
ALS cohort disclosed an area under the curve (AUC) of 0.83 (P < 0.0001), suggesting a good 
diagnostic accuracy of the split hand index.   Of further relevance, a split hand index value of 5.2 
was potentially useful in differentiating ALS from patients with other mimicking ALS disorders 
with a sensitivity of 74%, specificity of 80% (Fig. 1.4A).  In addition, sub group analysis of ROC 
curves in ALS patients with limb-onset disease revealed an AUC of 0.90 (P < 0.0001), 
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suggesting that the SI is an excellent diagnostic test at differentiating limb-onset ALS from 
mimic disorders (Fig 1.4B).  An SI value of 5.2 differentiated limb-onset ALS from controls with 
a sensitivity of 80% and specificity of 80% (Fig 1.4B).  Taken together, these findings suggest 
that the SI may be a useful diagnostic test at differentiating ALS, in particular limb-onset ALS, 
from patients with other neuromuscular disorders in a clinical setting.  
 
In order to assess the diagnostic potential of the split hand index, values were compared between 
ALS patients meeting the definite and probable category of the Awaji-Shima criteria at the time 
of testing to those patients classified as ―possible‖ ALS.  Although, as expected, the reduction in 
SI was most prominent in patients meeting the Awaji-Shima criteria (ALS DEFINITE/PROBABLE SI 
3.0 ± 0.5; patients with other neuromuscular disorders 9.1 ± 0.3, P < 0.001, Fig. 1.5A), a 
significant reduction in SI was also evident in patients classified as ―possible‖ ALS 
 
when compared to patients with other neuromuscular disorders (ALS POSSIBLE SI 5.1 ± 0.8; 
patients with other neuromuscular disorders (9.1 ± 0.3, P < 0.01)(Fig 1.5B).  Of relevance, 64% 
of patients classified as possible ALS by the Awaji criteria at the time of assessment, exhibited 
an SI of < 5.2.  Taken together, these findings suggest that assessing split hand index in a clinical 
cohort may reliably distinguish ALS from patients with other neuromuscular disorders and 
support a diagnosis of ALS in up to 64% of patients not meeting the Awaji criteria. 
 
Combining measures of disease severity, clinical assessment and the split hand index, it was 
evident that the SI significantly correlated with measures of peripheral disease burden, including 
the neurophysiological index (R = 0.8, P < 0.001), total MRC score (rho= 0.7, P < 0.001) and the 
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MRC score from the APB (rho=0.8, P < 0.001).  In addition, the SI had a significant negative 
correlation with the rate of progression of ALSFRS-R (rho = - 0.4, P < 0.05) suggesting that 
patients with rapid clinical progression had lower values for SI. 
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A
B
Total ALS Cohort
AUC=0.8
P<0.0001
SI 5.2
Limb Onset ALS
AUC=0.9
P<0.0001
SI 5.2
Figure 1.4: (A) Receiver operating characteristic (ROC) curve analysis revealed that the split 
hand index (SI) reliable differentiated amyotrophic lateral sclerosis (ALS) from patients with 
other neuromuscular disorders (NMS), with an area under the curve (AUC) of 0.83 (P<0.0001).  
In addition, a cut-off value of 5.2 differentiated ALS from NMS with a sensitivity of 74% and 
specificity of 80%. (B) Sub-group analysis of ROC curves in ALS patients with limb-onset 
disease suggested that the SI exhibited a greater diagnostic robustness, with an AUC of 0.9 
(P<0.0001), sensitivity of 80% and specificity of 80%. 
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Figure 1.5: (A) The split hand index (SI) was significantly reduced in patients with amyotrophic 
lateral sclerosis (ALS) classified as ‗definite/probable‘ according to the Awaji criteria 
(P<0.0001). (B) There was a significant reduction of SI in patients classified as ‗possible‘ ALS 
when compared to patients with other neuromuscular disorders (NMS) (P<0.0001), thereby 
suggesting that the SI may aid in the earlier diagnosis of ALS.  
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Discussion 
The present study has developed a novel neurophysiological biomarker, termed the split-hand 
index, based on the clinical observations obtained from ALS patients. In the current prospective 
study, the SI reliably distinguished ALS from patients with other neuromuscular disorders early 
in the disease process.  Specifically, a split hand index value of 5.2 or less reliably differentiated 
ALS from other neuromuscular disorders.  Although this reduction in the split hand index was a 
uniform finding across the different ALS phenotypes, it was most pronounced in limb-onset ALS 
patients.  Of further relevance, a substantial proportion of ALS patients classified as ―possible‖ 
on the Awaji-Shima criteria, exhibited an abnormal split-hand index, suggesting that the 
reduction in SI may be an early feature in ALS.  Further, the split-hand index correlated with 
established biomarkers of ALS disease progression, namely the ALSFRS-R, neurophysiological 
index, muscle strength scores and rate of ALSFRS-R progression.  Taken together, findings from 
the present series suggests a diagnostic utility of the split hand index in ALS, complementing 
other clinical techniques to potentially aid an earlier diagnosis of ALS.    
 
Diagnosis of ALS 
Currently, the diagnosis of ALS relies on identifying a combination of upper and lower neuron 
dysfunction, with evidence of disease progression (185).  In the absence of a pathognomonic test, 
clinical criteria were developed to aid an early diagnosis of ALS, encompassing both upper and 
lower motor neuron signs (14).  Such clinical criteria, however, were found to be insensitive, 
often resulting in a diagnostic delay (17, 184, 515, 517).  Consequently, a modification of the 
clinical criteria was developed whereby the finding of fasciculations and other electromyography 
(EMG) features of lower motor neuron dysfunction, were equated with clinical features of lower 
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motor neuron dysfunction (82).  Although the Awaji-Shima criteria increased the diagnostic 
sensitivity in some ALS phenotypes (74, 77, 518) extensive EMG sampling is typically required, 
potentially limiting its clinical applicability.  In addition, the EMG findings of lower motor 
neuron dysfunction are not specific for ALS.  
 
Less conventional neurophysiological techniques such as motor unit number estimation (MUNE) 
(523), axonal excitability (56, 57), neurophysiological index (NI) (522) and electrode 
impendence myography (84, 524), do not reliably differentiate ALS from mimic disorders. It 
should be acknowledged, however, that both MUNE and NI were developed primarily as tools 
for quantifying disease progression rather than being diagnostic biomarkers for ALS.  Further, 
sophisticated magnetic resonance imaging techniques detecting abnormalities of the 
corticomotoneuronal system and molecular studies assessing aberrant expression of muscle 
proteins, such as Nogo-A and Nogo-B, have also been proposed as non-neurophysiological 
diagnostic biomarkers (2, 184, 525, 526). These techniques, however, may not be widely 
available and their sensitivity may be limited.   
 
The split hand index is a simple neurophysiological measure that can be readily performed in a 
clinical setting without the need for sophisticated neurophysiological techniques.  The finding 
that the split hand index reliably differentiates ALS from patients with other neuromuscular 
disorders, in particular limb-onset ALS, underscores the diagnostic utility of the split hand index.  
In addition, the finding that the reduction in the split hand index was an early feature in ALS, 
being evident in 64% of ALS patients classified in the ―possible‖ diagnostic category according 
to the Awaji criteria, suggests a utility for the SI in establishing an earlier diagnosis of ALS.    
104 
 
The present study may also serve to re-affirm the underlying pathophysiology of ALS.  
Specifically, given that the thenar complex group of muscles (APB and FDI) exhibit a greater 
cortical representation (45), the clinical observation of the split hand sign may suggest a cortical 
onset of ALS (20, 44, 54).  The findings that preferential atrophy of APB and FDI muscles was a 
specific feature of ALS, as illustrated by the split hand index, provides support for a cortical 
origin of ALS.    
 
Utility of the split-hand index in ALS 
The ability to recruit ALS patients into treatment trials at an earlier stage in the disease process, 
and to reliably monitor the effects of therapeutic agents, remains an important trial design 
strategy in assessing the effectiveness of future therapeutic agents at an early stage in drug 
development.  At present, patient enrollment into therapeutic trials remains low (17, 516, 527), in 
part accounted for by reliance on stringent diagnostic criteria (14).   In particular, ALS patients 
who are in the early stages of the disease process may not be enrolled into therapeutic trials, the 
very group that would probably derive most benefit from any neuroprotective therapies (516, 
528).  The findings in the present study suggests a utility for the split hand index in establishing 
an earlier diagnosis of ALS and thereby aiding patient recruitment into therapeutic trials.  Of 
further interest, the finding that SI correlated with traditional measures of disease progression, 
such as the ALSFRS-R, muscle strength scores, neurophysiological index and ALSFRS-R 
progression rate, may suggest a role in complementing other neurophysiological biomarkers, 
such as MUNE and NI, in monitoring disease progression, although this has to be further 
confirmed in longitudinal studies.   
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Chapter 2 
Cortical Excitability Differences in Hand 
Muscles follow a Split‐Hand Pattern in Healthy 
Controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
106 
 
Summary 
Subsequent to establishing the diagnostic utility of the split hand sign in ALS; differences in 
cortical and axonal excitability characteristics of intrinsic hand muscles was explored with the 
aim of determining whether differences in excitability differentiate muscles which undergo 
preferential atrophy in amyotrophic lateral sclerosis namely the abductor pollicis brevis (APB) 
and first dorsal interosseous (FDI).  Excitability studies were undertaken using threshold tracking 
techniques in 26 healthy controls with responses recorded over APB, FDI and abductor digiti 
minimi.  Short interval intracortical inhibition was significantly greater over the APB and FDI.  
In addition, motor evoked potential amplitude was greater, while cortical silent period duration 
was longer when recording over the APB and FDI.  At a peripheral level, the strength-duration 
time constant was greater when recorded over the APB.  This study establishes that differences 
in cortical excitability follows the split-hand pattern in healthy controls, a finding potentially 
explained by evolution of specialized activity of APB/FDI in complex hand tasks.       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
107 
 
Introduction 
Preferential atrophy of the abductor pollicis brevis (APB) and first dorsal interosseous (FDI) 
with relative preservation of abductor digit minimi (ADM), termed the split-hand sign, is a 
specific clinical feature of amyotrophic lateral sclerosis (ALS)(20, 21, 519, 529).  The 
pathophysiological mechanisms underlying this unusual pattern of dissociated muscle atrophy 
remains to be fully elucidated, although both cortical and peripheral mechanisms have been 
proposed (54, 55, 519). 
 
A cortical basis for the split-hand was inferred from the knowledge that the APB and FDI 
muscles are vital in the execution of skilled hand movements, such as precision grip (530-539).  
Consequently these muscles would be expected to exhibit a greater cortical representation in 
comparison to the hypothenar muscles (45).   Importantly, significant differences in cortical 
excitability were reported previously between distal and proximal upper limb muscles(540).  
Specifically, the degree of intracortical inhibition and facilitation were significantly greater when 
recorded over the thenar muscles (APB) compared to biceps brachii, suggesting a more 
prominent cortical representation of the thenar muscles (540).  Given that anterior horn cell 
degeneration in ALS may in part be mediated by corticomotoneuronal excitotoxicity(25, 44, 49, 
50, 87), the development of the split-hand phenomenon could be explained by differences in 
cortical excitability between the muscles.  Importantly, transcranial magnetic stimulation (TMS) 
studies have reported a preferential dysfunction of corticomotoneuronal input to the thenar 
muscles (APB), thereby suggesting a cortical basis for the split-hand phenomenon (54).   
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At the peripheral level, differences in excitability properties of motor axons innervating the 
thenar and hypothenar muscles were reported in healthy humans, with evidence of more 
prominent upregulation of persistent Na
+
 conductances in motor axons innervating APB and  
FDI muscles compared to the ADM(55).  While these findings established significant differences 
in axonal excitability properties across the range of intrinsic hand muscles, thereby implying a 
peripheral basis for the split-hand, differences in cortical excitability between the 3 muscles was 
not assessed.  Consequently, this study combined threshold tracking TMS and axonal excitability 
techniques to dissect out the differences in cortical and axonal excitability between APB, FDI, 
and hypothenar muscles, with a specific aim of determining whether the excitability differences 
follow a split-hand pattern.   
 
Methods and Materials 
Participants 
Studies were undertaken on 26 healthy volunteers (14 men, 12 women; mean age 48.9 years, age 
range 24-67 years).  None of the subjects had symptoms or clinical signs of central or peripheral 
nervous system dysfunction, and were not receiving psychotropic medications at the time of 
testing.  Subjects gave written informed consent to the procedures, and all procedures were 
approved by the Western Sydney Local Health District Human Research Ethics Committee.   
Experimental tasks 
Axonal excitability 
Initially, axonal excitability studies were undertaken on the median and ulnar motor nerves 
according to a previously described protocol (354).   The median and ulnar nerves were 
stimulated at the wrist using 5 mm non-polarizable Ag-AgCl electrodes (3M Healthcare, MN, 
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USA) with the anode positioned ~ 10 centimeters proximal to the cathode over the lateral 
forearm. Stimulation was computer controlled and converted to current using an isolated linear 
bipolar constant current simulator (maximal output ± 50 mA; DS5, Digitimer, Welwyn Garden 
City, UK).  Compound muscle action potentials (CMAPs) were recorded from the abductor 
pollicis brevis (APB), first dorsal interosseous (FDI), and abductor digit minimi (ADM) muscles 
with the active (G1) electrode positioned over the motor point and reference (G2) electrode 
placed over the base of the proximal thumb (APB and FDI) and fifth digit (ADM), respectively.  
Such a belly-tendon arrangement of electrodes enabled minimal cross-talk between the three 
muscles.  Test current pulses were applied at 0.5s intervals and combined with either sub-
threshold polarizing currents or suprathreshold conditioning stimuli according to previously 
described protocol (354, 355).  The motor evoked potential (MEP) amplitude was measured from 
baseline to negative peak, with the target set at 40% of maximum for all tracking studies.  
Proportional tracking was utilized to determine the changes in threshold current required to 
produce and maintain a target response (86). 
 
The following axonal excitability parameters were measured: (i) strength-duration time constant 
(τSD) and rheobase, determined according to the Weiss formula (86, 336); (ii) threshold 
electrotonus (TE) recorded with sub-threshold depolarizing currents at 10-20 ms [TEd (10-20 
ms)], 40-60 ms [TEd (40-60 ms)], and 90-100 ms [TEd (90-100 ms)], and with hyperpolarizing 
currents at 10-20 ms, TEh (10-20 ms) and at 90-100 ms, TEh (90-100 ms); (iii) hyperpolarizing 
current-threshold relationship (I/V) calculated from polarizing current between +50 and -100%; 
(iv) recovery cycle parameters including the relative refractory period (RRP, ms), refractoriness 
at 2ms (%), superexcitability (%), and late subexcitability (%).   
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Cortical excitability 
Cortical excitability studies were undertaken using a 90 mm circular coil connected to 2 high-
power magnetic stimulators connected via a BiStim device (Magstim Co., Whitlands, South 
West Wales, UK).  The coil position was adjusted for each muscle such that an optimal 
stimulating site was determined as indicated by a point on the skull vertex at which maximal 
MEP amplitude was evoked by the smallest TMS current.    
 
(i) Paired-pulse threshold tracking TMS was undertaken according to a previously reported 
technique (416, 417).  Briefly, the MEP amplitude was fixed, and changes in the test stimulus 
intensity required to generate a target response of 0.2 mV (± 20%), when preceded by sub-
threshold conditioning stimuli, were measured.  The MEP was recorded over the APB, FDI, and 
ADM muscles.  Resting motor threshold (RMT) was defined as the stimulus intensity required to 
maintain the target MEP of 0.2 mV (±20%).  A value of 0.2 mV was selected as the tracking 
target, rather than the conventional value of 0.05 mV used in the constant stimulus TMS 
technique (401), given that the former target response (0.2 mV) lies in the middle of the linear 
logarithmic stimulus-response relationship over a hundred-fold range of responses from about 
0.02 to 2 mV (416).  As such, larger variations in MEP amplitude would translate to smaller 
variations in stimulus intensity (the outcome variable), potentially enabling more accurate 
recordings of TMS parameters.    
 
Short-interval intracortical inhibition (SICI) was determined over the following interstimulus 
intervals (ISIs): 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, and 7 ms, while intracortical facilitation (ICF)  was 
measured at ISIs of 10, 15, 20, 25, and 30 ms. Stimuli were delivered sequentially as a series of 
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three channels: Channel 1: stimulus intensity, or threshold (% maximal stimulator output) 
required to produce the unconditioned test response (i.e., RMT); Channel 2: sub-threshold 
conditioning stimulus (70% RMT); and Channel 3 tracks the stimulus (% maximal stimulator 
output)  required to produce the target MEP when conditioned by a sub-threshold stimulus equal 
in intensity to 70% of RMT.  A sub-threshold conditioning stimulus set to 70%RMT was shown 
previously to result in maximal SICI (485).  Stimuli were delivered every 5–10 s (stimulus 
delivery was limited by the charging capability of the BiStim system), and the computer 
advanced to the next ISI only when tracking was stable. 
 
(ii) Single pulse TMS technique was utilized to determine the MEP amplitude (mV) and 
cortical silent period duration (ms).  The MEP amplitude was recorded with magnetic stimulus 
intensity set to 150% of RMT and normalized by being expressed as a percentage of the relevant 
muscles‘ CMAP response.  Subsequently to recording the MEP, the cortical silent period (CSP) 
duration was assessed by instructing the subject to contract the target muscle at ~30% of 
maximal voluntary contraction with TMS intensity set to 150% of RMT.   The CSP duration was 
measured from onset of MEP to return of EMG activity (455).   
 
Recordings of the CMAPs and MEPs were amplified and filtered (3 Hz-3 kHz) using a Nikolet-
Biomedical EA-2 amplifier (Cardinal Health Viking Select version 11.1.0, Viasys Healthcare 
Neurocare Group, Madison, Wisconsin, USA) and sampled at 10 kHz using a 16-bit data 
acquisition card (National Instruments PCI-MIO-16E-4).  Responses were further filtered for 
electronic noise by using a Hum Bug (Hum Bug 50/60 Hz Noise Eliminator, Quest Scientific 
Instruments, North Vancouver, Canada).  Data acquisition and stimulation delivery were 
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controlled by QTRACS software (TROND-F, version 16/02/2009, © Professor Hugh Bostock, 
Institute of Neurology, Queen Square, London, UK).  Temperature was monitored with a 
purpose built thermometer at the stimulation site.  
 
Statistical Analysis 
SICI was measured as the increase in the test stimulus intensity required to evoke the target 
MEP.  Inhibition was calculated off-line as follows (417):  
Inhibition = (Conditioned test stimulus intensity – RMT)/RMT * 100 
Facilitation was measured as the decrease in the conditioned test stimulus intensity required to 
evoke a target MEP.  Each data point was weighted (by the QTRACS software) such that any 
measures recorded outside the threshold target window, defined as values within 20% of the 
tracking target of  0.2mV (peak-to-peak), contributed least to the data analysis. All results were 
expressed as mean ± standard error of the mean. Paired samples t-test was used for assessing 
differences between 2 groups, while analysis of variance (ANOVA) with post-hoc testing 
(Bonferroni correction) was used for multiple comparisons.  The Pearson correlation coefficient 
was used to examine the relationship between parameters.  A probability (P) value of <0.05 was 
considered statistically significant.  
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Parameter 
 
APB 
[SEM] 
FDI 
[SEM] 
ADM 
[SEM] 
P-value 
APB vs FDI 
P-value 
APB vs ADM 
P-value 
FDI vs ADM 
CMAP amplitude 
(mV) 
12.1 
[0.7] 
15.6 
[1.1] 
13.7 
[ 0.6] 
< 0.05 0.50 0.09 
       
RMT (%) 
55.6 
[1.7] 
57.2 
[2.1] 
55.5 
[1.9] 
0.26 0.46 0.07 
       
Peak SICI 
ISI 3ms (%) 
22.7 
[2.7] 
23.5 
[3.3] 
16.2 
[3.0] 
0.44 < 0.05 < 0.05 
       
MEP amplitude 
(%) 
18.4 
[2.6] 
14.9 
[1.3] 
12.7 
[1.1] 
0.09 < 0.05 < 0.05 
       
CSP duration 
(ms) 
200.4 
[8.1] 
202.4 
[6.8] 
187.2 
[6.0] 
0.38 < 0.05 < 0.001 
       
SDTC (ms) 
0.49 
[0.02] 
0.43 
[0.01] 
0.43 
[0.01] 
< 0.05 < 0.05 1.0 
       
Rheobase (mA) 
1.49 
[0.19] 
2.16 
[0.15] 
2.05 
[0.26] 
< 0.001 < 0.05 0.35 
       
TEd 
(10-20 ms) 
(%) 
69.0 
[1.0] 
67.3 
[0.9] 
64.5 
[1.0] 
0.10 < 0.01 < 0.05 
       
TEd 
(40-60 ms) 
(%) 
52.9 
[0.9] 
50.0 
[0.7] 
50.5 
[0.8] 
0.10 0.14 1.0 
       
TEd 
(90-100 ms) 
(%) 
45.3 
[0.8] 
43.2 
[0.8] 
45.2 
[0.7] 
0.34 1.0 0.44 
       
RRP (ms) 
3.7 
[0.3] 
3.3 
[0.1] 
3.3 
[0.2] 
0.12 0.12 0.45 
       
Superexcitability 
(%) 
-21.7 
[1.4] 
-23.2 
[1.1] 
-22.8 
[1.2] 
0.19 0.22 0.36 
       
Late subexcitability 
(%) 
14.6 
[1.0] 
14.6 
[1.4] 
7.6 
[1.28] 
0.50 < 0.001 < 0.001 
Table 2.1: Cortical and axonal excitability data.  Peak SICI at ISI 3 ms and CSP duration were 
reduced significantly, while the MEP amplitude was increased when recording over the APB 
and FDI muscles compared to ADM.  In addition, the CMAP amplitude was significantly larger 
when recording over FDI compared to APB.  In contrast, resting motor threshold was 
comparable between groups.  Of further relevance, the strength-duration time constant (SDTC) 
was increased significantly when recording over the APB.  Interestingly, depolarizing threshold 
electrotonus at 10-20 ms (TEd 10-20 ms) was increased significantly when recording over APB 
and FDI, while there was no significant difference in depolarizing threshold electrotonus at 40-
60 ms (TEd 40-60 ms) and threshold electrotonus at 90-100 ms (TEd 90-100 ms) across the 
range of intrinsic hand muscles.  Of further relevance, the RRP was comparable across the 3 
intrinsic hand muscles.  All data are expressed as mean (standard error of the mean).   
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Results 
Cortical  Excitability 
A complete sequence of recordings was obtained from all subjects.  Peak-to-peak CMAP 
amplitude was significantly smaller when recorded from the APB compared to the FDI (F=3.4, 
P<0.05, Table 1).  In contrast, CMAP amplitudes recorded over the ADM (P= 0.50) were 
comparable to those recorded from the APB but smaller when compared to FDI (P = 0.09), 
although this reduction was not significant.   
 
Paired-pulse threshold tracking TMS was utilized to assess SICI and ICF from the APB, FDI and 
ADM.  Initially, the resting motor threshold (RMT) was recorded from each muscle and defined 
as the stimulus intensity required to produce and maintain a target MEP of 0.2 mV.  The RMT 
was comparable between the muscles (Table 2.1).  Subsequently SICI, defined as the conditioned 
stimulus intensity required to produce and maintain the target MEP of 0.2 mV, was assessed.    It 
was significantly greater when recording over the APB and FDI compared to ADM (F = 6.0, P< 
0.005, Fig. 2.1A).  In addition, peak SICI was significantly greater when recording over the APB 
and FDI muscles compared to ADM (Fig. 2.1B, Table 2.1).  Following SICI, a period of 
intracortical facilitation may develop between ISI of 10-30ms.  The mean ICF between ISIs 10-
30 ms was not significantly different between the 3 muscles (Fig. 2.1A). 
 
Single-pulse TMS disclosed that the MEP amplitude, expressed as a percentage of the CMAP, 
was significantly greater when recording over the APB and FDI compared to the ADM (Fig. 
2.2A, Table 2.1).  In contrast, there were no significant differences in MEP amplitude between 
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APB and FDI muscles.  Of further relevance, the CSP duration was the significantly longer when 
recorded over the APB and FDI muscles compared to ADM (Fig. 2.2B, Table 2.1).  
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Figure 2.1:  (A) SICI was significantly greater when recording over the APB and FDI muscles 
compared to ADM.  (B)  In addition, peak SICI was also significantly greater when recording over the 
APB and FDI muscles.  *P< 0.05 
 
116 
 
             
 
 
 
 
 
Axonal Excitability 
Strength-duration time constant (τSD), a biomarker of nodal persistent Na+ conductance, and 
rheobase, defined as the threshold current for a stimulus of infinitely long duration, were 
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Figure 2.2: (A) The MEP amplitude, expressed as a percentage of the CMAP, was significantly 
greater when recording over the APB and FDI muscles compared to abductor ADM.  (B)  The 
CSP duration was significantly longer when recording from the APB and FDI muscles.   
*P< 0.05; ***P<0.001. 
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assessed to define the strength-duration properties of the median and ulnar nerve motor axons 
(85, 86, 333, 337, 541).  The strength duration time constant was significantly increased when 
recording over the APB muscle compared to the FDI and ADM (Fig. 2.3A, Table 2.1).  In 
addition, the rheobase was significantly reduced when recording over the APB compared to FDI 
(Fig. 2.3B, Table 2.1) and ADM (Fig. 2.3B, Table 2.1) muscles.  Of further relevance, the mean 
threshold to activate the median motor nerve was reduced when compared to the ulnar nerve 
(F=2.8, P = 0.06), although this reduction was not significant.   
 
Measurement of threshold electrotonus, a biomarker of paranodal and internodal axonal 
conductances (85, 86), revealed further differences between the three intrinsic hand muscles.  
Specifically, depolarizing threshold electrotonus at 10-20 ms was significantly increased when 
recording over the APB and FDI compared to ADM (F=5.2, P<0.01, Fig.2.4, Table 2.1).  In 
contrast, there were no significant differences in depolarizing TE at 40-60 ms (Fig. 2.4A) and 90-
100 ms (Fig 2.4A, Table 2.1).  In addition, there was no significant difference in hyperpolarizing 
TE between groups (F = 0.05, P = 0.96).   
 
Subsequent to assessing TE, the recovery cycle of axonal excitability was recorded in response to 
a supramaximal conditioning stimulus.  Late subexcitability was increased significantly when 
recording from the APB and FDI muscles (F = 11.4, P < 0.001, Fig. 2.5 A, B, Table 2.1).  In 
contrast, there were no significant differences in the RRP (Fig. 2.5A, Table 2.1), refractoriness at 
2 ms (F=0.5, P=0.61), and superexcitability (Fig. 2.5A, Table 2.1).  Further, there were no 
significant differences in hyperpolarizing I/V gradient between the APB, FDI and ADM muscles 
(F = 2.5, P = 0.09).  
118 
 
                    
 
 
 
 
 
 
 
 
0
1
S
D
T
C
 (
m
s)
1
10
R
h
eo
b
a
se
 (
m
A
)
APB FDI ADM
A
B
APB FDI ADM
*
*
*
*
Figure 2.3: (A) The strength-duration time constant, a biomarker of persistent Na
+
 
conductances, was significantly longer when recording from the APB and FDI muscles 
compared to ADM.  (B)  The rheobase was significantly smaller when recording over the APB.  
*P< 0.05; ***P < 0.001. 
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Figure 2.4:  (A) Depolarizing threshold electrotonus at 10-20 ms (TEd 10-20 ms), a biomarker 
of paranodal fast K
+
 currents, was significantly increased when recording over the APB and FDI 
compared to ADM. There were no significant differences in other depolarizing TE parameters. 
(B)  Scatter plots illustrating that TEd 10-20 ms was significantly greater when recording over 
APB and FDI.  *P< 0.05; **P< 0.01. 
 
Figure 2.5:  (A) Recovery cycle of excitability revealed that late sub-excitability was 
significantly larger when recording over APB and FDI compared to ADM.  There were no 
significant differences in the RRP and superexcitability.  (B)  Scatter plots illustrating a 
significant increase in late subexcitability when recording over APB and FDI.  ***P<0.001. 
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Correlation studies 
There were no significant correlations between SICI and strength duration time constant (R = -
0.05, P =0.34), TEd 10-20 ms (R = 0.14, P =0.13), or MEP amplitude (R = -0.13, P = 0.19).  In 
addition, MEP amplitude and CSP duration did not correlate with strength duration time constant 
or TEd (10-20 ms).   Taken together, these findings suggest that the changes in central and 
peripheral nerve excitability were independent processes.  
 
Discussion 
The present study has established significant differences in cortical and axonal excitability 
between the APB, FDI, and ADM muscles.  Specifically, SICI and MEP amplitude were 
significantly larger, while the CSP duration was significantly longer when recording from the 
APB and FDI.  Taken together, these findings establish the presence of significant differences in 
cortical excitability between the 3 intrinsic hand muscles, with implications of a greater strength 
of intracortical inhibition and larger corticomotoneuronal output to the APB and FDI muscles.  
Separately, the strength-duration time constant was significantly longer and rheobase smaller, 
but only when recording over the APB.  The differences in neurophysiological findings, 
particularly cortical excitability, could have potentially evolved from the differential use of these 
muscles in complex hand movements.  Mechanisms underlying the changes in central and 
peripheral nerve excitability and their clinical implications will form the basis of the discussion. 
 
Cortical mechanisms underlying differences in TMS parameters  
It has been well established that cortical mechanisms underlie the generation of many features of 
the muscle activation that occurs in response to TMS, such as SICI (150, 401).  Studies assessing 
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the effects of paired-pulse stimuli (conditioning-test paradigm) at short time intervals required to 
generate SICI have revealed a reduction in number and amplitude of indirect (I)-waves (waves I2 
and later) in corticospinal volleys (469, 470, 490, 542, 543), with implications that SICI 
originates at a cortical level, most likely the M1 cortex.  Interestingly the time course of I-wave 
inhibition was similar to the typical duration of inhibitory postsynaptic potentials mediated 
through GABAA receptors (469, 471), thereby suggesting that  SICI was mediated by inhibitory 
cortical interneurons acting via GABAA receptors (401, 441, 468, 544).   Studies in non-human 
primates have provided additional evidence for a cortical origin of SICI, whereby direct 
 
stimulation of the M1 cortex in macaque primates resulted in descending I-wave volleys, similar 
to that reported in humans (545).  In the present study, SICI was larger when recording over the 
APB and FDI, suggesting a greater potency of the inhibitory circuits subserving the APB and 
FDI muscles. Given that the APB and FDI are involved in the execution of numerous hand 
movements, one of which is precision grip (531-533, 536, 537, 546, 547), such findings may 
have evolved from the differential actions of these muscles in complex hand movements.  
 
In addition to SICI changes, the MEP amplitude was larger when recording over APB and FDI.  
The MEP amplitude is a biomarker of the density of corticomotoneuronal projections onto spinal 
motor neurons, in part reflecting the optimal conduction from M1 to spinal motor neurons (150, 
401). Consequently, the findings of larger MEP amplitudes would seem to imply a greater 
corticomotoneuronal input to spinal motor neurons innervating the APB and FDI.  Importantly, 
these findings are in keeping with previous studies that reported larger MEP amplitudes during 
performance of a complex task (190), further underscoring the notion that these changes in MEP 
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amplitude may have resulted from specific activity of APB and FDI muscles during the 
execution of complex hand tasks. 
 
Of further relevance, there were significant changes in the CSP duration between the 3 muscles.  
Specifically, the CSP duration is in part mediated by cortical inhibitory circuits, acting via 
GABAB receptors(150, 452, 453, 457, 458, 548, 549).  The CSP duration may also be influenced 
by the strength of corticomotoneuronal projections onto spinal motor neurons (401).   
Consequently, the findings in this study suggest further that intracortical inhibitory tone and 
corticomotoneuronal input were larger to the APB and FDI muscles.  Alternatively, it could also 
be argued that the changes in CSP duration could be a function of the MEP amplitude (550).  
This seems an unlikely explanation given that there was no correlation between CSP duration 
and MEP amplitude.     
 
In addition to a greater corticomotoneuronal output, a further explanation for these findings may 
relate to specific properties of corticomotoneurons innervating the APB and FDI muscles.  
Specifically, recent studies in macaque primates have established the existence of unique M1 
output neurons, identified as pyramidal tract neurons (PTN), that discharge in response to the 
observation of precision grip by a human experimenter (551).  Some of these PTNs with mirror 
properties were identified as exerting corticomotoneuronal effects on hand muscles, and while 
they discharged during action observation, were not associated with muscle contractions.  Of 
further relevance, the PTN discharges were reduced greatly during action observation compared 
with trials in which the monkey itself executed the grasp, which may reflect a mechanism for 
controlling the motor system in a way that suppresses undesired movement.  Given that these 
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PTNs with mirror properties appear to be important in execution of complex hand tasks, it could 
be argued that the corticomotoneuronal innervations of the APB and FDI motor neurons is more 
complex when compared to hypothenar motor neurons, thereby in-part accounting for the present 
findings. 
 
Alternatively, it could also be argued that the differences in cortical excitability could be related 
to the use of a circular coil, which exerts effects over a wider cortical area, thereby resulting in 
non-specific activation of the motor cortex (552).  This seems unlikely given that the coil 
position was altered such that an optimal MEP was elicited prior to assessment of each muscle.  
Importantly, previous TMS studies failed to establish any qualitative differences in the patterns 
of inhibition when using a circular or focal figure-of-eight coil (540).  It is accepted that 
inadvertent stimulation of short interval facilitatory circuits may have contributed to differences 
in cortical excitability, in particular the differences in SICI.  This is underscored by the fact that 
TMS studies utilizing the constant stimulus technique, with lower conditioning stimulus 
intensities, failed to document any significant differences in SICI between the different intrinsic 
hand muscles (552-555), while studies utilizing higher conditioning stimulus intensities reported 
findings similar to the present study (556).  A significant contribution from inadvertent 
stimulation of facilitatory pathways seems an unlikely explanation, given that in previous 
threshold tracking TMS studies we have established that maximal SICI develops when sub-
threshold conditioning stimuli were set to 70% of RMT (485).   
 
In addition to changes in cortical excitability, there were also significant differences in axonal 
excitability, although they were most prominent when recording over the APB.  Specifically, the 
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strength-duration time constant, a biomarker of  nodal persistent Na
+
 channel conductance (337), 
was increased significantly when recording over the APB.  Moreover, early depolarizing 
threshold electrotonus (TEd 10-20 ms), a biomarker of fast paranodal K
+
 conductances (85, 86), 
was increased when recording over the APB and FDI, but not the ADM.  While some of the 
axonal excitability findings are in keeping with previous studies (55), suggesting a greater degree 
of hyperexcitability of motor axons innervating the APB and FDI muscles, there were important 
differences.  Specifically, in the present study the τSD was only increased when recording from 
the APB, while Bae and colleagues reported comparable increases of τSD from the thenar and 
FDI muscles (55).  In addition, the relative refractory period and refractoriness were comparable 
between the three muscles, contrasting with previous findings (55).   A potential explanation for 
the discordant findings may relate to the variability of individuals to perform fractionated finger 
movements, a notion in part supported by a considerable overlap of axonal excitability values in 
this study.  It could also be argued that the changes in axonal excitability account for differences 
in the cortical excitability findings between the three muscles.  This seems unlikely, given that 
downstream axonal excitability changes are unlikely to influence corticomotoneuronal input to 
the motor neurons, a notion supported by an absence of correlation between measures of cortical 
and axonal excitability.  
 
Clinical implications 
Preferential atrophy of  the APB and FDI muscles, with relative preservation of the ADM, 
termed the split hand, is a specific feature of neurodegenerative disorders such as amyotrophic 
lateral sclerosis (ALS) (2, 20, 21, 130, 184, 519).  While the precise pathophysiological 
processes underlying the development of the split hand remains to be elucidated, both central and 
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peripheral mechanisms have been proposed (44).  A cortical basis for the split hand was based on 
observations that thenar muscles were responsible for fractionated finger movements and thereby 
receive a greater cortical representation and corticomotoneuronal input (44).  Consequently, 
greater corticomotoneuronal input onto spinal motor neurons innervating the APB and FDI 
muscles may result in preferential degeneration of these spinal motor neurons via a transsynaptic 
anterograde excitotoxic mechanism.   
 
The findings of greater SICI, MEP amplitude, and longer CSP duration to the APB and FDI 
would support a hypothesis of greater corticomotoneuronal input to these muscles and are 
concordant with previous TMS studies (54). In addition to cortical processes, differences in 
membrane properties of axons innervating the intrinsic hand muscles could contribute to 
development of the split-hand.  Previously, upregulation of persistent Na
+
 conductances, as 
measured by strength-duration time constant and latent addition, along with reduction in fast K
+
 
current were reported in APB and FDI axons (55).  Although upregulation of persistent Na
+
 
conductances was only evident in the APB axons in the present study, reduction in fast K
+
 
currents was evident in both the APB and FDI axons.  Ultimately, such changes in axonal 
excitability would render the APB and FDI axons hyperexcitable, thereby potentially 
predisposing them to neurodegeneration via Ca
2+
-mediated mechanisms (557). Given that 
persistent Na
+
 conductances were not upregulated in FDI axons; this may suggest a 
predominance of cortical processes in development of the split-hand phenomenon.  If verified in 
future ALS cohorts, such findings could be of potential pathophysiological significance.   
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Chapter 3 
ALS Pathophysiology: Insights from the  
Split-Hand Phenomenon 
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Summary 
Subsequent to the study in normal subjects establishing differences in cortical excitability that 
follow the split-hand pattern, the present study was aimed at assessing whether peripheral 
mechanisms, mediated through axonal dysfunction, may contribute to development of the split-
hand phenomenon in amyotrophic lateral sclerosis (ALS).  Median and ulnar nerve motor axonal 
excitability studies were undertaken in 21 ALS patients with motor responses recorded over the 
abductor pollicis brevis (APB), abductor digit minimi (ADM) and first dorsal interosseous (FDI) 
muscles, and results compared to 24 controls.  The split-hand index (SI), an objective biomarker 
of preferential atrophy of APB and FDI muscles, was significantly reduced in ALS (SI ALS 
7.8±1.7, SI CONTROLS 13.1±1.1, P<0.0001).  Axonal excitability studies identified significant 
prolongation of strength-duration time constant in ALS patients when recording over the APB 
(P<0.05) and ADM axons (P<0.05) but not FDI axons (P=0.22).  Greater changes in depolarising 
threshold electrotonus were also evident across the range of intrinsic hand muscles and were 
accompanied by increases of superexcitability in APB (P<0.01) and FDI (P<0.05) axons.  The 
present study reinforces the significance of the split-hand phenomenon in ALS and argues 
against a significant peripheral contribution in the underlying development. Axonal dysfunction 
may appear as a downstream process that develops secondary to the intrinsic pathophysiological 
origins of ALS.         
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Introduction 
Dissociated atrophy of intrinsic hand muscles, termed the split hand phenomenon, refers to 
preferential wasting of abductor pollicis brevis (APB) and first dorsal interosseous (FDI) muscles 
with relative preservation of the abductor digit minimi (ADM) (21, 558).  The split-hand sign 
appears to be an early and specific clinical feature of amyotrophic lateral sclerosis (ALS), not 
evident in other common clinical mimic neuromuscular disorders (20, 21, 54, 519, 529), 
although it has been reported with normal ageing and in some neurodegenerative disorders such 
as spinocerebellar ataxia type 3, juvenile muscular atrophy and autosomal dominant spinal 
muscular atrophy  (559, 560).   
 
The mechanisms underlying the development of the split-hand pattern of wasting in ALS 
remains to be elucidated, with resolution of this issue of potential pathophysiological importance 
in understanding ALS onset and patterns of disease spread.  Given that wasted intrinsic hand 
muscles are innervated by an overlap of similar myotomes (C8-T1), dysfunction of local spinal 
segments are unlikely to account for the split-hand phenomena in ALS per se.  Rather, three 
potential mechanisms have been proposed including a cortical-based process related to a larger 
central representation of the thenar complex group of muscles (APB/FDI), abnormalities at a 
peripheral level and increased metabolic demands of the motor neurons innervating the thenar 
and FDI muscles (20, 54, 519, 529). 
 
Perhaps of relevance, upregulation of persistent Na
+
 conductances, as reflected by an increase  
in strength-duration time constant, and reduction in K
+
 currents, have been extensively 
documented in ALS (31, 56-58, 126, 561, 562). Importantly, changes in axonal excitability, 
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particularly upregulation of persistent Na
+
 conductances, have been linked to the process of 
neurodegeneration and survival in ALS (57, 562).  While these studies established that 
dysfunction of axonal ion channel conductances was part of the pathophysiological process in 
ALS, only single nerves were assessed, precluding any conclusions as to whether specific or 
more generalized abnormalities in axonal excitability contributed to the development of the split-
hand phenomenon. 
 
A study in healthy controls reported a relative increase in strength-duration time constant and 
greater abnormalities of threshold electrotonus in motor axons innervating the APB and FDI 
muscles compared to ADM (55).  These findings implied that axons innervating the thenar 
muscles and FDI may seem physiologically prone to develop hyperexcitability and thereby 
susceptible to degeneration in ALS.  Recently, a greater increase in strength-duration time 
constant and more prominent abnormalities of depolarising threshold electrotonus were reported 
in axons innervating the APB muscle compared to ADM in sporadic ALS (563).  While these 
findings suggested that dysfunction at a peripheral axonal level may contribute to the 
development of the split hand, the excitability properties of FDI axons was not assessed.  As a 
consequence, axonal excitability properties of motor axons innervating the APB, FDI and ADM 
muscles were assessed ―en bloc‖, in order to determine whether dysfunction at a peripheral 
axonal level determined the pathophysiological basis of the split hand in ALS.    
 
Methods  
Studies were undertaken on 21 amyotrophic lateral sclerosis (ALS) patients with clinically 
probable or definite ALS (16 male, 5 female: mean age: 55 years, 32-73) as defined by the Awaji 
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criteria (82).  All patients provided written informed consent to the procedures which were 
approved by the Western Sydney Local Health District Human Research Ethics Committee.  
  
Clinical Phenotyping 
ALS patients were clinically staged using the amyotrophic lateral sclerosis functional rating 
scale-revised (ALSFRS-R) score (511) and according to site of disease onset as limb or bulbar-
onset.   Muscle strength was assessed by utilising the Medical Research Council (MRC) score 
(512), with the following muscle groups assessed bilaterally yielding a total MRC score of 90:  
shoulder abduction; elbow flexion; elbow extension; wrist dorsiflexion; finger abduction; thumb 
abduction; hip flexion; knee extension; ankle dorsiflexion.  In addition, ALS patients were 
classified according to the extent of lower motor neuron dysfunction as indicated by compound 
muscle action potential (CMAP) amplitudes, measured from baseline-to-peak, into ―early stage‖ 
and ―more advanced‖ patients as follows:  (i) APB normal amplitude (CMAP≥4 mV); reduced 
amplitude (<4 mV); (ii) ADM normal amplitude (CMAP≥5.5 mV); reduced amplitude (<5.5 
mV); (iii) FDI, normal amplitude (CMAP≥7.7 mV); reduced amplitude (<7.7 mV). All patients 
underwent extensive neurophysiological, radiological and biochemical investigations and 
patients with coexisting neurological disorders such as median and ulnar nerve entrapment 
neuropathies and peripheral neuropathy were excluded from the study.  Patients suffering with 
diabetes mellitus or chronic renal failure were excluded and all patients and controls were 
confirmed to not be on medications that could affect the results.     
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Axonal excitability studies 
All ALS patients underwent axonal excitability studies on the median and ulnar motor nerves 
according to a previously described protocol (354).   Briefly the median and ulnar nerves were 
stimulated at the wrist using 5 mm non-polarizable Ag-AgCl electrodes (3M Healthcare, MN, 
USA) with the CMAP responses recorded over APB, FDI and ADM muscles.  All studies were 
undertaken unilaterally, from the more clinically affected limb that exhibited a split-hand 
phenomenon.  As such, the changes in axonal excitability are more likely to reflect the 
pathophysiology underlying the split-hand.  The following axonal excitability parameters were 
measured: (i) strength-duration time constant (τSD) and rheobase; (ii) threshold electrotonus (TE) 
recorded with sub-threshold depolarizing currents at 10-20 ms (TEd [10-20 ms]), 40-60 ms (TEd 
[40-60 ms]), and 90-100 ms (TEd [90-100 ms]), and with hyperpolarizing currents at 10-20 ms, 
TEh [10-20 ms] and at 90-100 ms, TEh [90-100 ms]; (iii) hyperpolarizing current-threshold 
relationship (I/V) calculated from polarizing currents between +50 and -100%; (iv) recovery 
cycle parameters including relative refractory period (RRP, ms), superexcitability (%) and late 
subexcitability (%).   
 
In addition, the CMAP onset latency and twenty F-wave responses were also recorded from each 
muscle from which the neurophysiological index (NI) was derived (65).  The split-hand index 
(SI) was also calculated according to a previously reported formulae (529). 
SI = CMAPAPB * CMAPFDI 
CMAPADM 
 
Recordings of CMAP responses were amplified and filtered (3 Hz-3 kHz) using a Nikolet-
Biomedical EA-2 amplifier (Cardinal Health Viking Select version 11.1.0, Viasys Healthcare 
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Neurocare Group, Madison, Wisconsin, USA) and sampled at 10 kHz using a 16-bit data 
acquisition card (National Instruments PCI-MIO-16E-4).  Data acquisition and stimulation 
delivery were controlled by QTRACS software (TROND-F, version 16/02/2009, © Professor 
Hugh Bostock, Institute of Neurology, Queen Square, London, UK).  Temperature was 
monitored with a purpose built thermometer at the stimulation site and maintained at or above 
32
○
C. 
 
Statistical analysis 
Axonal excitability studies were compared to 24 age-matched controls (13 males; 11 females, 
mean age 51.1±2.2 years).  Student t-test was utilised to assess differences between means in 
patients and controls.  Pearson's correlation coefficients were used to examine the relationship 
between parameters.  Shapiro-Wilk test disclosed that all neurophysiological data, namely axonal 
excitability and conventional neurophysiological data, was normality distributed.  A probability 
(P) value of <0.05 was considered statistically significant, and the probability values were 
corrected for multiple comparisons.  Results were expressed as mean ± standard error of the 
mean and median (interquartile range). 
 
Results 
Clinical features 
The clinical features for the 21 ALS patients are summarised in Table 3.1.  A split-hand pattern 
of atrophy was evident in 53% of patients.  Bulbar-onset disease was evident in 40% and limb-
onset disease in 60% of ALS patients.  Although the split-hand sign was more frequently 
observed in limb-onset (62%) compared to bulbar-onset disease (37%), this difference was not 
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significant (P=0.33).  At time of assessment, the median disease duration from symptom onset 
was 10 (5-17) months, while the median ALSFRS-R was 43 (41-46), suggesting a moderate 
degree of disability.  In addition, the median total MRC score was 81 (74-87), upper limb MRC 
score 54 (50-58) and lower limb score 30 (28-30), reaffirming a mild to moderate degree of 
impairment.  Given that ALS patients were in the early stages of the disease at time of 
recruitment, 40% were receiving riluzole while 60% were not taking riluzole at the time of 
axonal excitability studies.   
 
Prior to conducting axonal excitability studies the degree of the lower motor neuron dysfunction 
was determined.  The CMAP amplitude was significantly reduced from all three muscles in ALS 
patients compared to controls (APB CMAPALS 5.6±0.8 mV, CMAPCONTROLS 8.4±0.5, P<0.001; 
FDI CMAPALS 5.5±0.9mV, CMAPCONTROLS 10.3±0.9mV, P<0.001; ADM CMAPALS 6.5±0.5mV, 
CMAPCONTROLS 10.1±0.5 mV, P<0.001).  In addition, the NI was also significantly reduced 
(APB NI ALS 1.3±0.2, NICONTROLS 1.9±0.2, P<0.001; FDI NIALS 1.3±0.3, NICONTROLS 2.9±0.2, 
P<0.0001; ADM NI ALS 1.6±0.2, NI CONTROLS 2.8±0.1, P<0.0001).   
 
Of further relevance, the spit-hand index was significantly reduced in ALS patients (SI ALS 
7.8±1.7, SI CONTROLS 13.1±1.1, P<0.0001).  While the reduction in SI was a ubiquitous finding, it 
was most prominent in limb-onset patients (SI LIMB-ONSET 6.7±1.3; SI BULBAR-ONSET 7.4±1.6), 
although this difference was not significant (P=0.39).  Taken together, these findings indicate a 
greater degree of lower motor neuron dysfunction in ALS patients, with split-hand pattern of 
atrophy being a feature in ALS.  
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PATIENTS AGE/ 
SEX 
SITE OF 
ONSET 
DURATION 
(MONTHS) 
ALSFRS-R 
 
MRC 
UL 
MRC 
LL 
MRC 
TOTAL 
1 51/M LIMB 21 33 47 18 65 
2 42/M LIMB 17 41 44 30 74 
3 73/M LIMB 30 44 51 30 81 
4 69/F LIMB 14 47 51 30 81 
5 62/M LIMB 5 46 58 30 88 
6 45/M LIMB 3 46 56 30 86 
7 48/M LIMB 5 42 60 20 80 
8 64/M LIMB 7 47 57 30 87 
9 41/M LIMB 6 43 53 27 80 
10 68/M LIMB 9 48 58 30 88 
11 66/M LIMB 9 47 50 30 80 
12 56/F LIMB 14 34 52 22 74 
13 68/M LIMB 12 42 26 30 56 
14 57/M BULBAR 3 44 60 30 90 
15 71/F BULBAR 12 42 42 30 72 
16 52/F BULBAR 24 36 54 30 84 
17 39/M BULBAR 10 32 47 20 67 
18 64/M BULBAR 30 23 54 28 82 
19 49/F BULBAR 21 42 60 30 90 
20 58/M BULBAR 4 43 60 30 90 
21 32/M BULBAR 4 43 54 30 84 
MEAN/MEDIAN 
SEM (IQR) 
55.9 
2.6  
10 
(5-17) 
43 
(41-46) 
54 
(51-58) 
30 
(28-30) 
81 
(74-87) 
      
 
 
 
Axonal excitability  
 
 
Table 3.1: Axonal excitability studies were undertaken on 21 amyotrophic lateral sclerosis 
(ALS) patents, 16 males (M) and 5 females (F).  All patients were clinically staged using the 
amyotrophic lateral sclerosis functional rating scale–revised (ALSFRS-R, range 0 to 48), as well 
as the Medical Research Council (MRC) score for muscle strength.  Muscle strength was 
assessed from the upper limbs (UL, maximal MRC score 60) and the lower limbs (maximal 
MRC score 30, see Methods), resulting in a total MRC score of 90.  All results were expressed 
as either me n ± standard error of the mean (SEM) or median with interquartile range (IQR). 
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The strength-duration time constant (ƮSD), a biomarker of nodal persistent Na
+
 conductance 
(86), was significantly longer in ALS patients when recording from APB (ALSAPB 0.51±0.02 
ms; controls 0.47±0.02 ms, P<0.05, Fig. 3.1A, B) and ADM (ALSADM 0.50±0.02 ms; controls 
0.43 ±0.01 ms, P<0.01, Fig. 3.1C, D), but not FDI muscles (ALS FDI 0.44±0.03 ms; controls 
0.43±0.01 ms, P=0.22, Table 2).  There were no significant differences in rheobase between ALS 
patients and controls (ALS APB 1.40±0.1 mA; controls 1.55±0.2 mA, P=0.16; ALS FDI 2.57± 
0.38 mA; controls 2.55±0.43 mA, P=0.49; ALS ADM 1.95±0.26 mA; controls 1.80±0.19 mA, 
P=0.33, Table 2).  The increase in ƮSD was independent of therapeutic status, being evident in 
patients receiving riluzole and those who were yet to be commenced on riluzole when recording 
from APB (APBSD ON RILUZOLE 0.52±0.02 ms, P<0.05; APB SD NO RILUZOLE 0.53±0.02 ms, 
P<0.05) and ADM (ADMSD ON RILUZOLE 0.50±0.03 ms, P<0.05; ADMSD NO RILUZOLE 0.50±0.02 
ms, P<0.05) muscles.   
 
Threshold Electrotonus, a biomarker of internodal and paranodal K
+
 currents (85), revealed 
greater changes in sub-threshold depolarizing TE when recording from all three muscles.  
Specifically, depolarizing TE at 90-100 ms was significantly greater when recording over the 
APB (ALS 50.3±1.5%; controls 44.7±0.8%, P<0.001, Fig. 3.2A, B), ADM (ALS 48.1±1.0%; 
controls 45.5±0.7%, P<0.05, Fig. 3.2C, D) and FDI (ALS 45.1±1.5%; controls 40.0±2.2%, P < 
0.05, Fig. 3.2E, F) muscles in ALS.  These changes were accompanied by a significant increase 
in TEd at 40-60 ms in APB (ALS 56.1±1.7%; controls 52.6±1.0%, P<0.05, Fig. 3.3A, B) and 
ADM (ALS 53.6±1.3%; controls 50.8±0.9%, P<0.05, Fig. 3.3C, D), but not FDI axons (P=0.11).   
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PARAMETER APB Control P FDI Control P ADM Control P 
          
SDTC 
(ms) 
0.52 0.47 0.03 0.44 0.43 0.33 0.50 0.43 0.01 
          
Rheobase 
(mA) 
1.35 1.55 0.19 2.57 2.56 0.49 1.95 1.81 0.33 
          
TEd 10-20ms 
(%) 
70.67 69.38 0.22 66.14 67.34 0.22 65.77 64.98 0.30 
          
TEd  40-60ms 
(%) 
56.08 52.65 0.04 52.52 50.40 0.11 53.55 50.76 0.04 
          
TEd 90-100ms 
(%) 
50.26 44.67 <0.005 45.19 39.95 0.03 48.07 45.45 0.02 
          
TEh 90-100ms 
(%) 
-125.92 -119.12 0.17 -120.15 -116.89 0.25 -116.74 -119.37 0.33 
          
Resting I/V 
gradient 
0.56 0.64 0.03 0.60 0.59 0.46 0.59 0.60 0.35 
          
Hyperpolarising 
I/V gradient 
0.41 0.36 0.04 0.59 2.29 0.08 0.37 0.51 0.20 
          
RRP 
(ms) 
3.61 3.43 0.3 3.13 3.35 0.14 3.37 3.31 0.40 
          
Superexcitability 
(%) 
-26.53 -21.58 0.007 -27.60 -23.14 0.01 -24.75 -23.49 0.24 
          
Late 
Subexcitability (%) 
11.85 13.32 0.17 12.12 13.97 0.21 11.34 7.98 0.06 
Table 3.2:  Axonal excitability studies were undertaken on the median and ulnar motor nerves with 
responses recorded from the abductor pollicis brevis (APB), first dorsal interosseous (FDI) and 
abductor digit minimi (AMD) muscles.  The strength-duration time constant (SDTC) was significantly 
prolonged in the APB and ADM motor axons.  In addition, greater changes in depolarising threshold 
electrotonus (TEd) were evident at 90-100 ms (TEd 90-100 ms) in motor axons innervating all three 
muscles and at 40-60 ms (TEd 40-60 ms) in the APB and ADM motor axons.  In contrast, there were 
no significant changes in the hyperpolarizing threshold electrotonus at 90-100 ms (TEh 90-100 ms) or 
relative refractory period (RRP) in the APB, ADM and FDI motor axons.  Interestingly, the resting and 
hyperpolarising current/threshold relationship (I/V), was increased in the APB motor axons.  
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 The type II abnormality, in which there is a sudden decrease in membrane excitability marked 
by an abrupt increase in threshold (86), was not evident in the ALS cohort from any of the 
muscles studied.  In addition, there were no significant changes in depolarising TE at 10-20 ms 
and in hyperpolarising TE when recording over the APB, FDI or ADM muscles when compared 
to controls (Table 3.2).   
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Figure 3.1:  The strength-duration time constant, a biomarker of persistent Na
+
 conductances, 
was significantly increased in the (A, B) abductor pollicis brevis (APB) and (C, D) abductor 
digit minimi (ADM) motor axons in amyotrophic lateral sclerosis (ALS) patients compared to 
controls.  *P < 0.05. 
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Figure 3.2:  Depolarising threshold electrotonus (TEd) is a biomarker of internodal slow K
+
 currents.  
There was a significant increase in TEd at 90-100 ms (TEd 90-100ms) when recording from the (A, 
B) abductor pollicis brevis (APB), (C, D) abductor digit minimi (ADM) and (E, F) first dorsal 
interosseous (FDI) muscles in amyotrophic lateral sclerosis (ALS) patients compared to controls.  
*P < 0.05; ***P < 0.001. 
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Figure 3.3:   Depolarising threshold electrotonus AT 40-60 ms, also a biomarker of internodal 
slow K
+
 currents, was increased when recording from the (A, B) abductor pollicis brevis (APB) 
and (C, D) abductor digit minimi (ADM) muscles in amyotrophic lateral sclerosis (ALS) 
patients compared to controls. *P < 0.05 
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In addition to changes in threshold electrotonus, there was a significant increase in 
superexcitability when recording from the APB (ALS -26.5±1.3%; controls -21.6±1.5%, P<0.01, 
Fig.3.4A, B) and FDI (ALS -27.6±1.4%; controls -23.1±1.2%, P<0.05, Fig. 3.4 C, D), but not 
ADM (ALS -24.8±1.2%; controls -23.5±1.3%, P=0.24).  There was no significant difference in 
the relative refractory period or late sub-excitability in ALS patients compared to controls when 
recording over the three muscles (Table 3.2). 
 
Finally, the current/threshold (I/V) relationship was significantly different between ALS 
patients and controls, but only when recording from APB axons.  Specifically, the resting (ALS 
0.55±0.02, controls 0.64±0.04, P<0.05) and hyperpolarising I/V (ALS 0.41±0.02, controls 
0.36±0.01, P<0.05) gradients were significantly increased in ALS patients when recording over 
the APB. In contrast, there were no significant differences in the current threshold relationship 
when recording from the ADM and FDI (Table 3.2). 
 
Correlations with clinical and neurophysiological parameters  
In order to further clarify the contribution of peripheral axonal dysfunction to the development of 
the split-hand in ALS, axonal excitability parameters were correlated with clinical features and 
established neurophysiological biomarkers of LMN loss including the CMAP amplitude and 
neurophysiological index.  Combining these parameters, it was evident that the ƮSD recorded 
from the APB and ADM was significantly correlated with CMAP amplitude (R APB = -0.49, 
P<0.05; R ADM = -0.53, P<0.01) and neurophysiological index (R APB = -0.46, P < 0.05;  
R ADM = -0.40, P<0.05).   
 
141 
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
 
 
 
 
 
 
 
 
 
-28
-24
-20
M
ea
n
 s
u
p
er
ex
ci
ta
b
il
it
y
 (
%
)
-28
-24
-20
M
ea
n
 s
u
p
er
ex
ci
ta
b
il
it
y
 (
%
)
ALS Controls
** APB
C D
-40
10
1 10 100
T
h
re
sh
o
ld
 c
h
a
n
g
e 
(%
)
Interstimulus interval (ms)
RRP
Late subexcitability
Superexcitability
*
ALS Controls
FDI
FDI
ALS
Controls
B
RRP
Late subexcitability
Superexcitability
-40
10
1 10 100
T
h
re
sh
o
ld
 c
h
a
n
g
e 
(%
)
Interstimulus interval (ms)
A
APB
Figure 3.4:  The recovery cycle of excitability revealed a significant increase in 
superexcitability when recording from the (A, B) abductor pollicis brevis (APB), (C, D) first 
dorsal interosseous (FDI) muscles in amyotrophic lateral sclerosis (ALS) patients compared to 
controls.  There was no significant difference in the relative refractory period (RRP) and late 
subexcitability between ALS patients and controls. *P < 0.05; **P < 0.01. 
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In addition, the ƮSD was significantly greater in ALS patients with a greater lower motor neuron 
dysfunction when recording from APB (ƮSD CMAP<4mV 0.56±0.03 ms, P<0.05; ƮSD CMAP>4mV 
0.48±0.01 ms, P<0.05) and ADM (ƮSD CMAP<5.5mV 0.65±0.05 ms, P<0.05; ƮSD CMAP>5.5mV 
0.41±0.03 ms, P<0.05) muscles.  In contrast, there was no significant correlation between the 
ƮSD recorded from FDI and the CMAP amplitude (R=0.15, P=0.26) and NI (R = -0.13, P=0.30). 
 
Of further relevance, depolarising threshold electrotonus at 90-100 ms was significantly 
correlated with CMAP amplitude (R = -0.49, P<0.05), NI (R=-0.46, P<0.05) and disease 
duration (Rho = 0.40, P < 0.05), but only when recording from the APB.  In contrast, there was 
no significant correlation of clinical scores with any of the axonal excitability parameters.  These 
findings suggest that while peripheral axonal dysfunction correlates with lower motor neuron 
dysfunction and thereby axonal degeneration, such axonal dysfunction does not appear to follow 
a split-hand pattern distribution. 
 
Discussion 
The split-hand pattern of atrophy is a specific clinical feature of ALS, for which the underlying 
pathophysiological basis remains to be elucidated (20, 529, 558).  Dysfunction at a peripheral 
axonal level has been proposed as a potential mechanism for the development of the split-hand 
phenomenon in ALS (563). The findings in the present study have established abnormalities 
across all motor axons innervating the APB, FDI and ADM muscles, although such changes did 
not follow a split-hand distribution.  Specifically, the strength-duration time constant was 
prolonged in APB and ADM axons, but not FDI axons.  Importantly, the prolonged τSD 
correlated with conventional biomarkers of lower motor neuron dysfunction, namely the CMAP 
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amplitude and neurophysiological index, suggesting that abnormalities of τSD were linked to the 
process of neurodegeneration.  In addition, greater changes to depolarising threshold electrotonus 
were also evident in axons innervating all three muscles, accompanied by an increase in 
superexcitability.  Taken together, these findings suggest widespread dysfunction of axonal 
membrane conductances, with evidence of reduced K
+
 currents in all three motor axons 
accompanied by upregulation of persistent Na
+
 conductances in APB and ADM axons.  
Importantly, the changes in axonal membrane conductance did not appear to follow a split-hand 
pattern, thereby arguing against a notion that axonal processes form the pathophysiological basis 
of the split-hand phenomenon in ALS.   
 
Axonal dysfunction and split-hand 
The strength-duration time constant is an established biomarker of persistent Na
+
 conductances 
(337).  In sporadic and familial ALS, prolongation of the τSD has been extensively documented 
and linked to the process of neurodegeneration (56-58, 126, 351, 561, 562). In addition,  
prolongation of τSD was reported to be a predictor of poorer survival in sporadic ALS (562).  
Importantly, a recent study documented significantly greater prolongation of the τSD in APB 
axons when compared to ADM axons (563).  While these findings imply a role for axonal 
dysfunction, particularly upregulation of persistent Na
+
 conductances, in the development of the 
split-hand sign in ALS, the function of FDI axons was not assessed.  In the present study, a 
comparable increase in τSD was evident in APB and ADM axons, while there was no significant 
increase of τSD in FDI axons.  As such, our findings could argue against a significant contribution 
of axonal dysfunction in development of the split-hand phenomenon in ALS.  Alternatively, the 
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differences in τSD between APB/ADM and FDI motor axons could be potentially explained by 
existence of a ―second split‖ in the ALS intrinsic hand muscles.   
 
Of further relevance, a significant reduction in depolarising TE was evident in the current ALS 
cohort and did not appear to follow a split-hand pattern.  Given that depolarising TE is a 
biomarker of internodal slow K
+
 currents (85, 86, 357), the findings from the study suggests that 
reduction in K
+
 currents was a feature in ALS, in keeping with the previously established 
modelled hypothesis (57).  The reduction in K
+
 currents, however, was comparable across the 
motor axons, further arguing against the notion that axonal dysfunction significantly contributed 
to development of the split-hand phenomenon in ALS.  
 
The changes in depolarising TE were accompanied by an increase in superexcitability, a 
biomarker of paranodal fast K
+
 channel conductances (85, 86, 357).  Interestingly, the changes in 
superexcitability followed a split-hand distribution, being most prominent in APB and FDI 
axons.  Consequently, it could be argued that a reduction in fast K
+
 conductances in the APB and 
FDI axons may contribute to development of the split-hand.   While such a notion could not be 
absolutely discounted, it seems unlikely that axonal dysfunction significantly contributed to the 
development of the split-hand in ALS given that other parameters of axonal ion channel function, 
namely τSD and depolarising TE, did not follow a split-hand pattern.  
 
A potential explanation for discordant findings between the current ALS cohort and previous 
studies (563) may relate to differences in lower motor neuron dysfunction.  Namely, 
degeneration of motor axons expressing an upregulation of persistent Na
+
 conductances could 
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have accounted for differences in τSD findings in ADM axons.  In addition, it could also be 
argued that such a neurodegenerative process may have also accounted for the ƮSD findings in 
the FDI axons.  This seems unlikely given that ƮSD appears to increase with a greater degree of 
lower motor neuron dysfunction and has been previously linked to the process of 
neurodegeneration (351).  Of further relevance, differences in the ability to perform fractionated 
finger movements by ALS patients could have also contributed to these discordant findings.  
This, again, seems unlikely given the absence of a significant correlation between axonal 
excitability parameters and ALSFRS-R fine motor scores in the present study.     
 
Differences in treatment practices, as pertaining to riluzole usage, may have contributed to the 
discordant findings.  Namely, none of the patients in the Japanese study were receiving riluzole 
at time of assessment, while 40% of ALS patients in the current cohort were receiving riluzole 
therapy.  Given that riluzole exerts modulating effects on axonal ion channel function (153), it 
could be argued that differences in axonal membrane function may have been accounted for by 
treatment practices.  This again seems unlikely given that previous studies have demonstrated 
that riluzole reduces superexcitability and refractoriness (480), findings not evident in the current 
cohort.  In addition, there were no differences in axonal function, particularly τSD prolongation, 
in ALS patients ―on‖ or ―off‖ riluzole.   
 
Upstream effects, at spinal motor neuron or supraspinal levels, may have accounted for the 
discordant axonal excitability findings.   Specifically, dysfunction of central nervous systems 
pathways may influence the biophysical properties of motor axons via transsynaptic processes 
(564, 565).  Given that cortical dysfunction may vary across the ALS phenotypes(40, 52), it 
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could be argued that the discordant findings simply reflect changes at a central nervous system 
level. 
 
What underlies the split-hand phenomenon in ALS?  
The pathophysiological mechanisms underlying the split-hand phenomenon in ALS remains to 
be fully elucidated.  Peripheral axonal processes, as previously suggested (563), don‘t appear to 
significantly contribute to the development of the split-hand. However, a preferential 
degeneration of lower motor neurons innervating the APB and FDI muscles, without a parallel 
change in axonal excitability, could not be absolutely discounted.  Rather, cortical mechanisms 
may be a more likely underlying mechanism for the split-hand phenomenon (54), especially in 
light of the knowledge that the thenar group of muscles (APB/FDI) are critical in execution of 
fractionated finger movements and thereby exhibit a larger cortical representation (44).  Cortical 
hyperexcitability is an established pathophysiological process in ALS and linked to the process 
of peripheral neurodegeneration (49-52, 126).  Given the larger cortical representation of the 
thenar muscles, it could be argued that preferential degeneration of APB/FDI motor neurons may 
be mediated by cortical processes via an anterograde transsynaptic excitotoxic mechanism, 
thereby resulting in the split-hand phenomenon.  Studies assessing cortical function to thenar 
(APB/FDI) and hypothenar muscles may yet prove useful in resolving the pathophysiological 
basis of the split-hand phenomenon in ALS.    
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Summary 
Subsequent to establishing the lack of a significant peripheral contribution to the mechanism 
underlying the development of the split-hand phenomenon in ALS; the present study dissected 
out the relative contribution of cortical and peripheral processes in the development of the split-
hand phenomenon.  Cortical and axonal excitability studies were undertaken on 26 ALS patients, 
with motor responses recorded over the APB, FDI and ADM muscles. Results were compared to 
21 controls.  Short interval intracortical inhibition (SICI), a biomarker of cortical excitability, 
was significantly reduced across the range of intrinsic hand muscles (APBSICI ALS 0.3±2.0 %, 
APBSICI controls 16.0±1.9%, P<0.0001; FDISICI ALS 2.7±1.7%, FDI SICI controls 14.8±1.9%, P<0.0001; 
ADMSICI ALS 2.6±1.5%, ADM SICI controls 9.7±2.2%, P< 0.001), although the reduction was most 
prominent when recorded over APB/FDI.  Changes in SICI were accompanied by a significant 
increase in motor evoked potential amplitude and reduction of cortical silent period duration, all 
indicative of cortical hyperexcitability, and these were most prominent from the APB/FDI.  At a 
peripheral level, a significant increase in strength-duration time constant and reduction in 
depolarising threshold electrotonus were evident in ALS, although these changes did not follow a 
split-hand distribution. Cortical dysfunction contributes to development of the split-hand in ALS, 
thereby implying an importance of cortical hyperexcitability in ALS pathogenesis. 
 
 
 
 
 
 
 
149 
 
Introduction 
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder of the 
motor neurons(2).  Weakness and wasting of the abductor pollicis brevis (APB) and first dorsal 
interosseous (FDI) muscles, with relative preservation of abductor digiti minimi (ADM), may be 
a clinical feature of ALS, termed the split-hand (20, 21).  The pathophysiological mechanisms 
underlying the development of this split-hand phenomenon have not been established, although, 
central and peripheral processes have been implicated (44, 55, 529). Resolution of this issue 
could provide unique insights into ALS pathophysiology and potentially guide future 
neuroprotective strategies. 
 
Debate continues regarding the mechanisms of motor neuron degeneration in ALS. It has been 
argued that corticomotoneuronal hyperexcitability may induce anterior horn cell degeneration via 
an anterograde glutamatergic mechanism (25). Support for such a mechanism has been indirectly 
provided by transcranial magnetic stimulation (TMS) studies establishing cortical 
hyperexcitability as an early feature of ALS and linked to neurodegeneration(49, 50, 52, 125, 
126).  Given that APB and FDI muscles are critical for execution of complex hand tasks, and 
thereby exhibit a larger cortical representation (45), it could follow that preferential dysfunction 
of corticomotoneuronal pathways innervating the APB/FDI motor neurons may underlie 
development of the split-hand (44). 
 
Previous TMS studies have established significant differences in cortical excitability across a 
range of upper limb muscles in healthy subjects (540, 566).  Specifically, the degree of 
intracortical inhibition and corticomotoneuronal output was greater to thenar muscles compared 
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to biceps brachii and hypothenar muscles, suggesting a greater cortical representation and 
corticomotoneuronal projections to thenar muscles (540, 566).  Interestingly, preferential 
dysfunction of thenar corticomotoneuronal projections has been reported in ALS (54). 
 
Peripheral processes have also been implicated in development of the split-hand phenomenon.  
Studies in healthy controls have reported more prominent persistent Na
+
 conductances and less 
K
+
 currents in the APB and FDI motor axons (55), thereby suggesting that motor axons 
innervating the APB/FDI were hyperexcitable and prone to degeneration.  Underscoring this 
notion were findings of more prominent hyperexcitability of APB axons in a Japanese ALS 
cohort (352).  In contrast, a more recent study established that axonal dysfunction was evident 
across the range of intrinsic hand muscles and was not consistent with a split-hand distribution 
(567).  Rather, it was suggested that abnormalities of axonal excitability may reflect downstream 
effects of primary neurodegenerative processes (567). Consequently, the aim of the present study 
was to determine whether cortical hyperexcitability underlies the development of the split-hand 
sign in ALS.  
 
Material and Methods 
Cortical and axonal excitability studies were undertaken on 26 patients with clinically probable 
or definite ALS as defined by the Awaji criteria (82).  The diagnosis of ALS was confirmed in 
patients initially classified as probable ALS by longitudinal follow-up.  All patients provided 
written informed consent to the procedures which were approved by the Western Sydney Local 
Health District Human Research Ethics Committee.   
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Clinical phenotype 
All ALS patients were clinically staged using the amyotrophic lateral sclerosis functional rating 
scale-revised (ALSFRS-R) score (511) and categorised according to site of disease onset.  
Muscle strength was assessed using the Medical Research Council (MRC) score (512), with the 
following muscle groups assessed bilaterally yielding a total MRC score of 90:  shoulder 
abduction; elbow flexion; elbow extension; wrist dorsiflexion; finger abduction; thumb 
abduction; hip flexion; knee extension; ankle dorsiflexion.   
 
Cortical excitability 
Cortical excitability studies were undertaken by applying a 90 mm circular coil connected to two 
high-power magnetic stimulators connected via a BiStim device (Magstim Co., Whitlands, South 
West Wales, UK) with recording of motor evoked response over the APB, FDI and ADM 
muscles.  The circular coil was chosen over a focal (figure-of-eight) coil as the former was easier 
to use with less frequent overheating of the coil itself.   Importantly, previous studies reported no 
qualitative differences in the pattern of inhibition and facilitation when using either a circular 
coil or a focal (figure-of-eight) coil (540).  In addition, a previous study incorporating the 
threshold tracking TMS technique utilised a focal coil (416) and established a similar pattern.  
This study reported two phases of short- interval intracortical inhibition at, ISI 1 ms and at ≤ 3 
ms, an identical pattern of short-interval intracortical inhibition to that reported in our own 
normative study (417). 
 
The circular coil was adjusted in both antero-posterior and medial-lateral direction until the 
optimal position for an MEP response was obtained from the relevant muscle according to a 
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previously reported technique (568).  Specifically, the optimal scalp position was established by 
determining the site at which the smallest TMS stimulus intensity (threshold) evoked an MEP 
response.  This point on the scalp was marked with a skin marking pencil and the coil was 
positioned over this site for the duration of the experiment by a purpose built coil stand.   
 
Paired-pulse threshold tracking TMS was undertaken according to a previously reported 
technique (417).  Briefly, the MEP amplitude was fixed and changes in the test stimulus intensity 
required to generate a target response of 0.2 mV (± 20%), when preceded by sub-threshold 
conditioning stimulus, was measured.  Resting motor threshold (RMT) was defined as the 
stimulus intensity required to maintain the target MEP response of 0.2 mV (±20%).   
Short-interval intracortical inhibition (SICI) was determined over the following interstimulus 
intervals (ISIs): 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, and 7 ms, while intracortical facilitation (ICF)  was 
measured at ISIs of 10, 15, 20, 25 and 30 ms. Stimuli were delivered sequentially as a series of 
three channels: channel 1: stimulus intensity, or threshold (% maximum stimulator output) 
required to produce the unconditioned test response (RMT); channel 2: sub-threshold 
conditioning stimulus (70% RMT); and channel 3 tracks the stimulus required to produce target 
MEP when conditioned by a sub-threshold stimulus (70% RMT).  Stimuli were delivered every 
5s and the computer advanced to next ISI only when tracking was stable. 
 
SICI was measured as the increase in the test stimulus intensity required to evoke the target 
MEP.  Inhibition was calculated off-line as follows (417):  
Inhibition = (Conditioned test stimulus intensity – RMT)/RMT * 100 
Facilitation was measured as the decrease in the conditioned test stimulus intensity required to 
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evoke a target MEP.   
 
Single pulse TMS technique was utilized to determine the MEP amplitude (mV), MEP onset 
latency (ms) and cortical silent period (CSP) duration (ms).  The MEP amplitude was recorded 
with magnetic stimulus intensity set to 150% of RMT.  Three stimuli were delivered at this level 
of stimulus intensity.  Central motor conduction time (CMCT, ms) was calculated according to 
the F-wave method (569).  Cortical silent period duration was assessed by instructing the subject 
to contract the target muscle at ~30% of maximal voluntary contraction with TMS intensity set 
to 150% of RMT.   The CSP duration was measured from onset of MEP to return of EMG 
activity.   
 
Axonal Excitability  
In the same sitting, axonal excitability studies were undertaken on the median and ulnar motor 
nerves according to a previously described protocol (354).  Compound muscle action potential 
(CMAP) responses were recorded from APB, FDI and ADM muscles with the active electrode 
positioned over the motor point and reference electrode placed over the base of the proximal 
thumb (APB and FDI) and fifth digit (ADM) respectively.  From the CMAP amplitude, the split-
hand index (SI) was calculated according to the previously reported formula (529): 
 
Split hand index = CMAP APB *CMAP FDI 
          CMAPADM 
 
The following axonal excitability parameters were measured: (i) strength-duration time constant 
(τSD) and rheobase; (ii) threshold electrotonus (TE) recorded with sub-threshold depolarizing 
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currents at 10-20 ms (TEd [10-20 ms]), 40-60 ms (TEd [40-60 ms]), and 90-100 ms (TEd [90-
100 ms]), and with hyperpolarizing currents at 10-20 ms, TEh [10-20 ms] and at 90-100 ms, TEh 
[90-100 ms]; (iii) hyperpolarizing current-threshold relationship (I/V) calculated from polarizing 
current between +50 and -100%; (iv) recovery cycle parameters including the relative refractory 
period (RRP, ms), superexcitability (%) and late subexcitability (%).   
 
Recordings of the CMAP and MEP responses were amplified and filtered (3 Hz-3 kHz) using a 
Nikolet-Biomedical EA-2 amplifier (Cardinal Health Viking Select version 11.1.0, Viasys 
Healthcare Neurocare Group, Madison, Wisconsin, USA) and sampled at 10 kHz using a 16-bit 
data acquisition card (National Instruments PCI-MIO-16E-4).  Responses were further filtered 
for electronic noise by using a Hum Bug (Hum Bug 50/60 Hz Noise Eliminator, Quest Scientific 
Instruments, North Vancouver, Canada).  Data acquisition and stimulation delivery were 
controlled by QTRACS software (TROND-F, version 16/02/2009, © Professor Hugh Bostock, 
Institute of Neurology, Queen Square, London, UK).  Temperature was monitored with a 
purpose built thermometer at the stimulation site.  
 
Statistical Analysis 
Cortical and axonal excitability studies in ALS patients were compared to control data obtained 
from 21 healthy controls (13 men, 8 women: mean age 50 years, 24-67 years).  Student t-test was 
used for assessing differences between two groups.  Pearson's and Spearman‘s correlation 
coefficients were used to examine the relationship between parameters.  Shapiro-Wilk test was 
used to assess for normality of data.  A probability (P) value of <0.05 was considered statistically 
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significant.  Results were expressed as mean ± standard error of the mean and median 
(interquartile range). 
 
Results 
Clinical features 
At time of testing, the median disease duration was 9.5 months (6-17 months), indicating that 
those studies were undertaken towards the earlier stages of the disease (Table 4.1).  In addition, 
the median ALSFRS-R score was 43 (41-46) while the median MRC sum score was 83 (79-88), 
suggesting a mild to moderate level of functional impairment at time of assessment. Seventy-
three percent of patients exhibited limb-onset disease while 27% reported bulbar-onset disease. 
The split-hand sign was evident in 62% of ALS patients at time of testing, but with follow-up 
95% of patients developed a split-hand sign.  The split-hand sign was more frequently observed 
in limb-onset ALS patients (73%) when compared to bulbar-onset disease (27%).   
 
Cortical excitability 
Prior to undertaking cortical and axonal excitability studies, the degree of peripheral disease 
burden was formally assessed.  There was a significant reduction of CMAP amplitude recorded 
over the APB (P<0.001), FDI (P<0.001) and ADM (P<0.001) muscles compared to controls.  
The split-hand index was significantly reduced in ALS (SI ALS 4.7±0.8; SI CONTROL 13.4±1.0, 
P<0.0005), confirming that the split-hand phenomenon was evident in the present ALS cohort.  
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PATIENT 
 
AGE SEX 
 
ONSET 
SITE 
 
DURATION 
(MONTHS) 
 
ALSFRS-RR 
 
 
MRC 
SUM 
 
SI 
 
1 32 M BULBAR 4 43 84 2.1 
2 57 M BULBAR 3 44 90 10 
3 52 F BULBAR 48 36 84 8.5 
4 64 F BULBAR 10 44 90 4.9 
5 58 M BULBAR 5 43 90 7.4 
6 58 M BULBAR 15 44 90 9.5 
7 48 F BULBAR 21 42 90 13 
8 64 M LIMB 7 47 87 5 
9 69 M LIMB 8 42 56 0 
10 57 F LIMB 9 45 83 6.4 
11 64 M LIMB 12 41 79 3.3 
12 60 M LIMB 6 42 82 1.7 
13 62 M LIMB 5 46 88 3.9 
14 51 M LIMB 20 33 65 0.1 
15 42 M LIMB 17 41 74 0 
16 48 M LIMB 5 42 80 9.8 
17 56 F LIMB 16 34 74 0.2 
18 44 M LIMB 3 46 86 0.9 
19 58 F LIMB 30 31 37 11.8 
20 68 M LIMB 10 48 88 6.3 
21 69 F LIMB 8 43 86 1.1 
22 66 M LIMB 9 47 80 2.8 
23 69 F LIMB 14 47 81 0 
24 69 F LIMB 8 46 79 7.9 
25 73 M LIMB 24 44 81 0 
26 65 M LIMB 17 41 71 5.3 
MEAN/ 
MEDIAN 
58.6 17M 19 LIMB 9.5  43 83 4.4 
SEM/(IQR) 1.9 9F 7 BULBAR (6-17) (41-46) (79-88) 0.8 
Table 4.1:  Clinical features for the 26 amyotrophic lateral sclerosis patients.  All patients were 
graded using the amyotrophic lateral sclerosis functional rating scale revised (ALSFRS-R).  
Muscle strength was assessed using the Medical Research Council (MRC) score.  The split hand 
index (SI) was calculated in all patients. 
 
157 
 
           
 
 
 
 
ADM
APB
FDI
A
B
C
-10
0
10
20
30
0 10 20 30
T
h
re
sh
o
ld
 C
h
a
n
g
e 
(%
)
Interstimulus Interval (ms)
-10
0
10
20
30
0 10 20 30
T
h
re
sh
o
ld
 C
h
a
n
g
e 
(%
)
-10
0
10
20
30
0 10 20 30
T
h
re
sh
o
ld
 C
h
a
n
g
e 
(%
)
ALS
CONTROL
(%
) 
(%
) 
Figure 4.1:  Short interval intracortical inhibition (SICI) was significantly reduced and 
intracortical facilitation (ICF) increased when recording over the (A) abductor pollicis brevis 
(APB) and (B) first dorsal interosseous (FDI) muscles.  (C) There was a significant reduction of 
SICI when recording over the abductor digit minimi (ADM) muscle, while there was no 
significant difference (NS) in ICF.  The degree of SICI reduction was more prominent when 
recording over the APB and FDI muscles. *P < 0.05; ***P< 0.001; ****P< 0.0001 
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Paired-pulse threshold tracking TMS studies disclosed a marked reduction of SICI across the 
range of intrinsic hand muscles, although this reduction was most prominent when recorded over 
the APB and FDI (Fig. 4.1A-C). Averaged SICI, between ISIs 1 to 7 ms, was significantly 
reduced over the APB (ALS 0.3±2.0 %; controls 16.0±1.9%; P<0.0001), FDI (ALS 2.7±1.7%; 
controls 14.8±1.9%; P<0.0001) and ADM (ALS 2.6±1.5%; controls 9.7±2.2%; P< 0.001, Fig. 4.2 
A-C) muscles, although the degree of reduction was more prominent over APB and FDI (SICI 
reduction APB, 98%; SICI reduction FDI 81%; SICI reduction ADM 73%, F = 2.8, P < 0.05, Fig. 
4.2D).  Of further relevance, peak SICI at ISI 3 ms was also significantly reduced across the 
range of intrinsic hand muscles (ALSAPB 2.8±3.2 %, controls APB 22.7±2.8, P<0.001; ALSFDI 
6.8±2.8%, controls FDI 23.5±2.5%, P<0.001; ALSADM 7.7±2.9%, controls ADM 16.1±3.2%, P< 
0.05, Fig. 4.3 A-C), although the reduction was again most prominent over the APB and FDI 
(SICI reduction APB, 81%; SICI reduction FDI 70%; SICI reduction ADM 52%, F = 2.0, P < 0.05, 
Fig. 4.3D).  
 
Following SICI, a period of intracortical facilitation develops between ISI 10-30ms.  The mean 
ICF between ISIs 10-30 ms was significantly increased in ALS patients when recorded over the 
APB (ALS -5.3±1.2%, controls -1.4±1.3%, P< 0.05) and FDI muscles (ALS -4.1±1.4%, controls 
-0.53±1.4 %, P<0.05) but not ADM (P=0.18). 
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Figure 4.2:  Mean short interval intracortical inhibition (SICI), over interstimulus intervals 1-7 
ms, was significantly reduced when recording over the (A) abductor pollicis brevis (APB), (B) 
first dorsal interosseous (FDI), and (C) abductor digit minimi (ADM) muscles.  (D) The 
reduction in mean SICI was most prominent when recording over the APB muscle.   
***P< 0.001; ****P< 0.0001 
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Figure 4.3:  Peak short interval intracortical inhibition (SICI) at interstimulus interval 3 ms was 
significantly reduced when recording over the (A) abductor pollicis brevis (APB), (B) first 
dorsal interosseous (FDI), and (C) abductor digit minimi (ADM) muscles.  (D)  The reduction in 
peak SICI was most prominent when recording from the APB.  *P < 0.05; ***P < 0.001.   
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Figure 4.4:  Motor evoked potential (MEP) amplitude, expressed as a percentage of the 
compound muscle action potential (CMAP) response, was significantly increased when 
recording over the (A) abductor pollicis brevis (APB), (B) first dorsal interosseous (FDI) and 
(C) abductor digit minimi (ADM) muscles.  (D)  The increase in MEP amplitude was most 
prominent when recording from the APB.  *P < 0.05; ***P < 0.001.   
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Single-pulse TMS technique disclosed that the MEP amplitude was significantly increased in 
ALS patients across the range of intrinsic hand muscles (ALSAPB 28.4±5.1%, controls APB 
18.1±2.4%, P<0.05; ALSFDI 24.2±3.6%, controls FDI 13.2±2.3%, P<0.05; ALS ADM 22.9±2.9, 
controls ADM 14.8±2.4%, P<0.05, Fig 4.4A-C).  Of further relevance, there was a trend for the 
MEP amplitude increase to be greater when recording over the thenar muscles (APB MEP INCREASE 
59%; FDI MEP INCREASE 57%; ADM MEP INREASE 48.6%, Fig. 4.4D).  Of further relevance, the CSP 
duration was significantly reduced when recorded over the APB (ALS 170.1 ± 8.5ms, controls 
200.4 ± 8.1ms, P < 0.05) and FDI (ALS 173.1 ± 9.2ms, controls 202.4 ± 6.8ms, P < 0.05) but not 
ADM (ALS 176.8 ± 9.2ms, controls 187.2 ± 6.0ms, P=0.17, Fig. 4.5).  In contrast, there were no 
significant differences in RMT (ALS APB 56.1 ± 1.9%, controls APB 56.2 ± 1.8%, P = 0.48; ALS 
FDI 55.5 ± 1.9%, controls FDI 58.0 ± 2.1, P = 0.20; ALS ADM 54.5 ± 1.8, controls ADM 56.3 ± 2.0, P 
= 0.25) and central motor conduction time (F = 0.01, P = 0.99) between groups.  
 
Axonal excitability 
The strength-duration time constant, a biomarker of nodal persistent Na
+
 conductance (85, 86, 
333, 337, 541), was significantly increased when recorded over APB (ALS 0.51 ± 0.02 ms, 
controls 0.46 ± 0.02ms, P < 0.05, Fig. 4.6A) and ADM (ALS 0.49 ± 0.02ms, controls 0.44 ± 
0.02ms, P < 0.05, Fig. 4.6B) muscles but not FDI (ALS 0.47 ± 0.02ms, controls 0.42 ± 0.02ms, 
P=0.06, Fig 4.6C).  In contrast, there were no significant differences in rheobase between ALS 
patients and controls across the range of intrinsic hand muscles (APB, P = 0.19; FDI, P = 0.49; 
ADM, P = 0.33). 
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Figure 4.5: (A) The cortical silent period (CSP) duration was significantly reduced when 
recording when recording over the (A) abductor pollicis brevis (APB) and (B) first dorsal 
interosseous (FDI) muscles.  (C) There was no significant (NS) reduction in CSP duration when 
recording over the abductor digit minimi (ADM) muscle. The reduction in CSP duration was 
most prominent when recording from the APB.  *P < 0.05. 
 
164 
 
            
 
 
A
C
B
0
1
S
D
T
C
 (
m
s)
*
APB
ADM
0
1
S
D
T
C
 (
m
s)
*
FDI
0
1
S
D
T
C
 (
m
s)
NS
ALS Control
Figure 4.6:  Strength duration time constant (SDTC), a biomarker of persistent Na
+ 
conductances, was significantly increased when recording from the (A) abductor pollicis brevis 
(APB) and (B) abductor digit minim (ADM) muscles, but not (C) first dorsal interosseous (FDI). 
*P < 0.05. 
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Threshold Electrotonus, a biomarker of internodal and paranodal K
+
 conductance (85), again 
disclosed the presence of the type I abnormality of TE, whereby sub-threshold depolarizing 
currents induced greater changes in threshold (570) when recording from all three muscles.  
Specifically, depolarizing TE at 90-100 ms was significantly greater in ALS patients when 
recorded from the APB (ALS 50.3 ± 1.5%; controls 44.7 ± 0.8%, P < 0.001), ADM (ALS 48.5 ± 
1.0%; controls 45.5 ± 0.7%, P < 0.05) and FDI (ALS 45.1 ± 1.5%; controls 40.0 ± 2.2%, P < 
0.05) muscles.  These changes in depolarising TE were accompanied by a significant increase in 
TEd at 40-60 ms when recording over APB (ALS 56.1 ± 1.7%; controls 52.6 ± 1.0%, P < 0.05) 
and ADM (ALS 53.6 ± 1.3%; controls 50.8 ± 0.9%, P < 0.05), but not FDI motor axons (P=0.11)  
 
Of further relevance, superexcitability was significantly increased when recording from the APB 
(ALS -25.9 ± 1.4%; controls -21.6 ± 1.5%, P < 0.05) and FDI (ALS -27.3 ± 1.4%; controls -23.1 
± 1.2%, P < 0.05), but not ADM (ALS -25.1 ± 1.2%; controls -23.5 ± 1.3%, P = 0.19).  In 
contrast, there were no significant changes in the relative refractory period (APB, P = 0.18; FDI, 
P = 0.14; ADM, P = 0.37) and late subexcitability (APB, P = 0.12; FDI, P = 0.15; ADM, P = 
0.10) between ALS patients and controls across the range of intrinsic hand muscles.  In addition, 
hyperpolarising I/V gradient was significantly increased in ALS patients when recording from 
the APB muscle (ALS 0.41±0.02, controls 0.36±0.01, P <0.05), but not the FDI (P = 0.08) and 
ADM (P = 0.12).   Taken together, these findings reveal that while the abnormalities of axonal 
excitability were evident in ALS, they did not appear to follow a split-hand pattern. 
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Correlation studies 
Combining clinical parameters with measures of cortical and axonal excitability, it was evident 
that the MEP amplitude (R = -0.40, P<0.01) and CSP duration (R=0.34, P<0.01) were 
significantly correlated with the split-hand index.  Of relevance, there was a significant 
correlation between SICI and MRC upper limb score (R = -0.3, P<0.05).   In contrast, there was 
no significant correlation between any of the axonal excitability parameters and split-hand index, 
CMAP amplitude, measures of cortical excitability and clinical parameters.  Taken together, 
these findings suggest that cortical hyperexcitability may be linked to the development of the 
split-hand phenomenon in ALS. 
 
Discussion 
In the present study, cortical and peripheral axonal techniques were utilised to dissect the relative 
contribution of central and peripheral processes in development of the ALS split-hand.  Cortical 
hyperexcitability, as indicated by a significant reduction in short interval intracortical inhibition 
and cortical silent period duration along with increases in motor evoked potential amplitude, was 
evident across the range of intrinsic hand muscles, although the degree of cortical 
hyperexcitability was most prominent when recorded from the APB and FDI muscles.  Of further 
relevance, there was a significant correlation between measures of cortical excitability and the 
split-hand index, suggesting that cortical hyperexcitability was associated with development of 
the split-hand phenomenon in ALS.   At a peripheral level, upregulation of persistent Na
+
 
conductances along with reduction in K
+
 currents was evident, but did not appear to follow a 
split-hand distribution and was not correlated with the split-hand index, thereby arguing against a 
significant peripheral contribution in driving the development of the split-hand phenomenon in 
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ALS.  The mechanisms underlying these central and peripheral excitability changes and their 
relevance for development of the split-hand phenomenon, with implications for ALS 
pathophysiology, will be discussed. 
 
Origins of the split-hand phenomenon in ALS 
While the pathophysiological mechanisms underlying the development of the split-hand 
phenomenon in ALS have not been established, central and peripheral processes have been 
implicated (44).  A cortical basis was inferred from clinical observations that thenar muscles 
(APB/FDI)  were critical in execution of complex hand tasks (44), and thereby would exhibit a 
greater cortical representation, a notion supported by TMS studies in healthy controls (54, 540, 
571).  Importantly preferential dysfunction of corticomotoneuronal pathways was previously 
established in ALS (54).   
 
The novel findings from the present study provide critical support for a cortical basis in 
development of the ALS split-hand.  Specifically, cortical dysfunction was heralded by marked 
reduction of SICI, a biomarker of strong inhibitory intracortical GABAergic function and weaker 
cortical glutamatergic facilitatory effects (426).  Importantly, abnormalities of SICI in ALS 
appear to be mediated by a combination of glutamate excitotoxicity and degeneration of 
inhibitory cortical neurons(129, 480).  The findings of more prominent SICI reduction when 
recorded over APB and FDI, would imply a greater level of cortical hyperexcitability to the APB 
and FDI motor neurons.  Of further relevance, intracortical facilitation, a biomarker of 
glutamatergic function (87, 426), was significantly increased when recorded from the APB and 
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FDI but not hypothenar muscles. Taken together, these findings suggest that cortical processes, 
namely cortical hyperexcitability, may underlie the development of the split-hand sign in ALS.  
There was also a marked increase in MEP amplitude in the ALS cohort and was correlated with 
the split-hand index.    Given that the MEP amplitude reflects the density of corticomotoneuronal 
projections onto motor neurons (401)  as well as the level of glutamatergic neurotransmission in 
the central nervous system (87), the present findings lend further credence to the notion that 
cortical processes contribute to the development of the split-hand sign in ALS. Alternatively, it 
could also be argued that the increase in MEP amplitude may represent less phase cancellation 
due to fewer motor units or possibly repetitive firing of corticomotoneurons (572).  In addition to 
changes in MEP amplitudes, a significant reduction of CSP duration was evident in the ALS 
cohort, but only when recorded over the thenar muscles (APB/FDI).  Importantly, the CSP 
duration reflects the degree of cortical inhibition and appears to be mediated by inhibitory 
neurons acting via GABAB receptors (452, 453, 457, 458, 548, 549). Consequently, findings that 
identified a significant reduction in CSP duration when recording over APB/FDI muscles, 
suggest a greater level of cortical disinhibition and cortical hyperexcitability to the APB/FDI 
muscles, providing further support for a cortical mechanism as the basis of the split-hand 
phenomenon in ALS.   
 
Alternatively, it could be argued that the differences in cortical excitability between the intrinsic 
muscles could be related to an interaction between stimulated cortical areas.  Given that 
electromyography techniques were not utilised to ensure electrical silence of the ―non-
stimulated‘ intrinsic hand muscles, especially the APB and FDI, such a notion could not be 
absolutely discounted. It has also been argued that peripheral mechanisms may contribute to 
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development of the split-hand sign in ALS (44).  More prominent membrane excitability 
abnormalities in the APB motor neurons, as indicated  by longer τSD, was recently reported in 
ALS (352).  Given that τSD is a biomarker of persistent Na
+
 conductances (85), and linked to 
axonal degeneration (57, 126, 351), these findings implied that upregulation of persistent Na
+
 
conductances contributed to development of the split-hand phenomenon, although the properties 
of FDI motor axons were not assessed.  In contrast, the present study established a comparable 
increase of τSD in APB and ADM axons, without significant increases of τSD in FDI axons, 
thereby arguing against a significant contribution of axonal dysfunction in development of the 
split-hand phenomenon in ALS.   
 
In addition, a significant reduction in depolarising TE was also evident across the range of 
recorded motor axons. Given that depolarising TE is a biomarker of slow K
+
 currents (85), the 
findings in the present study suggest that reduced slow K
+
 currents is a feature of ALS and in 
keeping with previous studies (56, 57, 567).   Importantly, the changes in depolarising TE did not 
appear to follow a split-hand distribution, thereby further arguing against a significant 
contribution of peripheral processes in development of the split-hand phenomenon in ALS.   
 
Split-hand phenomenon and ALS pathophysiology 
Emerging evidence suggests that genetic factors and molecular processes underlie the 
development of ALS (2).  Cortical hyperexcitability was proposed as an important 
pathophysiological mechanism, whereby motor neuron degeneration was mediated via glutamate 
excitotoxicity process (25).  Support for such a framework has been provided by TMS studies 
(49, 50) as well as transgenic SOD-1 mouse models studies (128).  Additional support for 
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glutamate-mediated excitotoxity is provided by transgenic SOD-1 mouse model and human 
studies identifying abnormalities of the astrocytic glutamate transporter, excitatory amino acid 
transporter-2 (137, 573). Importantly, ALS motor neurons exhibit increased expression of Ca
2+
-
permeable AMPA receptors, thereby rendering these more susceptible to excitotoxicity (142).   
 
The findings from the present study of more prominent cortical hyperexcitability to the APB and 
FDI muscles, together with an absence of a split-hand distribution of axonal excitability 
abnormalities, provide support for a cortical basis to ALS pathogenesis.  The significant 
correlation between cortical hyperexcitability and the split-hand index, further suggests that 
glutamate-mediated cortical hyperexcitability may underlie the preferential degeneration of 
motor neurons in ALS.     
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Chapter 5 
Cortical Hyperexcitability Precedes Lower 
Motor Neuron Dysfunction in ALS 
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Summary 
After establishing that cortical dysfunction contributed to development of the split-hand in ALS, 
The present study was undertaken to determine whether cortical hyperexcitability preceded the 
development of lower motor neuron (LMN) dysfunction in sporadic amyotrophic lateral sclerosis 
(ALS). Cortical excitability studies were undertaken in 24 ALS patients utilising the threshold 
tracking transcranial magnetic stimulation (TMS) technique, with motor evoked potential (MEP) 
recorded over the abductor pollicis brevis (APB) muscle.  In the same sitting, LMN function of 
the target APB muscle was assessed utilising a complex array of peripheral neurophysiological 
techniques, including conventional nerve conduction studies determining the compound muscle 
action potential (CMAP) amplitude and neurophysiological index, qualitative and quantitative 
electromyography (EMG) along with axonal excitability studies.   At the time of assessment, the 
anatomical and functional integrity of the lower motor neuronal circuits innervating the target 
APB muscle was preserved in all ALS patients, confirmed by a normal CMAP amplitude 
(P=0.37), absence of fasciculations, or features of neurogenic change. In addition, the 
neurophysiological index and markers of peripheral axonal excitability were well within 
established normal ranges. Despite this apparent ‗normality‘ cortical dysfunction was evident in 
ALS patients, with significant reduction of short interval intracortical inhibition (ALS 1.7±1.4%; 
controls 10.3±1.0%; P<0.01), resting motor threshold (P<0.05) and cortical silent period duration 
(P<0.001).   In addition, the MEP amplitude (P<0.05) and intracortical facilitation (P<0.05) were 
significantly increased, providing additional support for the presence of cortical hyperexcitability 
upstream to a seemingly intact lower motor neuronal system.  This study concluded that cortical 
hyperexcitability precedes the development of LMN dysfunction in ALS, suggesting a cortical 
origin for ALS.   
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Introduction 
The primacy of corticomotoneuronal dysfunction in ALS pathogenesis was first postulated by 
Charcot (1), although contrasting views have suggested that corticomotoneuronal dysfunction 
occurred either as an independent process to lower motor neuron (LMN) dysfunction or was 
secondary to LMN degeneration via a dying back process (188, 189, 574).  Resolution of this 
critical issue could potentially advance the understanding of ALS pathophysiology and would be 
of immense diagnostic and therapeutic significance. 
 
Although ongoing debate regarding the processes underlying motor neuron degeneration in ALS 
continues, corticomotoneuronal hyperexcitability via an anterograde transsynaptic glutamatergic 
process(25), has been proposed as an underlying mechanism.  Support for such mechanism has 
been provided by transcranial magnetic stimulation (TMS) studies establishing that cortical 
hyperexcitability was an early feature of ALS, linked to neurodegeneration and preceding the 
development of clinical features of LMN dysfunction(49, 50, 124, 174).    The recent 
identification of the c9orf72 hexanucleotide repeat expansion as the causative genetic mutation 
in both ALS and frontotemporal dementia (FTD) (172, 173) has provided further support for a 
cortical origin of ALS.   
 
As an alternative suggestion, corticomotoneuronal and spinal motor neuron degeneration may 
occur as independent processes in ALS.  The lack of correlation between corticomotoneuronal 
and spinal motor neuron densities on neuropathological studies was previously reported in ALS 
as evidence arguing against the primacy of corticomotoneurons in ALS pathogenesis (189)
,
(188).   
Such morphological techniques may potentially be confounded by the complexity of the human 
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motor system, particularly the synaptic relationship between corticomotoneurons and the spinal 
motor neurons (45).  Specifically, there appears to be considerable variability in the 
corticomotoneuron to spinal motor neuron synaptic ratios, and attempts to correlate upper and 
lower motor neurons on autopsy studies may not be meaningful (186).  Separately, evidence of 
hyperexcitable corticomotoneurons which may form the basis of ALS pathogenesis, will clearly 
not be detected by anatomical techniques.       
 
The functional integrity of corticomotoneurons may be non-invasively assessed by utilising TMS 
techniques (87), while lower motor neuron function may be interrogated by utilising 
neurophysiological techniques such as nerve conduction studies for determining CMAP 
amplitude, electromyography with the addition of more novel research-based techniques such as 
neurophysiological index and axonal excitability techniques (65, 85).  Consequently, the present 
study combined cortical assessment and clinical phenotype with a complex series of peripheral 
neurophysiological approaches, including qualitative and quantitative electromyography, to 
determine whether corticomotoneuronal hyperexcitability preceded lower motor neuron 
dysfunction in ALS.   
 
Materials and Methods  
Studies were undertaken on 24 patients with suspected ALS referred to our specialised 
multidisciplinary ALS clinic between January 2011 and March 2013.   The abductor pollicis 
brevis (APB) strength was clinically normal in these 24 ALS patients, and there was 
subsequently determined to be no neurophysiological evidence (see below) of lower motor 
neuron dysfunction within the APB muscle at the time of assessment. All patients progressed to 
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develop probable or definite ALS , as defined by the Awaji criteria (82),  during the follow-up 
period.  Patients were clinically staged using the ALS functional rating scale-revised (ALSFRS-
R) scale(511), while muscle strength was determined using the medical research council (MRC) 
rating scale (575).  Muscle strength was scored using the following muscle groups: shoulder 
abduction, elbow flexion and extension, wrist dorsiflexion, finger abduction and thumb 
abduction, hip flexion, knee extension and ankle dorsiflexion bilaterally, generating a maximal 
MRC score of 90.  All patients provided written informed consent to the procedures which were 
approved by the Western Sydney Local Health District Human Research Ethics Committee.   
 
Cortical excitability 
Paired-pulse threshold tracking TMS, using a 90 mm circular coil, was undertaken according to a 
previously reported technique (417).  Briefly, the motor evoked potential (MEP) amplitude was 
fixed and changes in the test stimulus intensity required to generate a target response of 0.2 mV 
(± 20%), when preceded by a sub-threshold conditioning stimulus, was measured (417).  The 
motor evoked potential (MEP) response was recorded over the abductor pollicis brevis muscle.  
Resting motor threshold (RMT) was defined as the stimulus intensity required to maintain this 
target MEP response. 
 
Initially, single pulse TMS was utilized to determine the MEP amplitude (mV), MEP onset 
latency (ms) and cortical silent period (CSP) duration (ms).  The MEP amplitude was recorded 
with magnetic stimulus intensity set to 150% of RMT. Three stimuli were delivered at this level 
of stimulus intensity.  Subsequently, the CSP duration was assessed by instructing the subject to 
contract the target APB muscle at ~30% of maximal voluntary contraction with three stimuli 
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delivered at 150% of RMT.   The CSP duration was measured from onset of MEP to return of 
EMG activity.   
 
Paired-pulse threshold tracking was undertaken to determine short interval intracortical 
inhibition and intracortical facilitation according to a previously established technique (417).   
Short-interval intracortical inhibition (SICI) was determined over the following interstimulus 
intervals (ISIs): 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, and 7 ms.  Intracortical facilitation (ICF) was measured 
at ISIs of 10, 15, 20, 25 and 30 ms. TMS stimuli were delivered at a frequency of 0.1 Hz 
(stimulus delivery was limited by the charging capability of the BiStim system) and the computer 
advanced to the next ISI only when tracking was stable.  SICI was measured as the increase in 
the test stimulus intensity required to  evoke the target MEP.  Inhibition was calculated off-line 
as follows (417):  
Inhibition = (Conditioned test stimulus intensity – RMT)/RMT * 100 
Facilitation was measured as the decrease in the conditioned test stimulus intensity required to 
evoke a target MEP.   
 
Peripheral studies 
Compound muscle action potential (CMAP) responses were recorded from the APB muscle with 
the active (G1) electrode positioned over the motor point and reference (G2) electrode placed 
over the base of the proximal thumb.  The resultant baseline-peak CMAP amplitude (mV) and 
onset latency (ms) were measured.   
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Axonal excitability studies were undertaken on the median motor nerve according to a 
previously described protocol (354).   Briefly, the median nerve was stimulated at the wrist using 
5 mm non-polarizable Ag-AgCl electrodes (3M Healthcare, MN, USA) with the anode 
positioned ~ 10 centimeters proximal to the cathode over the lateral forearm.  Test current pulses 
were applied at 0.5s intervals and combined with either sub-threshold polarizing currents or 
suprathreshold conditioning stimuli according to previously described protocols. Stimulation was 
computer controlled and converted to current using an isolated linear bipolar constant current 
simulator (maximal output ± 50 mA; DS5, Digitimer, Welwyn Garden City, UK).  A tracking 
target was set to 40% of maximum CMAP response and proportional tracking was utilized to 
determine the changes in threshold current required to produced and maintain a target response 
(354).  The temperature at recording site was maintained >32
○
C. 
 
The following axonal excitability parameters were measured: (i) strength-duration time constant 
(τSD) and rheobase; (ii) depolarising and hyperpolarising threshold electrotonus (TE); (iii) 
current-threshold relationship (I/V); (iv) relative refractory period (RRP, ms), superexcitability 
(%) and late subexcitability (%).  In addition, the neurophysiological index (NI) was derived 
according to a previously reported formula (65).   
 
Qualitative needle electromyography (EMG) was undertaken on all patients, studying at least 3 
regions and the APB muscle, utilising a 26G concentric needle.  Quantitative EMG assessment, 
using Multi-MUP software (Synergy EMG machine, Neurocare Group, Madison, USA) was 
undertaken according to a previously reported technique (73).  In total, 20 motor unit action 
potentials (MUAP) were collected from four different sites within the APB muscle using a 26G 
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concentric needle electrode.  The MUAP peak-to-peak amplitude (mV) and duration (ms) were 
recorded. 
 
Recordings of the CMAP and MEP responses were amplified and filtered (3 Hz-3 kHz) using a 
Nikolet-Biomedical EA-2 amplifier (Cardinal Health Viking Select version 11.1.0, Viasys 
Healthcare Neurocare Group, Madison, USA) and sampled at 10 kHz using a 16-bit data 
acquisition card (National Instruments PCI-MIO-16E-4).  Data acquisition and stimulation 
delivery were controlled by QTRACS software (version 16/02/2009, © Professor Hugh Bostock, 
Institute of Neurology, Queen Square, London, UK).   
 
 Statistical Analysis 
Cortical excitability studies in ALS patients were compared to control data obtained from 33 
healthy controls (16 men, 17 women; mean age 55.7±1.7 years), while axonal excitability studies 
were compared to 24 healthy controls (12 men, 12 women; mean age 50.8±2.1 years).  
Quantitative EMG studies in ALS patients were compared to 20 age-matched healthy controls (6 
men, 14 women, mean age 52.8±2.9 years). All data was tested for normality using the Shapiro-
Wilk test.   Student t-test was used for assessing differences between two groups, while analysis 
of variance (ANOVA) with post-hoc testing (Bonferroni correction) was used for multiple 
comparisons. Wilcoxon signed rank test for used to compare differences between clinical 
variables that exhibited a non-parametric distribution.  Pearson's correlation coefficients were 
used to examine the relationship between parameters.  A probability (P) value of <0.05 was 
considered statistically significant.  Results were expressed as mean ± standard error of the mean 
or median (interquartile range). 
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Results 
Clinical Characteristics 
At time of testing the 24 ALS patients (14 male, 10 female; mean age 60.9±2.2 years) reported a 
median disease duration from symptom onset of 14.5 months (6-24 months), indicating that their 
assessment was undertaken towards the earlier stages of the disease.  Limb-onset disease was 
evident in 37.5 %, while 62.5% of ALS patients exhibited bulbar-onset disease.   
 
The median ALSFRS-R score was 43.5 (40-46) while the median ALSFRS-R fine motor sub 
score was 12 (10-12).  Of further relevance, the median total MRC sum score was 89 (84-90, 
maximum score when normal 90), while the upper limb score was 60 (58-60, maximum score 
60) and lower limb score was 30 (30-30, maximum score 30)(Table 5.1).  Importantly, the 
muscle strength of the target APB muscle was normal in all patients at time of TMS testing. 
 
All ALS patients progressed to clinically definite ALS, as per the Awaji criteria (82), over a 
median follow-up period of 22 months.  In total, 33% of patients died during the follow-up 
period, with the median disease survival being 19 months.  There was a significant reduction in 
the ALSFRS-R (33.5 [29.8-41.3], P<0.001) and total MRC (80.5 [72-88], P<0.001) scores 
during the follow-up period.  In addition, there was a significant reduction in the APB muscle 
MRC score (MRC score 4 [3.75-5], P<0.01), signifying the development of clinical weakness in 
the target muscle.   
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Neurophysiological studies 
Conventional neurophysiological investigations were undertaken to assess for the presence of 
lower motor neuron dysfunction in the target APB muscle. The CMAP amplitude (ALS   9.9±0.9 
mV; controls 9.5±0.5 mV; P=0.37), and neurophysiological index (ALS 2.1±0.2; controls 
2.3±0.1 mV, P=0.22) were comparable between ALS patients and controls.   
 
Qualitative needle EMG examination of the APB muscle was normal at time of TMS testing.  
Importantly, quantitative EMG testing was also within normal limits.  Specifically, the mean 
MUAP amplitude (ALS 1327.96 ±112.5 µV; controls 1203.3±165.4 µV; P=0.39) and duration 
(ALS 10.6±0.4 ms; controls 11.2±0.5 ms; P=0.11) were similar between ALS patients and 
controls confirming the absence of lower motor neuron dysfunction in the target APB muscle at 
time of assessment.  Importantly, all patients developed weakness and atrophy of the tested APB 
muscle over the follow-up period (mean 22 months), indicating the evolution of LMN 
dysfunction.   
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Patient Age 
(Years) 
Sex Onset Disease 
duration 
(Months) 
ALSFRS-R MRC 
SUM 
1 64 M BULBAR 53 42 82 
2 57 M BULBAR 2 44 90 
3 40 M BULBAR 9 40 86 
4 78 F BULBAR 12 40 90 
5 68 F BULBAR 19 40 83 
6 58 M BULBAR 17 38 79 
     7 71 M BULBAR 8 46 89 
8 62 M BULBAR 12 44 89 
9 50 F BULBAR 22 42 90 
10 58 M BULBAR 11 43 90 
11 62 M BULBAR 24 44 90 
12¶ 81 F BULBAR 108 38 88 
13 52 F BULBAR 24 46 90 
14 79 F BULBAR 6 44 90 
15 60 M BULBAR 23 46 89 
16 73 F LIMB 6 42 83 
17 45 M LIMB 6 48 90 
18 42 M LIMB 4 46 90 
19 71 F LIMB 24 40 86 
20 66 F LIMB 38 38 83 
21 68 M LIMB 6 48 88 
22# 47 M LIMB 84 46 79 
23* 53 F LIMB 60 37 84 
24 57 M LIMB 6 48 90 
Mean (SEM), 
Median(IQR) 
60.9 
(±2.2) 
  14.5 
(6-24) 
43.5 
(40-46) 
89 
(84-90) 
Table 5.1:  Clinical characteristics of 24 amyotrophic lateral sclerosis (ALS) patients at the time 
of initial assessment.  All patients were assessed using the ALS functional rating scale-revised 
(ALSFRS-R), and the Medical Research Council (MRC) score.  The data is expressed as mean 
(standard error of the mean, SEM) and median (interquartile range, IQR). ¶ Patient 12 exhibited 
a predominantly upper motor neuron form of ALS, while patient #22 exhibited a flail-arm 
variant ALS and patient *23 a predominant bulbar palsy form of ALS.  All patients, however, 
developed clinical evidence of LMN dysfunction in the target abductor pollicis brevis muscle 
with follow-up (median 22 months).     
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Cortical excitability 
Paired-pulse threshold tracking TMS studies disclosed a marked reduction of short interval 
intracortical inhibition in ALS (Fig. 5.1).  Specifically, averaged SICI between ISIs 1-7 ms, was 
significantly reduced in ALS patients when compared to controls (ALS 1.7±1.4%; controls 
10.3±1.0%; P<0.01).  Peak SICI at ISI 1 ms (ALS 0.7±0.8%; controls 6.1±1.2%; P<0.001, Fig. 
5.2A) and 3 ms (ALS 3.2±1.8%; controls 15±1.5%; P<0.001, Fig. 5.2B) was also significantly 
reduced in ALS patients.  Of further relevance, while the reduction of SICI was a uniform feature 
in ALS, the reduction was more prominent in patients with limb-onset disease (ALSLIMB 
0.16±1.54; ALS BULBAR 3.98±1.54, F = 13.2, P<0.001, Fig. 5.2C). 
      
 
 
 
Figure 5.1:  Short interval intracortical inhibition (SICI) was significantly reduced in 
amyotrophic lateral sclerosis (ALS) patients when compared controls. 
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Figure 5.2: Peak short interval intracortical inhibition (SICI) at interstimulus interval (ISI) of 
(A) 1 ms and (B) 3 ms was significantly reduced in amyotrophic lateral sclerosis (ALS) patients 
when compared to controls.   (C) The reduction in SICI was most prominent in ALS patients 
with limb-onset disease. *P < 0.05; ***P< 0.001. 
 
184 
 
           
                      
 
 
 
 
-5
-4
-3
-2
-1
0
1
A
v
er
a
g
ed
 I
C
F
 
(I
S
I 
1
0
-3
0
 m
s,
 %
)
ALS
Controls
Limb-onset
Bulbar-onset
Controls
*
*
*
A
-5
-4
-3
-2
-1
0
1
A
v
er
a
g
ed
 I
C
F
 
(I
S
I 
1
0
-3
0
 m
s,
 %
)
B
Figure 5.3:  (A)  Intracortical facilitation (ICF), averaged over interstimulus interval (ISI) of 10-
30 ms, was significantly increased in amyotrophic lateral sclerosis (ALS) patients when 
compared to controls.  (B)  The increase in ICF was similar in ALS patients with limb and 
bulbar-onset disease. *P < 0.05. 
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Intracortical facilitation was significantly increased in ALS patients when compared to controls 
(ALS -3.3±1.0%; controls -0.4±1.0%; P<0.05, Fig. 1, Fig. 3A). This increase in ICF was a 
ubiquitous finding, evident in bulbar and limb-onset ALS patients (bulbar-onset -3.9±1.7%; 
limb-onset -2.6±1.3%; P=0.27, Fig 5.3B).  
 
Single pulse TMS studies disclosed a significant reduction of the RMT in ALS patients (ALS 
54.9±2.2%; controls 60.5±1.4%; P<0.05, Fig. 5.4A).  This reduction in RMT was a uniform 
finding, evident in both bulbar and limb onset ALS patients (bulbar-onset 55.9±3.6%; limb-onset 
53.4±2.1%).  The CSP duration was also significantly reduced in ALS when compared to 
controls (ALS 180.0±9.1 ms; controls 216.7±3.8 ms; P<0.001, Fig. 5.4B), and again was a 
ubiquitous finding in ALS (bulbar-onset 177.6±11.2 ms; limb-onset 188.4±10.7, P=0.33).  In 
addition, the MEP amplitude was significantly increased in ALS patients (ALS 32.1±3.8%; 
controls 24.1±2.5%; P<0.05, Fig.5.4C), and was comparably increased in both bulbar and limb 
onset patients.  
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Figure 5.4:  (A) The resting motor threshold (RMT) was significantly reduced in amyotrophic 
lateral sclerosis (ALS) patients.  (B)  The cortical silent period duration was significantly 
reduced in ALS patients when compared to controls.  (C) The motor evoked potential (MEP) 
amplitude, expressed as a percentage of the compound muscle action potential amplitude, was 
significantly increased in ALS patients. *P < 0.05; ***P < 0.001. 
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Axonal Excitability 
In the same sitting, axonal excitability studies were undertaken on the median nerve at the wrist.  
The strength-duration time constant was comparable between groups (ALS 0.48 ± 0.02 ms; 
controls 0.48±0.02ms, P=0.45), as was the rheobase (P=0.21).  In addition, depolarizing TE at 
90-100 ms (ALS 46.8±1.1%; controls 44.9±0.7%, P = 0.09), and 40-60 ms (ALS 54.5 ± 1.6%; 
controls 52.8±0.9%, P=0.18), as well as hyperpolarising TE at 90-100 ms (P=0.42) was not 
significantly different in ALS patients when compared to controls. 
 
The recovery cycle of excitability was also within normal limits in the ALS patients, with RRP 
(P=0.09), superexcitability (P=0.45) and late subexcitability (P=0.17) being similar between 
ALS patients and controls. In addition, there was no significant difference in the hyperpolarising 
I/V (P=0.29), resting I/V (P=0.19) and minimum I/V  (P=0.06) gradients  in ALS patients when 
compared to controls.   
 
Discussion 
In the present study, cortical and peripheral neurophysiological techniques were utilised to 
determine whether cortical hyperexcitability preceded the development of lower motor neuron 
dysfunction in ALS.   Cortical hyperexcitability, as indicated by a significant reduction in short 
interval intracortical inhibition, resting motor threshold, and cortical silent period duration along 
with an increase in intracortical facilitation and motor evoked potential amplitude, was evident in 
the present ALS patient cohort when recorded from the APB muscle.  Importantly, these central 
changes were evident when there was no clinical or neurophysiological evidence of lower motor 
neuron dysfunction within the target APB muscle.  Taken together, these findings suggest that 
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cortical dysfunction may be identified and indeed precedes the development of LMN 
dysfunction, thereby favouring a cortical origin to the subsequent neurodegeneration that 
develops in ALS.  
 
Corticomotoneuronal integrity and ALS  
Although the pathophysiological mechanisms underlying ALS appear to be multifactorial, with 
evidence of a complex interaction between molecular and genetic factors (2); a cortically-based 
mechanism has been suggested whereby motor neuron degeneration in ALS may be mediated by 
corticomotoneuronal hyperexcitability via an anterograde glutamate-mediated excitotoxic 
process, the so-called ―dying forward‖ hypothesis (25).  Indirect support for a cortical origin of 
ALS has been provided by TMS studies identifying cortical hyperexcitability as an early feature 
in ALS, and linked to the process of anterior horn cell degeneration (49, 50, 122-124).  Further, 
longitudinal studies in familial ALS cohorts have established that cortical hyperexcitability 
precedes the clinical development of ALS (50), although subclinical LMN dysfunction was not 
conclusively excluded.   
 
Cortical hyperexcitability was evident in the present ALS cohort prior to development of lower 
motor neuron dysfunction.  Evidence of cortical hyperexcitability was indicated by a marked 
reduction in SICI.  It has been previously established that SICI reflects a balance between strong 
inhibitory tone, largely mediated by intracortical GABAergic circuits, along with weaker 
glutamatergic facilitatory effects on cortical output neurons (426, 488).  In ALS, reduction of 
SICI appears to be mediated by degeneration of inhibitory cortical circuits along with glutamate-
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mediated excitotoxicity (480, 497).  Consequently, the finding of marked reduction in SICI, 
when recorded from a clinically and neurophysiologically normal target muscle, along  
with a significant increase in intracortical facilitation, a biomarker of glutamatergic function (87, 
426), support the possibility that cortical hyperexcitability precedes the lower motor neuron 
dysfunction in ALS.   
 
Further, a marked increase in MEP amplitude was also evident in the present ALS cohort.  The 
MEP amplitude appears to be modulated by a variety of neurotransmitter systems, and 
importantly is enhanced by glutamatergic transmission (441).    Increases in MEP amplitude are 
well established in ALS, correlate with motor neuron degeneration and appear to be excitotoxic 
in nature (49, 51).  Consequently, the finding of increased MEP amplitude, in the setting of a 
normal target APB muscle, provides further support for a role of cortical hyperexcitability in 
ALS pathogenesis.  Additional support for a cortical origin for ALS is provided by findings of a 
significant reduction in CSP duration, a biomarker of long-latency cortical inhibition(457, 458, 
548),  and RMT, a biomarker of cortical neuronal membrane excitability (426), in the setting of 
normal LMN function.  Importantly, these neurophysiological findings are in keeping with recent 
neuropathological studies suggesting that pathogenic proteins involved in ALS disseminate from 
cortical neurons, via axonal projections and synaptic contacts to the spinal and bulbar motor 
neurons cord (576, 577). 
 
At a peripheral level, the integrity of the lower motor neurons innervating the target APB muscle 
was established from a combination of electromyography and axonal excitability techniques.   
Given that qualitative EMG assessment may be insensitive at detecting LMN dysfunction in a 
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clinically normal muscle (73), the more sensitive quantitative EMG analysis was undertaken, and 
confirmed the absence of LMN dysfunction within the target APB muscle.  Of relevance, 
upregulation of persistent Na
+
 conductances along with reduction in internodal slow and 
paranodal fast K
+
 currents has been established in ALS (57, 58, 561), and linked to development 
of neurodegeneration and fasciculations.  The findings of normal axonal excitability in the 
present ALS cohort further confirm the functional integrity of axons innervating the APB muscle 
in the presence of cortical hyperexcitability.  
 
Therapeutic implications in ALS 
The finding that cortical dysfunction may be identified prior to lower motor neuron dysfunction 
implies a cortical origin of ALS.  In terms of the process of neurodegeneration, there remains no 
unifying pathway. Support for a glutamate-mediated process has been provided by molecular 
studies identifying dysfunction of the astrocytic glutamate transporter, excitatory amino acid 
transporter 2 (EAAT-2), in human and animal studies (133, 578, 579). Importantly, down 
regulation of EAAT-2 function has been reported as a pre-symptomatic feature in ALS (578), 
with evidence emerging of spinal motor neurone degeneration occurring as a secondary to 
dysfunction of corticomotoneuronal pathways (128).  While anti-glutamatergic agents, such as 
riluzole appear to exert modest clinical effectiveness in ALS (148, 528), in part related to partial 
normalisation of excitability(480), strategies aimed at restoring astrocytic function  may yet 
prove to be of therapeutic benefit.  
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Chapter 6 
The Split-Hand Plus Sign in ALS: Differential 
Involvement of the Flexor Pollicis Longus and 
Intrinsic Hand Muscles 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
192 
 
Summary: 
 
The selective vulnerability of muscles in ALS was further explored by measuring the strength of 
the flexor pollicis longus (FPL), a key muscle involved in fractionated thumb movements which 
appears relatively spared in amyotrophic lateral sclerosis (ALS) when compared to the thenar 
group of muscles. This clinical sign termed the split hand plus sign was prospectively assessed 
for diagnostic utility in ALS. In total, 103 patients (37 ALS and 66 non-ALS) with 
neuromuscular symptoms underwent assessment of FPL and APB strength using the Medical 
Research Council (MRC) score.  A median nerve strength index (MSI) was developed to 
quantify differential involvement by expressing the APB strength scores as a fraction of the FPL 
strength score. The APB muscle strength was significantly reduced when compared to FPL 
strength in ALS patients (P<0.0001), but was comparable in the non-ALS disorders (P=0.91).  In 
addition, there was a significant reduction of MSI scores in ALS patients (MSI ALS 0.8; MSI non-
ALS 1.0, P<0.01). Analysis of receiver operating characteristic (ROC) curves disclosed that MSI 
< 0.9 exhibited an area under the curve of 0.86 (P<0.001) with a sensitivity of 85% and 
specificity of 86% for limb-onset ALS. In conclusion, the split hand plus sign distinguished 
ALS from non-ALS neuromuscular disorders, thereby reinforcing the phenomenon of selective 
involvement of muscles and establishing a diagnostic utility of this novel clinical sign in ALS.   
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Introduction 
Preferential atrophy of the abductor pollicis brevis (APB) and first dorsal interosseous (FDI) 
muscles, termed ―the split hand sign‖, appears to be a specific clinical feature for amyotrophic 
lateral sclerosis (ALS)(20, 21, 44, 54, 519).  Consequently, the finding of a split hand sign may 
aid in the diagnosis of ALS, complementing other clinical and neurophysiological techniques 
(519).  In addition to its diagnostic utility, the split hand sign may provide insights into ALS 
pathophysiology.  
 
Of further relevance, relative preservation of other key muscles involved in complex thumb 
movements, namely the flexor pollicis longus (FPL), appears to be a clinical feature of ALS.   
Although the APB and FPL muscles are innervated by the same spinal motor neurons (C8,T1) 
and nerve (median nerve), the function of FPL is relatively preserved in ALS (personal 
observation).   This novel clinical phenomenon, that we termed the split-hand plus sign, may be 
of further diagnostic utility in a clinical setting.  To date, the sensitivity and specificity of this 
novel sign has not been prospectively assessed.   The importance of prospectively assessing the 
diagnostic utility of the split-hand plus sign is underscored by previous reports questioning the 
specificity of the related split hand sign in ALS (559, 560).   If established to be specific for 
ALS, the split-hand plus sign could potentially complement other clinical and 
neurophysiological findings in the diagnosis of ALS.   
 
In order to assess its diagnostic utility, the split-hand plus sign was quantified by expressing the 
Medical Research Council (MRC) strength scores of the APB and FPL muscles in a novel index 
termed Median Nerve Strength Index (MSI).  Consequently, the present study assessed the 
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diagnostic utility, and thereby specificity, of the novel split-hand plus sign in contributing to the 
diagnosis of ALS. 
 
Materials and Methods 
In total, 103 patients were recruited from our multidisciplinary neuromuscular clinics at 
Westmead and Prince of Wales Hospitals, between April 2011 and Mar 2012.  All patients 
underwent clinical assessment, with the muscle strength graded using the Medical Research 
Council (MRC) strength score (575). Following extensive clinical assessment, investigations and 
follow-up 37 patients were diagnosed as ―definite‖ or ―probable‖ amyotrophic lateral sclerosis 
(22 male, 15 female; mean age 61.5 years, Fig. 1) according to the Awaji criteria (82).  All ALS 
patients were classified according to the region of symptom onset (limb or bulbar onset), and 
were staged using the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised 
(ALSFRS-R)(511). Results were compared to 66 non-ALS patients (NALS : 37 Male; 29 
Female; mean age 48.3 years; Fig 1). All patients provided informed consent for testing which 
was approved by the Sydney South West Area Ethics committee. 
 
Muscle strength was assessed in the following muscle groups generating a maximum Medical 
Research Council (MRC) score of 90: Upper limbs; shoulder abduction, elbow flexion and 
extension, wrist dorsiflexion, finger abduction and thumb abduction bilaterally; Lower limbs; hip 
flexion, knee extension and ankle dorsiflexion bilaterally. Specifically, FPL muscle strength was 
assessed by instructing the patients to flex the distal phalanx of the thumb against resistance. The 
APB and FPL muscle strength was recorded to generate the MSI as represented by the following 
formula:  
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Statistical Analysis  
Differences in muscle strength scores between and within groups were assessed using the 
Wilcoxon signed rank test, while the Mann Whitney U test was utilized to assess differences in 
MSI between ALS and non-ALS patients.   Receiver Operating Characteristic Curves (ROC) 
were undertaken to determine the diagnostic utility of MSI. Results are expressed as mean ± 
standard error of mean and median (interquartile range).  P<0.05 was considered statistically 
significant. 
 
Results 
Clinical characteristics  
The clinical features for ALS patients are summarised in Figure 6.1.  At the time of initial 
assessment, 76 % of patients were classified as ―definite‖ or ―probable‖ ALS according to 
Awaji-Shima criteria, while 24% were classified as ―possible‖ ALS.  54% of ALS patients 
exhibited limb-onset disease while 46% presented with bulbar-onset disease.  Median disease 
duration from symptom onset was 12(9-24) months, while the median ALSFRS-R score was 41 
(30.5-44) and MRC sum score was 79 (67-88), signifying a mild to moderate degree of 
impairment.  The diagnosis in the non-ALS cohort is outlined in Figure 1.  None of the patient in 
this cohort developed ALS.  The median MRC sum score for the non-ALS cohort was 84 (78-90) 
and was comparable to ALS patients.  
              APB MRC score 
                     FPL MRC score 
 
 
MSI= 
== 
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Neuromuscular Disease 
n=103
ALS n=37 
(22 M; 15 F)
Non-ALS n=66 
(37 M; 29 F)
•Neuropathy N=26
•Neuronopathies N=9                  
•Muscular Dystrophies  N=10
•Myotonic Dystrophy
/Myotonia Congenita N=7
•Acquired myopathies N=11
•Others N=3
Limb Onset 
n=20
Bulbar Onset 
n=17
Figure 6.1: Flow diagram of prospective patient recruitment for assessment of the split hand 
plus sign with subsequent differentiation into Amyotrophic Lateral Sclerosis (ALS) and non-
ALS groups based on the reference standard (Awaji Criteria). The ALS group was subdivided 
into limb and bulbar-onset disease. Non-ALS NALS group comprised a heterogeneous group of 
inherited and acquired neuromuscular disorders and included the following: (i) neuropathy 
[chronic inflammatory demyelinating polyradiculoneuropathy; Guillain-Barre syndrome; 
isolated peripheral nerve vasculitis; Kennedys disease]: neuronopathy [Sjorgen‘s syndrome 
ganglionopathy; spinal muscular atrophy; Hirayama‘s disease]: muscular dystrophy [Duchene‘s 
muscular dystrophy; Becker‘s muscular dystrophy; fascioscapulohumeral muscular dystrophy; 
limb girdle muscular dystrophy; central core myopathy; congenital myopathy; adult-onset 
Pompes disease]:  myotonic dystrophy [myotonic dystrophy; myotonia congenital]: acquired 
myopathies [inclusion body myositis; inflammatory myopathy; myopathy of undetermined 
cause]: others [Ehlers-Danlos syndrome; complicated hereditary spastic paraplegia]. 
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Differences in the FPL and APB muscle strength scores 
In the ALS cohort, the APB muscle was significantly weaker when compared to FPL (P < 0.01, 
Fig. 6.2).   
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Figure 6.2: (A) In amyotrophic lateral sclerosis (ALS) patients, the abductor pollicis brevis 
(APB) was significantly weaker when compared to flexor pollicis longus (FPL), as measured by 
the Medical Research Council (MRC) strength score scatter plots. (B) The median MRC score 
was significantly reduced for the APB muscle compared to the FPL. 
 
198 
 
In contrast, there was a comparable degree of APB and FPL weakness in the non-ALS cohort 
(Fig. 6.3).   
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Figure 6.3: (A) The Medical Research Council (MRC) score for the abductor pollicis brevis 
(APB) and flexor pollicis longus (FPL) were similar in non-amyotrophic lateral sclerosis (non-
ALS) patients. (B) Median MRC scores were comparable between the APB and FPL. 
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Figure 6.4: (A) The median nerve strength index (MSI, see Methods) was significantly reduced 
in amyotrophic lateral sclerosis (ALS) patients compared to non-amyotrophic lateral sclerosis 
(non-ALS). (B) Receiver operating characteristic (ROC) curve revealed that a cut-off value of 
0.9 exhibited a sensitivity of 84% and specificity of 86% in differentiating ALS from non-ALS 
disorders.   The area under the curve (AUC) was 0.86 (P<0.001) indicating a ―good‖ diagnostic 
potential for the MSI in differentiating ALS from non-ALS. 
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The MSI score was significantly reduced in ALS patients when compared to non-ALS (MSIALS 
0.8[0-1.0]; MSInon-ALS 1.0 [1.0-1.0], P<0.01, Fig. 6.4A). Subgroup analysis disclosed that the 
MSI was significantly reduced in limb-onset ALS patients when compared to bulbar-onset ALS 
(MSILIMB-ONSET 0.75[0-0.8]; MSIBULBAR-ONSET 1.0 [0.6-1.0], P<0.01, Fig. 6.4B).  Although the 
MSI was higher in the bulbar-onset ALS patients, it continued to be significantly reduced when 
compared to non-ALS (P<0.001).   
 
Diagnostic utility of MSI 
Assessment of the entire ALS cohort, disclosed and area under the curve of 0.8 (P<0.001), 
suggesting a good diagnostic accuracy of the MSI.  Of relevance, an MSI value of 0.9 
differentiated ALS from non-ALS cohort with a sensitivity of 66% and specificity of 86%.  
Subgroup analysis disclosed that in limb-onset ALS patients, an MSI value of 0.9 differentiated 
ALS from non-ALS with a sensitivity of 84% and specificity of 86%, with the area under the 
curve being 0.86 (P<0.001). 
 
Discussion 
The present study suggests that the split hand plus sign is a specific feature of ALS, clearly 
distinguishing ALS from non-ALS disorders.  The split hand plus sign was characterised by a 
greater weakness and atrophy of the APB muscle when compared to the FPL, and was reflected 
by a significantly reduced median nerve strength index.  Although the reduction in MSI was 
evident across the clinical spectrum of ALS, it was most pronounced in ALS patients with limb-
onset disease.  Importantly, a diagnostic MSI cut-off value of 0.9 reliably distinguished ALS 
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from non-ALS mimic disorders, thereby suggesting that the split hand plus sign may 
complement the diagnosis of ALS especially in limb-onset disease.  
 
In the absence of a pathognomonic test, the diagnosis of ALS is based on clinical criteria, relying 
on the identification of a combination of upper and lower motor neuron signs (14, 82, 580).  
Upper motor neuron signs may be evident in ALS mimic disorders such as multifocal motor 
neuropathy with conduction block (581), potentially resulting in an erroneous diagnosis of ALS.  
The finding in the present study that the split-hand plus sign was a specific feature of ALS, 
clearly distinguishing ALS from non-ALS disorders, underscores the clinical utility of this novel 
clinical sign. 
 
Although the specificity of the split-hand plus sign was high (84%), it was not 100%. Analysis 
of non-ALS patients with an MSI < 0.9 revealed that in 30% of cases assessment of FPL strength 
revealed a comparable or greater weakness than APB, a pattern that was distinct to that evident 
in ALS.    In the remaining in 70% of non-ALS patients with MSI < 0.9, other clinical features, 
such as the presence of myotonia, distinguished non-ALS from ALS patients.  Taken together, 
the findings in the present study suggest that the split-hand plus sign may be of utility as a 
complementary clinical finding in the diagnosis of ALS.   
 
Although the reduction in MSI was also evident in bulbar-onset ALS patients, this reduction was 
not as pronounced as in limb-onset disease, thereby potentially limiting the diagnostic utility of 
the split-hand plus sign in bulbar-onset ALS.  A likely explanation may relate to relative 
preservation of upper limb function in the current cohort of bulbar-onset ALS patients at the time 
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of assessment.  Assessment of FPL, with either Magnetic Resonance Imaging (MRI) techniques 
for detecting muscle wasting, or needle EMG techniques for detecting lower motor neuron 
(LMN) dysfunction, may prove diagnostically useful.  Further, correlation of FPL strength scores 
with more objective biomarkers of LMN dysfunction, such as abnormalities on needle EMG 
assessment, may be of further diagnostic utility.    
 
The split-hand plus sign and the pathophysiology of ALS 
In addition to being of diagnostic utility, split-hand plus sign may provide unique insights into 
ALS pathophysiology.  Specifically, the ―dying forward‖ hypothesis proposed that ALS was 
primarily a disorder of corticomotoneurons, with corticomotoneuronal hyperexcitability 
mediating anterior horn cell degeneration (25).   The ‗dying forward hypothesis‘ has been 
suggested as the basis of the split-hand sign in ALS, with the affected thenar group of muscles 
having a greater corticomotorneuronal input compared to other intrinsic hand muscles  (54). 
Given the varied function of the APB and FPL (582), with the suggestion that the FPL exhibits 
less cortical representation (547, 583), the finding in the present study that the split-hand plus 
sign was specific to ALS, would lend support to a cortical mechanism in ALS.  Future studies 
should combine central and peripheral nerve excitability techniques to the FPL muscle in order 
to dissect out the relative contributions of central and peripheral mechanisms to the development 
of the split-hand plus sign in ALS.   
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Chapter 7 
Cortical Excitability differences between Flexor 
Pollicis Longus and Abductor Pollicis Brevis  
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Summary 
After establishing that the split-hand plus sign was specific to ALS, the present study was 
undertaken to assess the relative contributions of central and peripheral mechanisms to the 
development of the split-hand plus sign. Although abductor pollicis brevis (APB) and flexor 
pollicis longus (FPL) share a common peripheral nerve supply, these muscles subserve different 
functions and may be differently affected in neurodegenerative disease such as amyotrophic 
lateral sclerosis (ALS).  As a consequence, differences in cortical excitability may potentially 
develop in relation to these functional differences.  Cortical excitability was assessed using the 
threshold tracking transcranial magnetic stimulation (TMS) technique in 15 healthy controls with 
motor responses recorded over the APB and FPL using surface electrode recordings.  Short-
interval intracortical inhibition (SICI) was significantly reduced from the FPL compared to APB 
(SICI FPL 6.9±1.8%; SICI APB 10.7±1.4%, P<0.01).  In addition, the FPL motor evoked potential 
amplitude (MEPFPL 14.7± 2.3%; MEPAPB 21.7±3.9%; P<0.01) and cortical silent period duration 
(CSPFPL 174.7 ± 6.7ms; CSPAPB 205.4±3.9ms, P<0.01) were significantly smaller.  The findings 
in the present study indicate that cortical inhibition and corticomotoneuronal output is reduced 
when recording over the FPL.  The differences in cortical excitability may develop as a 
consequence of varied function and could potentially explain the dissociated muscle atrophy 
evident in ALS.      
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Introduction 
Preferential wasting of the thenar complex, including the abductor pollicis brevis (APB) and first 
dorsal interosseous (FDI), appears to be a specific clinical feature in amyotrophic lateral sclerosis 
(ALS) (20, 21, 519, 584).  This pattern of dissociated atrophy of the intrinsic hand muscles has 
been termed the split hand (21).  Recently, this dissociated pattern of muscle wasting has been 
extended to include the flexor pollicis longus (FPL) with relative preservation of FPL strength in 
ALS, a phenomena termed the ―split-hand plus sign‖ (585). 
  
The pathophysiological mechanisms underlying this dissociated pattern of muscle wasting in 
ALS remains unclear.  Dysfunction of local spinal segments is unlikely to account for such a 
pattern of muscle wasting given that all involved muscles are innervated by the same myotomes 
(C8, T1).  Rather, a cortical mechanism has been proposed, whereby corticomotoneurons 
mediate anterior horn cell degeneration via an anterograde transsynaptic excitotoxic mechanism 
(25).  Given that the thenar muscles are critically important for execution of fine fractionated 
finger movements, thereby potentially exhibiting a greater cortical representation, it was 
hypothesized that a cortical mechanisms underlies the development of dissociated muscle 
atrophy (the split-hand) in ALS (25, 44).  Given the recent observation that the novel split-hand 
plus sign is a specific feature of ALS (585), it could also be hypothesized that a cortical 
mechanisms was responsible for the split-hand sign.     
 
Cortical function and corticomotoneuronal output may be assessed by using paired pulse TMS 
techniques (401, 417, 468).  Paired-pulse TMS has provided unique insights into the excitability 
of motor cortical inhibitory and facilitatory circuits, termed short interval intracortical inhibition 
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(SICI) and intracortical facilitation (ICF), thereby enabling an understanding into the cortical 
representation and the functional organization of motor outputs (401, 417, 468-470).  Perhaps of 
relevance, the amplitude and time course of SICI is greater to the thenar complex when 
compared to the more proximal upper limb muscles (420, 540), a finding attributed to differences 
in cortical excitability (540, 586).   
 
In contrast to thenar and proximal upper limb muscles, little is known about the cortical function, 
corticomotoneuronal representation and input to the FPL.  Consequently, utilizing threshold 
tracking TMS techniques, the present study assessed cortical excitability from the FPL compared 
to thenar muscles in healthy controls, to determine whether differences in cortical excitability 
could form an underlying substrate and the pathophysiological basis for the development of the 
split hand-plus phenomena in ALS. 
 
Materials and Methods: 
Subjects 
A total 15 healthy subjects (10 men and 5 women) were assessed, with median age of 34 years 
(age range 25 to 55 years).  At the time of assessment, none of the subjects were medicated with 
psychotropic medications that could potentially influence cortical excitability.  All subjects 
provided informed consent to the experimental procedures, which was approved by the South 
East Sydney and Sydney West Area Health Service Human Research Ethics Committees.  
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Peripheral nerve studies 
Prior to undertaking cortical excitability studies, the median nerve was stimulated electrically at 
the wrist, for APB recordings, and at the elbow for FPL recordings, using 5-mm Ag-AgCl 
surface electrodes (ConMed, Utica, USA).  The resultant compound muscle action potential 
[CMAP] was recorded from the APB and FPL muscles using surface electrodes according to 
previously reported methods (417, 587).  For APB recordings, the G1 electrode was positioned 
over the belly of the APB while the G2 electrode was positioned over the base of the thumb.  The 
positions of the recording electrodes were altered for the FPL muscle, such that the G1 electrode 
was positioned over the FPL belly 6-8 cm proximal to the radial styloid while the G2 electrode 
was placed on the radial styloid.  The resultant CMAP onset latency and peak-peak amplitude 
were recorded from the APB and FPL muscles.   
 
Cortical excitability  
Cortical excitability studies were undertaken by applying a 90 mm circular coil to the motor 
cortex with currents generated by two high-power magnetic stimulators connected via a BiStim 
(Magstim Co., Whitland, South West Wales, UK).  The coil position was adjusted for each 
muscle such that a maximal motor evoked potential (MEP) was elicited prior to proceeding with 
cortical excitability studies.  The stimulating coil was adjusted such that the direction of current 
flow within the motor cortex was in a posterior-anterior direction when recording MEPs from 
both muscles.   
 
 
 
208 
 
TMS threshold tracking   
In the conventional paired-pulse technique, the conditioning and test stimuli are kept at constant 
intensity, and changes in the motor evoked potential [MEP] amplitude are measured.  In the 
present study the target MEP was of predetermined, fixed amplitude and changes in the test 
stimulus intensity required to generate this target response, when preceded by a subthreshold 
conditioning stimulus, was measured (416, 417).  The threshold-tracking strategy used a target 
response of 0.2 mV [± 20%], located in the middle of the established linear relationship between 
the logarithm of the MEP amplitude and the stimulus intensity (416, 417).  Resting motor 
threshold [RMT] was defined as the stimulus intensity required to produce and maintain this 
target MEP response.   
 
Initially, the MEP amplitude was recorded with magnetic stimulus intensity set to 150% of RMT, 
and three stimuli were delivered at this level of stimulus intensity.  Subsequent to recording the 
MEP responses, the cortical silent period (CSP) duration was assessed by instructing the subject 
to contract each muscle at ~30% of maximal voluntary contraction with stimulus intensity again 
set to 150% of RMT. Three stimuli were delivered at this level of stimulus intensity and the CSP 
was recorded contralateral to the side of stimulation.  The CSP duration was measured from 
onset of MEP to return of EMG activity (455).  The resumption of EMG activity was assessed 
visually.   
 
Paired-pulse stimuli 
Subsequently, a paired-pulse TMS technique was applied to determine the short-interval 
intracortical inhibition (SICI) and intracortical facilitation (ICF).  Briefly, the changes in test 
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stimulus intensity required to generate the target MEP response of 0.2 mV, when preceded by a 
sub-threshold conditioning stimulus (set to 70% of RMT) reflected SICI and ICF.  Short-interval 
intracortical inhibition (SICI) was determined over the following interstimulus intervals (ISIs): 1, 
1.5, 2, 2.5, 3, 3.5, 4, 5, and 7 ms, while ICF was measured at ISIs of 10, 15, 20, 25 and 30 ms. 
Stimuli were delivered sequentially as a series of three channels: channel 1: stimulus intensity, or 
threshold (% maximal stimulator output) required to produce the unconditioned test response 
(i.e., RMT); channel 2: sub-threshold conditioning stimulus (70% RMT); and channel 3 tracks 
the stimulus or threshold (% maximal stimulator output)  required to produce the target MEP 
when conditioned by a sub-threshold stimulus equal in intensity set to 70% of RMT. Stimuli 
were delivered every 5–10 s (stimulus delivery was limited by the charging capability of the 
BiStim system) and the computer advanced to the next ISI only when tracking was stable. 
 
All CMAP and MEP recordings were amplified and filtered (3 Hz-3 kHz) using a Grass ICP511 
AC amplifier [Grass-Telefactor, Astro-Med Inc., West Warwick, RI, USA] and sampled at 
10 kHz using a 12-bit data acquisition card (National Instruments PCI-MIO-16E-4).  Data 
acquisition and stimulus delivery (both electrical and magnetic) were controlled by QTRACS 
software, Institute of Neurology, Queen Square, London, UK). 
 
Data Analysis  
SICI was measured as the increase in the test stimulus intensity required to evoke the target 
MEP.  Inhibition was calculated off-line as follows (417):  
Inhibition = (Conditioned test stimulus intensity – RMT)/RMT * 100 
210 
 
Facilitation was measured as the decrease in the conditioned test stimulus intensity required to 
evoke a target MEP.   
 
Each data point was weighted [by the QTRACS software] such that any measures recorded 
outside the threshold target window, defined as values within 20% of the tracking target of  
0.2mV [peak-to-peak], contributed least to the data analysis. All results were expressed as mean 
± standard error of the mean. The neurophysiological variables were normally distributed as 
assessed by the Shapiro-Wilk test for normality.  Paired samples t-test was used for assessing 
differences between two groups, while repeated measure analysis of variance (ANOVA), with 
ISI as the within subject factor and ―muscle type‖ as the between subject factor.  Pearson's 
correlation coefficient was used to examine the relationship of the TMS parameters between 
each muscle and with CMAP amplitude.  A probability (P) value of <0.05 was considered 
statistically significant.  
 
Results 
A complete sequence of recordings was obtained from all subjects.  Peak-to-peak CMAP 
amplitude was greater when recorded from the abductor pollicis brevis compared to the flexor 
pollicis longus muscle (CMAPAPB 18.1 ± 1.4 mV; CMAPFPL 11.6 ± 1.2 mV, P < 0.01).  In 
contrast, the median nerve distal motor latency was comparable between the two muscles 
(CMAPAPB 3.9 ± 0.1 ms; CMAPFPL 3.5 ± 0.6 ms), consistent with previously reported normative 
data (417, 587). 
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Differences in intracortical inhibition and facilitation between APB and FPL   
Paired-pulse threshold tracking TMS techniques were utilized to assess the cortical function of 
the APB and FPL muscles. The resting motor threshold (RMT), defined as the stimulus intensity 
required to produce and maintain the target MEP response of 0.2 mV, was comparable between 
the two muscles (RMTFPL 53.8 ±3.2 %; RMTAPB 55.0 ±2.7%, P=0.37).   
 
Subsequent to establishing a similar level of RMT, short interval intracortical inhibition was 
assessed as a biomarker of cortical inhibitory interneuronal network function (426). Repeated 
measure ANOVA demonstrated a significant effects of group or ―muscle type‖ (F = 9.3,  
P < 0. 001,) and interstimulus interval (F = 8.2, P < 0.05).  In contrast the group (muscle type) x 
ISI interaction was not significant.  
 
There was a significant reduction of SICI magnitude and time course when recording over the 
FPL muscle.  In addition, while the presence of the previously established peaks of SICI at ISI of 
1 and 2.5-3 ms (416, 417, 491) were re-affirmed when recording from the APB (Fig. 7.1, black 
arrows), only one smaller peak, at ISI 2.5 ms, was evident when recording over the FPL muscle 
(Fig. 7.1).  Short interval intracortical inhibition at ISI 2.5-3 ms (FPL 11.6 ± 2.9%; APB 15.5 ± 
2.3%, P < 0.05, Fig. 7.2A) and ISI 1 ms (FPL 6.8 ± 2.0%; APB 12.6 ± 1.8%, P < 0.05, Fig. 7.2B) 
were significantly smaller when recording over the FPL.   
 
Following SICI, a period of intracortical facilitation develops between ISIs 10-30ms.  This 
phenomenon was evident when recordings were undertaken from both muscles.  Further, the 
mean ICF, recorded between ISIs 10-30 ms, was not significantly different between the two 
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muscles (ICFFPL -0.6 ±1.2%; ICFAPB -0.9 ±1.6%, F= 0.5, P=0.4, Fig. 7.1).   
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Figure 7.1:  Short interval intracortical inhibition, defined as the stimulus intensity required to 
maintain a target response of 0.2 mV (see Methods), was recorded from both the abductor 
pollicis brevis (APB) and flexor pollicis longus (FPL) muscles.  Two previously reported SICI 
peaks, at an interstimulus interval (ISI) of 1 and 3 ms, were again evident when recording over 
the APB.  The SICI was significantly smaller when recording over the FPL compared to APB, 
and the previously established peaks at an ISI of 1 and 3 ms (as indicated by arrows) were not 
evident when recording over FPL. 
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Figure 7.2:  Peak short interval intracortical inhibition (SICI), defined as the difference between 
the conditioned test stimulus intensity recorded on channel 3 and unconditioned stimulus 
intensity recorded on channel 1 (see methods), at interstimulus intervals (ISI) of (A) 2.5-3 ms 
AND (B) at ISI 1 ms, was significantly reduced when recording over the flexor pollicis longus 
(FPL) compared to abductor pollicis brevis (APB). * P < 0.05. 
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Single pulse TMS techniques disclosed that the MEP amplitude, expressed as percentage of the 
CMAP response, was significantly smaller when recording over the FPL muscle (MEPFPL 14.7 ± 
2.3%; MEPAPB 21.7 ± 3.9%; P < 0.01, Fig. 7.3A).  The MEP latency was significantly shorter to 
the FPL muscle (MEP latency FPL 18.8 ± 2.2 ms; MEP latency APB 20.0 ± 2.1 ms; P < 0.01), perhaps 
reflecting the shorter conducting distance to the FPL.  In addition, mean CSP duration was 
significantly shorter when recording over the FPL muscle (CSPFPL 174.7 ± 6.7ms; CSPAPB 205.4 
± 3.9ms, P < 0.01, Fig. 7.3B).  
 
Correlation studies 
In order to determine whether the differences in CMAP amplitudes between the APB and FPL 
could potentially account for the cortical excitability findings, correlation studies were 
undertaken.  There was no significant correlation between CMAP amplitudes and any of the 
TMS parameters, thereby suggesting that differences in CMAP amplitudes did not account for 
the cortical excitability findings.   
 
Of further relevance, it could also be argued that the observed differences in SICI were in part 
accounted for by differences in the MEP amplitude.  As such, SICI was correlated with the 
absolute MEP amplitude and MEP amplitude expressed as percentage of CMAP response.  There 
was no significant correlation between the absolute MEP amplitude (R = 0.17) or expressed 
MEP amplitude (R = 0.2) and SICI. This finding suggests that the reduction in cortical inhibitory 
effects in the FPL is independent of MEP size. 
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Figure 7.3:  (A)  The motor evoked potential amplitude (MEP), expressed as a percentage of the 
compound muscle action potential response, was significantly smaller when recording from the 
flexor pollicis longus (FPL) compared to abductor pollicis brevis.  (B) The cortical silent period 
(CSP) duration was significantly shorter when recording from the FPL compared to APB.  
**P < 0.01. 
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Discussion 
Using threshold-tracking TMS experimental paradigms the present study has established 
significant differences in cortical excitability between the abductor pollicis brevis and flexor 
pollicis longus.  Specifically, short interval intracortical inhibition was significantly reduced 
when recorded from the flexor pollicis longus muscles.  Further, the time course of SICI was 
different, with two peaks evident from the APB and one peak when recording over the FPL.  In 
addition, the motor evoked potential amplitude and cortical silent period duration were 
significantly reduced when recorded from the flexor pollicis longus.  Taken together, these 
findings suggest differences in cortical excitability between the FPL and APB, with potentially 
less cortical output onto the spinal motor neurons innervating the FPL muscle.  
 
Cortical processes appear to underlie differences in TMS parameters between APB and FPL 
 
Short interval intracortical inhibition appears to be cortical in origin, mediated by GABAergic 
inhibitory interneurons acting via GABAA receptors (401, 441, 468, 544).   Evidence supporting 
a cortical origin of SICI was provided by epidural recordings, in which the descending 
corticomotoneuronal volleys were inhibited during SICI (469, 470, 490, 542, 543).  Further 
support for a cortical origin of SICI is provided by positron emission tomography (PET) studies 
revealing significant changes in cerebral blood flow in the motor cortex with paired-pulse TMS 
studies (588).  
 
In the present study, there were significant differences in both the duration and degree of SICI 
when recording over the APB and FPL muscles, with SICI being significantly greater from the 
APB.  Given that SICI is mediated by inhibitory interneuronal motor cortical networks (401, 
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441), the findings would seem to suggest that inhibitory circuits sub-serving the 
corticomotoneurons directed to the APB were of greater potency.  Such findings would also be in 
keeping with previous TMS studies that demonstrated regional differences in cortical 
excitability, with cortical inhibition being greater in intrinsic hand muscles (420, 540).    
 
Of further relevance, the two phases of SICI, at ISI 1- and 3 ms, appear to be mediated by 
distinct cortical synaptic circuits(589, 590).  In the present study, the earlier phase of SICI, at ISI 
1 ms, was not evident when recording over the FPL, while the second larger peak was 
significantly smaller when compared to recordings obtained from the APB.  Such a finding 
would suggest that distinct cortical inhibitory circuits may underlie the generation of SICI in the 
two muscles, with the inhibitory effect being smaller when recorded from the FPL.  
 
Providing further support for the notion that cortical output was less to the FPL, was the finding 
that the MEP amplitude, a measure of the density of corticomotoneuronal projections onto 
anterior horn cells (401), was significantly smaller when recorded from the FPL.  Further, the 
CSP duration was also significantly shorter from FPL.  Given that the CSP duration may be 
influenced by the density of corticomotoneuronal projections onto the anterior horn cells, with 
CSP duration being longest for intrinsic hand muscles (401), this finding further supports the 
suggestion that cortical output to the FPL was less when compared to APB.    
 
It may also be suggested that the differences in the present TMS findings may be accounted for 
by use of a circular coil, which exerts effects over a wider cortical area, thereby resulting in non-
specific activation of the motor cortex (591).  This seems an unlikely explanation given that the 
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coil position was altered between each study such that an optimal MEP response was elicited 
prior to assessment of each muscle.  Importantly, previous TMS studies failed to establish any 
qualitative differences in the pattern of inhibition when using either a circular or focal figure of 
eight coil (540).   
 
It has also been suggested that differences in resting motor thresholds and MEP amplitude could 
in part explain the SICI findings (540).  Specifically, higher subthreshold conditioning stimuli 
may result in activation of facilitatory circuits, thereby resulting in reduced SICI (590, 592).  
Given that motor thresholds were comparable between the two muscles and that sub-threshold 
conditioning stimuli were set to 70% of the RMT, a value at which SICI appears to be maximal 
(590), it seems unlikely that inadvertent activation of facilitatory circuits is a likely explanation 
for the observed findings.  In addition, the absence of correlation between MEP amplitude and 
SICI would suggest that the differences in intracortical inhibition represent a true reduction in 
cortical inhibition onto anterior horn cells innervating the FPL muscle rather than MEP related 
effects.    
 
The difference in cortical excitability between the APB and FPL muscles remains to be fully 
elucidated.  Previously, differences in cortical excitability were established between the proximal 
upper limb muscles and APB.  This finding was attributed to smaller corticomotoneuronal output 
onto the anterior horn cells innervating the proximal muscles (45, 593).  By analogy, the 
differences in cortical excitability between the thenar muscles (APB) and FPL could also be 
accounted for by smaller corticomotoneuronal output onto the anterior horn cells innervating the 
FPL. 
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Clinical implications 
The split-hand plus sign, whereby the function of FPL is relatively preserved compared to APB, 
was recently reported to be a specific feature of ALS, distinguishing ALS from mimic disorders 
(585).  Given that FPL and APB are innervated by the same spinal segment (C8/T1) and nerve 
(median), cortical mechanisms may potentially underlie the development of the split hand plus 
sign in ALS.  Of relevance, a cortical basis has been suggested as a possible mechanism for other 
forms of dissociated intrinsic hand muscle atrophy described in ALS, namely the split hand sign 
(54, 584), with that stronger corticomotoneuronal output mediating neurodegeneration via a 
transsynaptic anterograde excitotoxic process.  The findings in the present study, revealing 
differences in cortical excitability between the APB and FPL, may lend further credence to the 
notion that cortical mechanism underlie the development of the split hand plus sign.  If 
confirmed in ALS cohorts, this finding would have pathophysiological significance, in particular 
suggesting that ALS has a central basis.   
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Chapter 8 
Cortical Hyperexcitability and the  
Split-Hand Plus Phenomenon: 
Pathophysiological insights in ALS 
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Summary 
Differences in cortical excitability between the APB and FPL elicited in the previous experiment, 
suggested that cortical mechanisms may underlie the development of the split hand plus sign in 
ALS. In an attempt to understand the pathophysiological mechanisms underlying this clinical 
phenomenon, threshold tracking transcranial magnetic stimulation technique was utilized to 
assess whether cortical mechanisms may be a significant contributing influence. Cortical 
excitability studies were undertaken on 17 ALS patients, with motor evoked potentials (MEP) 
recorded from thenar muscles and FPL.  Split-hand plus index (SHPI) was derived by dividing 
motor amplitudes recorded over APB with those recorded over FPL. The SHPI was significantly 
reduced in ALS (SHPIALS 0.87±0.12; SHPICONTROLS 1.7±0.2, P<0.001).  Cortical studies 
disclosed significant increases in MEP amplitudes recorded over thenar muscles (P<0.05), but 
not FPL (P=0.11), and were significantly correlated with the SHPI (R= -0.83, P<0.01).  The 
cortical silent period duration was reduced from thenar muscles (P<0.01).  Although there was a 
ubiquitous reduction in short-interval intracortical inhibition (APB, P<0.01; FPL<0.05), this 
reduction was more prominent over the thenar muscles.   Findings from the present study suggest 
that cortical dysfunction in the form of hyperexcitability contributes to the pathophysiological 
basis of the split-hand plus sign in ALS. 
 
 
 
 
 
 
 
 
 
 
 
222 
 
Introduction 
The split-hand plus sign refers to preferential involvement of motor pathways that innervate 
thenar muscles, with apparent preservation of the flexor pollicis longus (FPL) (594).  Recently, 
the split-hand plus sign was identified as a clinical feature of amyotrophic lateral sclerosis 
(ALS), distinguishing ALS from mimic disorder (594).   
 
The pathophysiological mechanisms underlying the split-hand plus phenomenon remains to be 
elucidated, although a cortical basis has been proposed (571).  While the thenar muscles and FPL 
are innervated by the same myotomes (C8,T1) and nerve (median), their function is different.  
Thenar muscles are critical for execution of fine fractionated finger movements (45), and may be 
expected to possess greater cortical representation and corticomotoneuronal input.  Given that 
corticomotoneuronal hyperexcitability has been postulated to trigger anterior horn cell 
degeneration in ALS by means of an anterograde transsynaptic excitotoxic process (2, 25, 87), 
and also associated with development of the split-hand phenomenon (54), the development of the 
split-hand plus sign may potentially be explained by excessive glutamate excitotoxity.   
 
Differences in cortical excitability have been previously established in healthy controls across a 
range of upper limb muscles (420, 540, 571, 595).  Importantly, significant differences in cortical 
excitability were recently reported between thenar muscles and FPL (571). Specifically, short-
interval intracortical inhibition, motor evoked potential amplitude and cortical silent period 
duration were significantly larger when recorded over the thenar muscles. This suggests a greater 
cortical representation/corticomotoneuronal input and simultaneously greater inhibition of the 
thenar muscles. Consequently, studies were undertaken with the aim of determining whether 
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differences in cortical excitability could form the pathophysiological basis for the split hand-plus 
phenomena in ALS. 
 
Materials and Methods 
Studies were undertaken on 17 patients with clinically probable or definite ALS (11 male, 6 
female: mean age: 62 years, 40-83) as defined by the Awaji criteria (82).  All patients provided 
written informed consent to the procedures which were approved by the South-Eastern Sydney 
and Illawarra Area Health Service Human Research Ethics Committee. 
Phenotyping 
ALS patients were clinically staged using the Amyotrophic Lateral Sclerosis Functional Rating 
Scale-Revised (ALSFRS-R)(511) and Medical Research Council (MRC) rating scale for strength 
(512).  The total MRC sum score was derived by assessing the following muscle groups 
bilaterally: shoulder abduction, elbow flexion and extension, wrist dorsiflexion, finger extension, 
finger abduction, thumb abduction, distal thumb flexion, hip flexion, knee extension, and ankle 
dorsiflexion, yielding a maximal score of 120.  Hand function was separately assessed using the 
Trigg‘s hand function score (434), while upper motor neuron (UMN) dysfunction was assessed 
by a specific UMN score (514).  ALS patients were classified according to the site of disease 
onset as either limb or bulbar-onset.   
 
Neurophysiological studies 
Prior to undertaking cortical excitability studies, the degree of lower motor neuron dysfunction 
was determined by recording the compound muscle action potential (CMAP) responses from the 
APB and FPL muscles.  The median nerves were stimulated at the wrist (APB) and elbow (FPL) 
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using 5 mm non-polarizable Ag-AgCl electrodes (3M Healthcare, MN, USA).  Stimulation was 
computer controlled and converted to current using an isolated linear bipolar constant current 
simulator (DS5, Digitimer, Welwyn Garden City, UK).  CMAP responses were recorded from 
the APB and FPL muscles with the active electrode positioned over the motor point and 
reference electrode placed over the proximal thumb (APB) and radial styloid (FPL) according to 
previously reported techniques (571, 596).  A novel split-hand plus index was derived according 
to the following formula: 
Split-hand plus index = APBCMAP amplitude/FPLCMAP amplitude 
 
Cortical Excitability 
Cortical excitability was undertaken by applying TMS to the motor cortex by means of a 90 mm 
circular coil oriented to induce current flow in a posterior-anterior direction. The coil was 
adjusted until the optimal position for the motor evoked potential (MEP) was obtained from the 
APB and FPL muscles as described previously (587, 596). Currents were generated by 2 high-
power magnetic stimulators that were connected via a BiStim module (Magstim Co.), such that 
conditioning and test stimuli could be independently set and delivered through one coil. 
 
Paired-pulse threshold tracking TMS was undertaken according to previously reported 
technique (416, 596).  Specifically, the MEP amplitude was fixed and changes in the test 
stimulus intensity required to generate a target response of 0.2 mV (±20%), when preceded by 
sub-threshold conditioning stimuli, were measured.  Resting motor threshold (RMT) was defined 
as the stimulus intensity required to maintain the target MEP response of 0.2 mV (±20%) (416, 
596). 
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Short-interval intracortical inhibition (SICI) was determined by using subthreshold conditioning 
stimuli (70% RMT) at increasing interstimulus intervals (ISIs) as follows: 1, 1.5, 2, 2.5, 3, 3.5, 4, 
5, and 7 ms.  Subsequently, intracortical facilitation (ICF) was measured at ISIs of 10, 15, 20, 25 
and 30 ms.  Stimuli were delivered sequentially as a series of three channels according to a 
previously reported (596).  SICI was measured as the increase in the test stimulus intensity 
required to evoke the target MEP.  Inhibition was calculated off-line as follows (596). 
Inhibition = (Conditioned test stimulus intensity–RMT)/RMT*100 
Facilitation was measured as the decrease in the conditioned stimulus intensity required to evoke 
a target MEP.  The SICI recorded from each muscle group was normalized so as to assess the 
degree of SICI reduction between the muscles.  
 
Single pulse TMS technique determined the MEP amplitude (mV), MEP onset latency (ms) and 
cortical silent period duration (ms).  The MEP amplitude was recorded with magnetic stimulus 
intensity set to 150% RMT and was expressed as a percentage of the CMAP response.  Cortical 
silent period (CSP) duration was assessed by instructing the subject to contract the target muscle 
at ~30% of maximal voluntary contraction with TMS intensity set to 150% RMT.   The CSP 
duration was measured from onset of MEP to return of EMG activity (455).   
 
Recordings of CMAP and MEP responses were amplified and filtered (3 Hz-3 kHz) using a 
GRASS ICP511 AC amplifier (Grass-Telefactor, Astro-Med Inc., USA) and sampled at 10 kHz 
using a 16-bit data acquisition card (National Instruments PCI-MIO-16E-4).  Data acquisition 
and stimulation delivery were controlled by QTRACS software (TROND-F, version 
226 
 
16/02/2009).  Temperature was monitored with a purpose built thermometer at the stimulation 
site.  
 
Statistical Analysis 
Cortical excitability in ALS patients was compared to previously reported healthy controls (10 
men and 5 women, mean age 34 years) (571).  Unpaired sample t-test was used for assessing 
differences between two groups.  All data was normally distributed as assessed using the 
Shapiro-Wilk test.  Correlation between neurophysiological and clinical parameters was 
analyzed by either a Pearson‘s or Spearman‘s rank test.  All results are expressed as mean ± 
standard error of the mean or median (interquartile range).  
 
Results 
Clinical features:  From the clinical cohort of 17 ALS patients, limb-onset disease accounted for 
65% of patients, while bulbar-onset disease was present in 35% (Table 1).  At the time of 
assessment, the mean disease duration from symptom onset was 22.7±3.7 months.  In addition, 
the median ALSFRS-R score was 42 (39-45) while the median Trigg‘s hand functions core 1 (0-
1), and the total MRC score was 96 (84-97), suggesting a mild-moderate degree of disability.  Of 
relevance, the UMN score was 12 (6-14), indicating a significant degree of UMN dysfunction. 
The split-hand plus sign, whereby preferential weakness of the thenar muscles was evident 
compared to the FPL (594), was evident in 62% of patients, while the split-hand sign, which 
refers to preferential dysfunction of the thenar muscles and first dorsal interosseous (20, 21, 
558), was evident in 50% of patients.   
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Neurophysiological studies:  Prior to undertaking cortical studies, the degree of the lower motor 
neuron dysfunction was determined for each muscle.  The CMAP amplitude was reduced when 
recorded over the APB (ALS 8.1±1.2 mV, controls 18.1±1.5mV, P<0.0001) and FPL (ALS 
9.1±1.8 mV, controls 11.6±1.2 mV, P=0.08).  The split-hand plus index was significantly 
reduced in ALS patients (SHPIALS 0.87±0.12; SHPICONTROLS 1.7±0.2, P<0.001), suggesting 
preferential dysfunction of the motor neurons innervating the APB muscles.  The reduction in 
split-hand plus index was a ubiquitous finding, evident in both limb and bulbar-onset patients 
(SHPI LIMB-ONSET 0.95±0.2; SHPI BULBAR-ONSET 0.88±0.17).   
 
Cortical function:  Transcranial magnetic stimulation studies identified an inexcitable motor 
cortex in three ALS patients. As such, cortical excitability was undertaken on 14 ALS patients. 
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Patients Age (years) 
/sex 
Disease 
onset 
Disease 
duration 
(months) 
MRC 
Sum 
score 
Triggs 
hand 
score 
UMN 
score 
ALSFRS-R 
1 79/M LIMB 51 84 1 12 39 
2 83/F LIMB  8 80 1 8 38 
3 71/F LIMB  24 75 3 14 32 
4 54/M LIMB  16 85 0 14 41 
5 67/M LIMB  9 96 1 2 30 
6 71/M LIMB  19 85 1 8 42 
7 40/M LIMB  15 98 0 14 40 
8 65/M LIMB  49 72 3 14 36 
9 69/M LIMB  28 74 1 14 46 
10 58/F LIMB  10 86 1 5 45 
11 62/M LIMB  22 97 0 2 45 
12 57/M LIMB  18 97 0 14 44 
13 49/F BULBAR 37 96 0 12 42 
14 62/F BULBAR  45 96 0 15 40 
15 50/M BULBAR  7 100 0 6 46 
16 47/M BULBAR  8 100 0 1 46 
17 62/F BULBAR  35 96 1 10 42 
Mean  
(SD) 
61.5 
(11.5) 
 23.5 
(14.8) 
    
Median  
(IQR) 
   96 
(84-97) 
1 
(0-1) 
12  
(6-14) 
42 
(39-45) 
Table 8.1: Clinical details for 17 amyotrophic lateral sclerosis (ALS) patients. Muscle strength 
was clinically assessed using the Medical Research Council (MRC) yielding a maximal MRC 
score of 120 (see Methods).  In addition, hand function was assessed by using the Trigg‘s hand 
score (see Methods).  Upper motor neuron (UMN) score was used to assess the degree of UMN 
dysfunction ranging from 0= no UMN dysfunction to 16 maximal dysfunction.  The amyotrophic 
lateral sclerosis functional rating scale- revised (ALSFRS-R) was used to assess for the degree of 
functional impairment. All data are expressed as mean (standard deviation, SD) or median 
(interquartile range, IQR) 
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Figure 8.1: The motor evoked potential (MEP) amplitude, expressed as a percentage of the 
compound muscle action potential response, was significantly increased when recording from 
the (A) abductor pollicis brevis, but not the (B) flexor pollicis longus muscles in amyotrophic 
lateral sclerosis (ALS) patients compared to controls. *P < 0.05 
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Figure 8.2: The cortical silent period duration was significantly reduced when recording from 
the (A) abductor pollicis brevis, but not the (B) flexor pollicis longus muscles in amyotrophic 
lateral sclerosis (ALS) patients compared to controls. **P < 0.01 
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Single pulse TMS technique determined that the MEP amplitude, expressed as a percentage of 
the CMAP response, was increased in ALS when recorded from the APB (ALS 37.6±6.8%; 
controls 19.3±3.3%, P<0.05, Fig.8.1A).  The MEP amplitude was not significantly increased 
when recording from the FPL (ALS 21.4±3.0%; controls 14.7±2.2%, P=0.11, Fig. 8.1B).  In 
addition, the CSP duration was significantly reduced when recorded over the APB (ALS 
163.5±8.8 ms; controls 198.0±5.2 ms, P<0.01, Fig.8.2A), but not FPL (ALS 171.6±8.4ms; 
controls 176.3±6.3 ms, P=0.45, Fig.8.2B).  There were no significant differences in the RMT 
between groups when recorded over APB (P=0.33) and FPL (P=0.37) muscles.   
 
Paired-pulse TMS studies disclosed that SICI was significantly reduced in ALS (Fig. 8.3).  
Specifically, averaged SICI over ISIs 1-7 ms was significantly reduced when recording over 
APB (mean SICIAPB 4.3±2.2%; controls 11.6±1.3%, P<0.01, Fig 8.3A, 8.4A).  In addition, peak 
SICI at ISI 1 ms (ALS 0.9±1.0%; controls 10.8±1.8%; P<0.001, Fig. 8.3A) and 3 ms (ALS 
8.0±3.6%; controls 16.5±1.2%; P<0.05, Fig.8.3A) was also significantly reduced when recorded 
over the APB.  Averaged SICI (ALS 2.2±1.8%; controls 6.5±1.7%, P<0.05, Fig 8.3B, Fig.8.4B), 
peak SICI 1 ms (ALS 4.1±2.4%; controls 11.3±2.2%, P<0.05, Fig.8.3B) and ISI 3 ms (ALS 
0.68±1.1%; controls 6.3±1.9%, P<0.05, Fig. 8.3B) were also reduced in ALS when recorded 
over FPL.  The extent of SICI reduction was greater when recorded over thenar muscles (SICI 
APB REDUCTION 0.62; SICI FPL REDUCTION 0.70, P< 0.01, Fig. 8.4C).    
 
Following SICI, a period of ICF develops (596).  There were no significant differences in ICF 
between groups when recording over APB (P=0.18, Fig. 8.3A) and FPL (P=0.42, Fig. 8.3B), 
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although these findings should be interpreted cautiously as the study could have been potentially 
underpowered to detect differences in ICF.   
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Figure 8.3: Short -interval intracortical inhibition (SICI), defined as the stimulus intensity 
required to maintain a target output of 0.2 mV (see methods) was significantly reduced in 
amyotrophic lateral sclerosis (ALS) patients compared to controls when recording from both the 
(A) abductor pollicis brevis, but not the (B) flexor pollicis longus muscles.  
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Correlations 
Combination of clinical and neurophysiological parameters determined that the MEP amplitude 
recorded over the APB were inversely correlated with the CMAP amplitude (R = -0.82, P<0.01) 
and split-hand plus index (R = -0.83, P<0.01).  In addition, the CSP duration, recorded from the 
APB was significantly correlated with the ALSFRS-R (R = -0.53, P<0.05).   
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Figure 8.4: Average short -interval intracortical inhibition (SICI), between interstimulus 
intervals (ISI) of 1-7 ms, was significantly reduced in amyotrophic lateral sclerosis (ALS) 
patients compared to controls when recording from both the (A) abductor pollicis brevis (APB) 
and (B) flexor pollicis longus (FPL) muscles.  (C) The degree of SICI reduction was greater 
when recording over the APB. *P< 0.05; **P< 0.01.  
 
234 
 
Discussion 
In the present study, threshold tracking TMS techniques were utilized to investigate the 
pathophysiological processes that may contribute to development of the split-hand plus 
phenomenon in ALS (594).  Cortical dysfunction was evident when recording over both the APB 
and FPL, although the apparent degree of excitatory/inhibitory imbalance was more prominent to 
the thenar eminence.  Specifically, the MEP amplitude was significantly increased while the CSP 
duration reduced when recorded from thenar muscles.  In addition, SICI was more prominently 
reduced when recorded over the APB.  There was a significant correlation between cortical 
hyperexcitability and the split-hand plus index, a biomarker of the split-hand plus sign.  These 
findings suggest that cortical mechanisms may in-part contribute to the development of the split-
hand plus sign in ALS.      
 
Prior to undertaking a discussion on the pathophysiological mechanisms underlying the split-
hand plus sign, the diagnostic utility of this novel sign was reassessed.  A previous study 
established the diagnostic utility of the split-hand plus sign, which reliably distinguished ALS 
from mimic disorders (594).  Importantly, the sensitivity and specificity appeared comparable to 
the more conventional split hand sign (20, 21, 529, 558).  The present study established a 
comparable sensitivity of the split-hand plus and split-hand sign in ALS patients. Of further 
relevance, the significant correlation between the MEP amplitude and split-hand plus index 
suggests that cortical hyperexcitability may contribute to development of the split-hand plus 
phenomenon.   
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Origin of the split-hand plus sign 
The MEP amplitude is a biomarker of the density of corticomotoneuronal projections onto 
anterior horn cells (87, 441) and may be enhanced by glutamate excitotoxity (444).  Increases in 
MEP amplitude have been extensively documented in ALS (31, 49, 50) and linked to motor 
neuron degeneration (49, 126), a finding re-affirmed in the present study.  The MEP amplitude, 
expressed as a percentage of CMAP response, was significantly increased when recorded over 
the thenar muscles, a finding that could be explained by a combination of thenar muscle wasting 
and cortical hyperexcitability.   
       
Of further relevance, a significant reduction in CSP duration was evident when recording from 
thenar muscles but not FPL.  Given that CSP duration is mediated by cortical inhibitory 
processes acting via GABAB receptors (87, 453, 455, 457, 458, 548), the present findings would 
seem to suggest more prominent cortical disinhibition, and thereby excitatory/inhibitory 
imbalance, of the thenar muscles, thereby underscoring the notion of a cortical basis for the split-
hand plus phenomenon.  In addition, abnormalities of SICI were also evident in the present ALS 
cohort and appeared to be more prominent when recorded from thenar muscles.  Importantly, 
SICI appears to be a biomarker of cortical inhibitory interneuronal function acting through 
GABAA receptors(401, 441, 468, 544), as well as glutamate-mediated cortical excitability (478, 
597).  Given that there was a more prominent reduction of SICI when recorded over the thenar 
muscle, these findings may suggest a more prominent imbalance of cortical excitatory-inhibitory 
tone, with GABA receptors leading to glutamate-mediated excitotoxicity and loss of inhibition, 
thereby implying a cortical basis for the split-hand plus phenomenon in ALS.   
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A potential explanation for the vulnerability of thenar motor neurons to glutamate-mediated 
excitotoxicity may relate to greater cortical representation and more prominent 
corticomotoneuronal input to thenar muscles.  Differences in cortical representation were 
postulated to reflect varied functions of the muscles in execution of complex hand tasks (45).  
Specifically, the FPL appears to have evolved a well developed sensory function in human 
dexterity, with a high capacity in sensing thumb forces during voluntary movement as well as 
exhibiting a greater role in proprioceptive acuity of the thumb (598, 599).  Recent TMS studies 
have established more prominent corticomotoneuronal projections to thenar motor neurons when 
compared to the FPL motor neurons (571).  Consequently, thenar motor neurons could be more 
prone to glutamate-mediated excitotoxic degeneration in ALS by virtue of a more prominent 
corticomotoneuronal supply.  
 
A potential limitation of the present study relates to the possibility that recordings over the FPL 
muscle were confounded by volume conduction.  While such a possibility could not be 
discounted, it seems an unlikely explanation for cortical excitability differences given that 
responses recorded over the thenar muscles could also be confounded by volume conduction.  In 
addition, given that the control population was significantly younger than the ALS cohort, the 
possibility of the aging process confounding the results could not be discounted.  
 
Alternatively, it could be argued that peripheral mechanisms contributed to development of the 
split-hand plus phenomenon in ALS.  Hyperexcitability of axons innervating the thenar muscles 
was postulated to contribute to development of dissociated muscle atrophy in ALS (563).  Recent 
studies have failed to establish that abnormalities of axonal excitability followed a split-hand 
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pattern distribution (600), but rather argued that these changes in axonal excitability reflected 
downstream effects of primary pathophysiological processes.  While a peripheral contribution to 
the split-hand plus phenomenon could not be absolutely discounted, the findings of more 
prominent cortical hyperexcitability, when recording over the thenar muscles, suggests a 
predominance of cortical processes in development of the split-hand plus phenomenon in ALS.   
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SUMMARY AND CONCLUSIONS 
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The studies comprising this thesis were undertaken in order to gain further insights into the 
pathophysiological mechanism underlying the development of ALS, particularly the role of 
corticomotoneurons.  In chapter 1, the specificity of the split-hand sign, which refers to 
preferential dysfunction of the thenar complex group of muscles (APB and FDI) compared to the 
hypothenar group, was established in ALS by developing a novel split-hand index.  The split-
hand index was determined to be a robust diagnostic marker of ALS, reliably differentiating ALS 
from neuromuscular mimic disorders with a diagnostic cut off value of 5.2.   Given that the 
thenar and hypothenar muscles are innervated by the C8/T1 myotomes, it was inferred that 
cortical mechanisms form the basis of the split-hand sign in ALS.   
 
Consequently, in chapter 2, threshold tracking transcranial magnetic stimulation and axonal 
excitability techniques were utilised to dissect out differences in corticomotoneuronal input and 
biophysical properties of the motor axons innervating the thenar and hypothenar muscle groups 
in healthy controls.  Importantly, this series of studies established a greater corticomotoneuronal 
input and greater cortical representation of the thenar group of muscles.  In contrast, the 
peripheral axonal properties of the motor axons innervating the thenar and hypothenar muscles 
did not follow a split-hand pattern.  As such, the findings in the present study confirmed, for the 
first time, the existence of differences primarily in corticomotoneuronal input between the thenar 
and hypothenar muscles underlying the preferential thenar intrinsic hand muscle (split-hand) 
wasting noted in ALS thereby suggesting a cortical basis for selective muscle vulnerability in 
ALS.  
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Recent studies in ALS patients, however, suggested that peripheral processes, namely differences 
in motor axonal excitability, formed the basis of the split-hand in ALS.  This notion was 
investigated in chapter 3, whereby axonal excitability studies were undertaken on motor axons 
innervating the thenar (APB and FDI) and hypothenar muscles.  The studies in chapter 3 
confirmed that changes in axonal excitability did not follow a split-hand pattern, thereby arguing 
against a significant contribution of peripheral processes to the development of the split-hand 
phenomenon in ALS.   
 
In chapter 4, simultaneous cortical and axonal excitability studies were undertaken on ALS 
patients in order to assess whether corticomotoneuronal hyperexcitability formed the basis of the 
split-hand sign and thereby the pathophysiological basis in ALS.  While cortical 
hyperexcitability was established as a global phenomenon in ALS irrespective of the recording 
muscle, the degree of cortical hyperexcitability was greater over the thenar group of muscle 
(APB and FDI).  Corresponding changes in axonal excitability did not follow a split-hand 
pattern.  Taken together, these findings imply a cortical basis for the split-hand sign and re-
enforced the importance of cortical hyperexcitability in ALS pathogenesis. 
 
Complementing the results of chapters 1-4, the findings in chapter 5 provided additional support 
for a cortical basis of ALS pathophysiology.  Utilising a combination of threshold tracking TMS, 
axonal excitability and needle electromyography techniques, the findings in chapter 5 established 
the development of corticomotoneuronal hyperexcitability prior to onset of lower motor neuron 
dysfunction in ALS.  Importantly, all ALS patients progressed to develop LMN dysfunction in 
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the target APB muscle during follow-up.  As such, the findings in chapter 5 provided strong 
support for an important role of the corticomotoneuronal system in ALS pathogenesis.  
 
The theme of selective motor neuronal degeneration was further examined in chapter 6.  
Specifically, a novel split hand plus sign was described to be a specific feature of ALS, and 
refers to preferential dysfunction of APB muscle with relative preservation of the flexor pollicis 
longus (FPL) muscle, despite a common myotomal innervation (C8/T1).  These findings 
reinforced the phenomenon of selective vulnerability of motor neurons in ALS, with implications 
for a cortical basis of ALS pathogenesis.     
 
In order to explore the possibility of a cortical basis of the split hand plus sign, threshold tracking 
TMS studies were undertaken in healthy controls, with responses recorded over the APB and 
FPL muscles.  In concordance with studies in chapter 2, the findings in chapter 7 established 
greater corticomotoneuronal input and cortical representation of the APB muscle.  The 
differences in critical excitability between the APB and FPL muscles was attributed to functional 
differences, but more importantly suggested that cortical processes could mediate the 
development of the split hand plus sign in ALS.   
 
In an attempt to further explore this possibility, threshold tracking TMS studies were undertaken 
in a cohort of ALS patients with responses recorded over the APB and FPL muscles.  The study 
detailed in Chapter 8, significantly confirms a greater degree of cortical hyperexcitability over 
the APB, implying the importance of cortical processes in development of the split-hand plus 
phenomenon, and thereby inferring a cortical basis for ALS pathogenesis.   
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In summary, the findings of the present thesis suggest that corticomotoneuronal dysfunction, 
namely hyperexcitability, forms the basis of ALS pathogenesis, resulting in development of 
specific clinical features and progressive neurodegeneration. This finding is supported by 
previous studies on the occurrence of cortical hyperexcitability preceding the onset of clinical 
disease in genetic mutation carriers in ALS and by the association of frontotemporal lobe 
dementia (FTLD), a pure cortical dysfunction, as a disease spectrum of ALS.  Future therapeutic 
strategies aimed at modulating cortical hyperexcitability, either via pharmacological or cell based 
approaches, may prove therapeutically useful. 
 
 
Future Directions 
Cortical hyperexcitability appears to precede the development of LMN dysfunction in ALS when 
assessing one body region (the upper limb).  Future studies will utilise threshold tracking TMS 
techniques in order to explore whether the development of cortical hyperexcitability occurs prior 
to onset of disease in other body regions, such as cranial and lumbosacral.  These studies will 
assist in establishing the pattern of disease spread, namely whether the corticomotoneurons are a 
conduit for ALS progression in a non-contiguous manner.  In addition, longitudinal studies will 
be undertaken on the recently described c9orf72 hexanucleotide expansion carriers combining 
threshold tracking TMS techniques with measures of peripheral disease burden including motor 
unit number estimation (using Bayesian statistical method), conventional nerve conduction 
studies and needle electromyography techniques. Longitudinal studies in this cohort will help 
confirm the finding reported in SOD-1 mutation carriers that cortical hyperexcitability is an 
acquired phenomenon even in genetic ALS and appears to precede the onset of clinical disease.  
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Of further relevance, the role of corticomotoneurons in ALS pathogenesis will be further 
investigated by combing threshold tracking TMS techniques with sophisticated neuroimaging.   
Specifically, cross-sectional and longitudinal studies will be undertaken on apparently ―sporadic‖ 
ALS patients and c9orf72 mutation carriers.  The corticomotoneuronal function will be assessed 
by utilising cortical thickness analysis, resting state networks and sodium coil imaging in concert 
with TMS studies, in order to establish the timing and site of disease onset, along with patterns 
of disease spread.  Ultimately, such an approach will shed further light on ALS pathogenesis, 
with the hope of uncovering novel therapeutic targets. 
 
Separately, prognostic biomarkers for ALS will be developed focussing on the split-hand index.  
Although cross-sectional study suggested a prognostic utility of the split-hand index in ALS, 
longitudinal studies, over 24 months, will be undertaken to assess and compare the prognostic 
utility of the split-hand index with established prognostic biomarkers in ALS, including the 
ASLFRS-R, CMAP amplitude, neurophysiological index,  motor unit number estimation (using 
Bayesian statistical method), dynamometry and electrode impedance myography.  If established 
to be of prognostic utility, the split hand index, will provide a simple neurophysiological 
prognostic biomarker in future therapeutic trials.      
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GLOSSARY OF ABBREVIATIONS 
ADM                    abductor digiti minimi 
AHC                     anterior horn cell 
ALS                      amyotrophic lateral sclerosis 
ALSFRS-R           amyotrophic lateral sclerosis functional rating scale-revised 
AMPA                  α amino 3 hydroxy 5 methyl 4 isoxazole proprionic acid 
ANOVA               analysis of variance 
APB                      abductor pollicis brevis 
AR                        androgen receptor 
ATP                      adenosine tri phosphate 
CMAP                  compound muscle action potential 
CMCT                  central motor conduction time 
CSP                      cortical silent period  
DAP                     depolarizing after depolarization            
DNA                     deoxyribonucleic acid 
EMG                    electromyography 
FDI                       first dorsal interosseous 
FPL                      flexor pollicis longus 
FTD                     frontotemporal dementia 
FUS                     fused in sarcoma 
GABA                 gamma amino butyric acid 
ICF                      intracortical facilitation 
ITPR                    inositol 1,4,5-triphosphate receptor 
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I/V                      current threshold relationship 
KD                     Kennedy‘s Disease 
LA                      latent addition 
LICI                    long interval intracortical inhibition 
LMN                   lower motor neuron 
MEP                   motor evoked potential 
MMNCB           multifocal motor neuropathy with conduction block 
MND                 motor neuron disease 
MRC                 Medical Research Council 
MT                    motor threshold 
MUNE              motor unit number estimation 
MUP                 motor unit potential 
NCS                 nerve conduction study 
NI                    neurophysiological index 
NMDA            N-methyl, D-aspartate receptor 
PBP                 progressive bulbar palsy 
PLS                 primary lateral sclerosis 
PMA               progressive muscular atrophy 
PSW               positive sharp waves 
PTN               pyramidal tract neuron 
RMT              resting motor threshold 
RNA               ribonucleic acid 
ROC               receiver operating characteristic  
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RRP               relative refractory period 
SBMA           spinobulbar muscular atrophy 
SDTC            strength duration time constant 
SI                   split-hand index   
SICI               short-interval intracortical inhibition 
SMA              spinal muscular atrophy 
SOD               superoxide dismutase 
SR                  stimulus response curve 
STARD          standards for reporting of diagnostic accuracy 
TARDBP       transactive region deoxyribonucleic acid binding protein 
TEd                threshold electrotonus depolarising 
TEh                threshold electrotonus hyperpolarising 
TMS               transcranial magnetic stimulation 
UMN              upper motor neuron 
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